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Abstract:  
 
Autophagy is an evolutionarily conserved process that is important for the 
maintenance of cellular homeostasis and also genomic integrity. Autophagy is a 
self-digestive process that takes place in the cytoplasm, however recent studies by 
Eileen White and colleagues demonstrated that defective autophagy leads to 
accumulation of DNA damage in vitro and in vivo [1] [2]. This discovery leads to a 
question: whether there is increased DNA damage incidences or defective DNA 
damage repair in autophagy deficient cells. Autophagy and DNA damage are two 
important areas for cancer research. The aim of this project is to provide a better 
understanding of the role of autophagy plays in DNA damage and DNA damage 
response.  
 
The activation of Chk1 facilitates its degradation. The results presented in this 
project illustrate that autophagy deficient cells exhibit elevated proteasomal 
activities and autophagy inhibition leads to activation of Chk1. These combined 
factors contribute to increased degradation of Chk1 in autophagy deficient cells. 
This was manifested first as decreased phospho-Chk1 in response to DNA damage, 
later on when the loss of autophagy effect is more pronounced; decrease in total 
Chk1 protein level was observed. Chk1 is a crucial DNA damage response mediator 
that plays roles in cell cycle checkpoints and DNA damage repair. Cells without 
autophagy appear to have intact cell cycle checkpoints in response to starvation or 
DNA damaging agents; however they show deficiency in homologous 
recombination (HR) repair pathways. Autophagy deficient cells display increased 
spontaneous cell death and formation of micronuclei. Defective HR pathways in 
autophagy deficient cells lead to hyper-dependency on non-homologous end-joining 
(NHEJ) process.  Since HR and NHEJ are the two main ways of repairing double 
strand breaks (DSB), it is not surprising that inhibition of NHEJ following DSB 
inducing agents in autophagy deficient cells results in persistence of damage lesions 
and increased cell death.  
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This project demonstrated that loss or inhibition of autophagy leads to defective 
DNA damage response pathways. We established that Chk1 is de-regulated in 
autophagy deficient cells and this has differential downstream effects on DNA 
damage response.   
 
These findings potentially provide a novel synthetic lethal strategy to selectively 
kill autophagy-deficient cells, which are implicated in a number of diseases 
including certain cancers.  
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Chapter 1. Introduction  
 
1.1 Autophagy – Definition and Classification.   
 
Autophagy is a fundamental catabolic process that is well conserved from yeast to 
higher eukaryotic cells. It is a self-digestive mechanism where metabolites are 
recycled in the cells. During the process, cellular proteins, organelles (e.g. 
mitochondria and endoplasmic reticulum (ER) membranes) and cytoplasm are 
sequestered and degraded in the lysosomes by hydrolases.  
 
Autophagy is constitutively active at basal levels in the cells; it is thought to 
degrade long-lived proteins and organelles in bulk as a mean of recycling cellular 
building blocks and maintaining cellular homeostasis and integrity. Autophagic 
activities are up-regulated when the cells undergo metabolic stress such as 
starvation and hypoxia [3]. In this case it plays the role of an adaptive survival 
mechanism; autophagy acts as a ‘cannibalistic’ process that fuels cell bioenergetics 
through self-digestion and recycling of cellular contents. Because of its self-eating 
nature, autophagy mediated survival is temporary and provides an opportunity for 
the cells to deal with the stressful environment. Prolonged activation of autophagy 
due to continuous metabolic stress can contribute towards cell death [4]. It is 
thought that autophagy is an accelerator rather than effector in programmed cell 
death under normal physiological conditions. Dying cells very often display 
accumulation of autophagosomes and autophagy is considered to be an important 
mediator of the clearance of cell corpses [5]. In cancer cells, there is evidence that 
autophagy can act as a cell death mechanism, alternative to apoptosis [6]. It is well 
acknowledged that defective apoptosis is one of the major transformations during 
tumourigensis [7], therefore autophagic cell death can be potentially utilised to 
eliminate tumour cells. In fact, Autophagy is required for a number of cancer 
therapeutic drugs to achieve sufficient killing [8]  [9]. 
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The relationships between apoptosis and autophagy is complex and the two 
processes frequently overlap each other. ATG1 overexpression in Drosophila leads 
to cell death which display apoptotic characteristics [10]. Autophagy has been 
found to be a apoptosis-independent cell death mechanism in Dictyostelium, which 
does not have genes that encode proteins in the apoptotic pathways [11]. 
 
Three main types of autophagy have been described; they are macroautophagy, 
microautophagy, and chaperone-mediated autophagy. The three processes share 
common molecular machinery to a certain degree, the protein/organelle cargoes are 
degraded in the lysosomes for all three types. The three processes are well 
coordinated and complement each other’s functions to maintain cellular 
homeostasis [12] [13]. Macroautophagy (hereafter autophagy) is the most 
characterized process which degrades long-lived proteins and removes damaged 
organelles. The formation of autophagosomes that contain bulk proteins and 
organelles distinguishes this type of autophagy from other autophagic processes.  
Microautophagy is a process where cytoplasm is directly engulfed by the lysosome 
through invagination [14]. Chaperone-mediated autophagy is able to degrade 
cytosolic proteins selectively. Specific substrate proteins containing the amino acid 
motif KFERQ are recognised by the hsc70 chaperone in the cytoplasm [15]. Hsc70 
and its substrate protein bind to lysosome-associated membrane protein type 2A 
(LAMP-2A) which is localized on the lysosomal membrane. The substrate protein 
is unfolded by hsc70 and translocated into lysosomes where it is degraded [16]. 
Selective autophagy is a process where specific organelles, pathogens and proteins 
are post tranlationsl modified and recognised by adaptor proteins such as p62 and 
NBR1, which bind to autophagosome proteins including LC3. The cargo is tethered 
to the site of autophagosome and engulfed into the vesicle [17] .  
 
1.2 The process of autophagy 
 
Autophagy is a highly dynamic process where a series of membrane-trafficking 
events take place. As illustrated in Figure 1.1, the autophagy process consists of 
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four major steps, namely initiation, elongation, maturation and fusion. mTOR 
(mammalian target of Rapamycin) is an inhibitory regulator of autophagy in 
response to a number of stimuli,  phosphorylating and inhibiting the ULK complex. 
The ULK complex activates Beclin 1, which is the key component of a complex 
which generates double membranes to form phagophores. Phagophores grow to 
enclose cellular contents in the cytoplasm such as proteins and organelles and fuse 
at both ends forming vesicular autophagsosomes. Autophagy is completed when 
autophagosomes fuse with lysosomes forming autolysosomes where the contents 
are degraded.  
 
Autophagy is a housekeeping process that takes place in nearly all cell types, and is 
up-regulated by a range of stimuli, such as starvation, hypoxia and DNA damage. 
These signalling pathways are described as follows.  
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Figure 1.1 Autophagy is a multi-step process.  
 
(Figure adapted from Liu and Ryan, 2012.) Double membraned phagophores 
elongate to enclose cytoplasm and organelles into vesicles called autophagosomes, 
which are eventually fused with lysosomes where the contents are degraded. mTOR 
kinase is a sensor initiating autophagy in response to growth factors and nutrients. 
Double membraned structures called phagophores elongate to enclose cellular 
contents and fuse to form autophagosomes. Autophagosomes are trafficked to fuse 
with lysosomes which contain acidic hydrolases that degrade the contents of 
autophagosomes.  
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1.2.1 Autophagy levels are modulated in response to a variety of stimuli in 
mammalian cells. 
  
mTOR kinase [18] is a key inhibitory regulator of autophagy in response to a 
spectrum of signals including growth factors (e.g. insulin-like factors, PDGF 
(platelet-derived growth factor), VEGF (vascular endothelial growth factor) and 
EGF (epidermal growth factor)), nutrients (e.g. amino acids and glucose), energy 
(ATP) and oxygen as demonstrated in figure 1.2. When there are sufficient nutrients 
in the cells, autophagy is kept at low levels. mTOR constitutively inhibits the 
initiation of autophagy through the phosphorylation of the Atg13-ULK-FIP200 
complex. Autophagy can be regulated in both mTOR dependent or independent 
manners, depending on the stimuli, as illustrated in Figure 1.2. Besides autophagy, 
mTOR is also a master regulator of protein synthesis, cell cycle control and cell 
proliferation, in accordance with nutrient availability [19]. mTOR kinase exits in 
two structurally and functionally distinct complexes mTORC1 and mTORC2. 
mTOR signalling pathways are frequently hyper-activated in human cancers and 
deregulated in metabolic diseases [20].  
 
In recent years, it was discovered that nutrient-availability signals are relayed to 
mTORC1 by different pathways. AMPK mediates mTORC activities in response to 
glucose availability [21]  and Class III PI3K regulates mTORC according to the 
availability of amino acids and growth factors [22]. 
 
Growth factors are molecules secreted by cells, which stimulate the proliferation 
and/or differentiation of the secreting cells by autocrine signalling, or stimulate 
neighbouring cells by paracrine interactions. Growth factors bind to receptor 
tyrosine kinases (RTKs) on the cell surface and in turn PI(3)K is recruited to the 
cell membrane and activated generating PIP3 (phosphatidylinositol-3,4,5-
trisphosphate). This leads to a signalling cascade at the membrane. Akt, Rheb and 
mTORC1 complex are in turn activated [23].  
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The concentrations of amino acids are the dominating signals for the activation of 
the multi-protein complex mTORC1 [24]. During the final steps of autophagy, 
autophagosomes containing proteins and organelles fuse with lysosomes where the 
macromolecules are broken down to small basic parts. Proteins are digested into 
amino acids by the acidic hydrolases. Recent studies have demonstrated that 
mTORC1 can localise to the outer surfaces of lysosomes and sense amino acids 
within the vesicles [25]. mTOR lysosomal activation pathways are conserved from 
yeast to mammalian cells [26]. The pathway is regulated by Rag GTPases, 
GATOR1 and GATOR2 complexes [27] [28]. Since mTOR is a key inhibitory 
regulator of autophagy, the cells may utilise this mechanism to lower autophagic 
activity in response to lysosomal amino acids.  
 
Lysosomes have been thought to be a cellular factory of degradation and recycling; 
in recent years, works from Sabatini and Ballabio’s labs have demonstrated that 
lysosomal surfaces are also a signalling hub regulating mTOR and autophagy 
activities [27] [29]. In addition, the positioning of lysosomes is regulated by 
nutrient availability and this also plays a role in mTORC1 signalling and autophagy 
activation [30]. mTOR is the best characterised nutrient sensing autophagy 
regulator; other mTOR independent amino acid signalling pathways that negatively 
regulate autophagy have also been reported [31] [32]. The molecular details of these 
mTOR-independent pathways remain to be explored. 
 
Glucose is the primary energy source for mammalian cells [33] and autophagy 
activities are modulated in accordance with glucose availability. AMPK is activated 
when the cells are under conditions of glucose starvation. AMPK activates 
autophagy through two mechanisms - it activates the ULK1 complex through 
phosphorylation and it inactivates mTORC1 by phosphorylating Raptor and TSC2 
(tuberous sclerosis 2) [34]. The activation of the ULK1 complex marks the 
initiation of autophagy (Chapter 1.2.2), which promotes cell survival in the 
presence of energy stress.   
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Besides nutrient availability as outlined above, autophagy can also be up-regulated 
by genotoxic stress such as DNA damage and reactive oxygen species (ROS) [35]. 
The p53 tumour suppressor plays important roles in cell cycle regulation, DNA 
damage responses and programmed cell death. It is reported that p53 is lost in over 
50% of cancers [36]. Nuclear p53 and cytosolic p53 have been found to play 
opposing roles in autophagy regulation. In the nucleus, p53 plays the role of a 
transcription factor [37], and in the presence of genotoxic stress, p53 can activate a 
number of autophagy genes including AMPK, ULK1 and ULK 2 [38] [39] [40]. 
Nuclear p53 also activates damage-regulated autophagy modulator 1 (DRAM1) 
[41], which consists of multiple splice variants that regulate autophagy [42]. The 
exact mechanisms through which DRAM1 modulates autophagy remain to be 
elucidated. In contrast, cytoplasmic p53 mainly inhibits autophagy [37]. Moreover, 
p73 is a tumour suppressor transcription factor that belongs to the p53 protein 
family. p73 can also induce autophagy, in a DRAM-independent way [43].  
 
Other autophagy-modulating molecules include Bcl-2 [44] and BNIP3 (Bcl-
2/adenovirus E1B 19-kDa interacting protein 3) [45]. These are also frequently 
involved in cancer. Bcl-2 protein is an important regulator of programmed cell 
death, inhibiting autophagy indirectly through its interaction with Beclin-1, a 
protein essential for autophagy initiation, through BH3 (Bcl-2 homology 3) 
domains. Bcl-2, as an anti-apoptotic protein, is considered to modulate autophagy 
levels to prevent over-eating of the cells and cell death [44]. Autophagy is also 
activated in response to hypoxia. BNIP3 and BNIP3L are two essential elements for 
hypoxia-induced autophagy; they contain BH3 domains that disrupt the interactions 
between Beclin-1 and Bcl-2 [46]. Hypoxia induced autophagy is thought to be a 
pro-survival mechanism utilized by cancer cells.  
 
To summarise as shown in Fig. 1.2, autophagy is constitutively kept at low levels 
when there are sufficient nutrient signals and can be activated by energy stress or 
genotoxic stress.  
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Figure 1.2 Autophagy levels are modulated in response to a variety of stimuli in 
mammalian cells.  
 
Autophagy is inhibited in the presence of sufficient glucose, amino acids and 
growth factors and the nutrient-sensing kinase mTOR is a master inhibitor of 
autophagy. Autophagy is up-regulated by stress signals such as hypoxia, ROS and 
DNA damage.  
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A number of small molecules have been found to activate autophagy; some of them 
have shown potential to be used to treat protein aggregate diseases ( as reviewed in 
[47] and [48]). Rapamycin is an mTOR inhibitor and has been shown to reduce 
protein aggregates through up-regulation of autophagy [49]. Trehalose, an mTOR-
independent autophagy activator, is a chemical chaperone and how it activates 
autophagy is not fully understood. Resveratrol induces autophagy through 
deacetylase sirtuin 1. Other molecules such as Ca2+ channel inhibitors, calpain 
inhibitors and dopamine antagonists have also been shown to inhibit autophagy in 
an mTOR-independent way [48]. Autophagy is an important mechanism that 
mediates the clearance of protein aggregates. These molecules have shown 
protective effects against protein neurodegenerative diseases such as Huntington’s 
[47].  
 
1.2.2 Initiation of autophagy  
 
To date more than 30 genes in yeast [50] have been identified to be directly 
involved in the execution of autophagy, they are known as the Atg gene family. 
Most Atg proteins are well conserved from yeast to mammalian cells and it is likely 
that there are more autophagy related genes expressed in higher eukaryotic cells 
[51]. ULK1 and ULK2 (Unc-51 like kinase) are the mammalian homologues of 
yeast Atg1.  They are found in a stable complex with Atg13 and FIP200 (focal 
adhesion kinase family-interacting protein). As demonstrated in Fig. 1.2, mTORC1 
is a molecular switch for autophagy in response to glucose, amino acids, growth 
factors and DNA damage. mTORC1 phosphorylates all members of the Atg13-
ULK-FIP200 complex during nutrient replete conditions and this leads to the 
inhibition in the kinase activities of the complex. The initiation of autophagy is 
constitutively kept at low levels. The activity of the Atg13-ULK-FIP200 complex is 
controlled by phosphorylation at different sites. During starvation, mTORC1 kinase 
activity is suppressed in response to the lack of growth factor signalling, ULK1/2 
complex is activated through auto-phosphorylation and it in turn  phosphorylates 
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Atg13 and FIP200 [52]. Activated Atg13-ULK-FIP200 complex drives the 
induction of autophagy.  
 
During the initiation of autophagy, double membranes are isolated to form a unique 
structure termed a phagophore. Phagophores elongate to sequester cellular contents 
such as proteins and organelles. There has been much debate on where the 
membrane forming phagophore / autophagosome originates. Based on studies of 
specific markers on autophagosome membranes, it was speculated that it came from 
plasma membrane and/or mitochondrial membrane and/or ER [53] [54]. There were 
no direct experiments demonstrating the origin of autophagosomes, until recently, 
Hamasaki and colleagues have shown compelling direct evidence that 
autophagosomes form at the contact sites between mitochondria and ER [55].  
 
There are a number of genes critical for phagophore formation (Fig. 1.1). Beclin 1 
protein is the mammalian ortholog of yeast Atg6; it provides structural scaffolding 
for autophagosome biogenesis. Beclin 1 was first discovered as an interacting 
partner of anti-apoptotic protein Bcl-2 [56]. Bcl-2 sequesters Beclin 1 through 
interaction with the Beclin 1 BH3 domain. This interaction can be disrupted either 
by competitive replacement by other proteins containing BH3 domains or by 
phosphorylation of Bcl-2 [57]. During starvation, Beclin 1 is released from the Bcl-
2 complex. Free Beclin 1 then forms a core complex with Vps34 and Vps15, two 
proteins involved in vacuolar sorting pathways. Vps34 is a class III 
phosphoinositide-3-kinase (PI3K) [58] and Vps15 is a non-catalytic regulatory unit 
in the complex.  
 
In the nutrient replete state, AMBRA (autophagy/beclin-1 regulator 1) protein binds 
to the PI3K core complex through interaction with Beclin 1, and it tethers the 
complex to the dynein cytoskeleton. AMBRA is activated by ULK1 through 
phosphorylation during autophagy, releasing the PI3K core complex to sites of 
phagophore nucleation [59]. The Beclin core complex can recruit other subunits, 
forming protein complexes that regulate autophagy or other membrane trafficking 
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events differentially. ATG14 is the mammalian homologue of yeast Atg14L, it is 
also known as BARKOR (Beclin 1-associated autophagy-related key regulator) [60]. 
[Vps15-Vps34-Beclin]-ATG14 targets the protein complex to sites of phagophore 
nucleation, now known to be the contact sites between mitochondria and ER. It was 
recently discovered that the activated Atg13-ULK-FIP200 complex phosphorylates 
Beclin-1 on Ser14 to enable autophagy induction of Vps15-Vps34-Beclin]-ATG14 
complex  [61]. The kinase activity of the Vps15-Vps34-Beclin complex converts 
phosphatidylinositol (PI) to phosphatidylinositol 3-phosphate (PI3P), leading to an 
enrichment of PI3P on the inner membrane where the autophagosome is to be 
formed. PI3P in turn recruits the Atg18−Atg2 complex [62]. UVRAG (UV-
irradiation-resistance-associated gene) is another binding partner to the [Vps15-
Vps34-Beclin] PI3K complex. It is mutually exclusive to ATG14L and is also a 
positive regulator of autophagosome formation [63].  These initial events mark the 
initiation of autophagy.  
 
1.2.3 Elongation of autophagosomes during autophagy  
 
During the elongation stage of autophagosome formation, two molecular 
conjugation systems are recruited to the PI3P signalling hub on the inner membrane 
of autophagosomes. They are the Atg12-Atg5-Atg16 complex and the LC3-
phosphatidylethanolamine (PE) complex. Autophagy conjugation systems share 
structural and functional similarities to ubiquitin conjugation pathways during 
proteasomal degradation. Proteasomal target proteins are covalently tagged with 
ubiquitin molecules on lysine residues. Three enzymes are involved in the process, 
namely E1, E2 and E3. E1 is the ubiquitin-activating enzyme, which covalently 
attaches the ubiquitin molecule onto itself. The ubiquitin on E1 is subsequently 
transferred to the intermediate protein E2, before it is finally transferred to the E3 
ubiquitin ligase. As ubiquitination progresses, specificity increases. E3 protein 
mediates target substrate protein recognition and the transfer of ubiquitin from E2 
to target protein [64].  
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Figure 1.3 Two conjugation systems are required for the formation and 
elongation of phagophores into an enclosed autophagosome.  
 
A series of conjugation events converts LC3-I to LC3-II and leads to the formation 
of the Atg12-Atg5-Atg16 complex.  
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As illustrated in Fig 1.3, Atg7 is an E1-like enzyme which activates and covalently 
transfers ubiquitin-like protein Atg12 to an E2-like enzyme Atg10. Atg10 in the 
Atg10-Atg12 complex is then replaced by Atg5. Atg16L (Mammalian homologues 
of yeast Atg16) is subsequently recruited, forming the Atg12-Atg5-Atg16L 
complex. Atg16 targets the complex to the membrane of the phagophore [65]. 
 
In the other conjugation system, newly synthesised LC3 (Atg8 in yeast) was first 
processed by cysteine protease Atg4 forming cytosolic LC3-I [66]. Upon autophagy 
induction, E1 like Atg7 activates LC3-I and transfers it to the E2-like enzyme Atg3, 
Atg12-Atg5 covalently attaches PE to LC3-I, which leads to the formation of the 
LC3-II–PE complex. Atg16L in the Atg12-Atg5-Atg16L complex facilitates the 
localisation of the anchoring LC3-II-PE complex to phagophores. These two 
conjugation systems are crucial for phagophore elongation and enclosure; 
phagophores eventually fuse at both ends to form enclosed autophagosomes. 
 
1.2.4 Fusion of autophagosomes with lysosomes  
 
Completed autophagosomes are transported towards endosomes and lysosomes 
along actin microfilaments and microtubules. Autophagosomes eventually fuse with 
endosomes and/or lysosomes. The fused vesicles are sometimes referred to as 
autolysosomes. The molecules involved in this step are part of the membrane-
trafficking pathways and are less specific to autophagy. Lysosome-associated 
membrane protein LAMP2 and the small GTPase Rab7 are essential for the docking 
and fusion of autophagosomes with lysosomes [67].   
 
Once the cargoes of autophagosomes are degraded in the lysosomes, cellular 
building blocks such as amino acids, carbohydrates and lipids are released from the 
vacuoles into the cytoplasm where they can be picked up and re-used. Lysosomes 
are not exclusive to autophagic pathways; endosome vesicles resulting from 
endocytosis also fuse with autophagosomes or lysosomes.  
 
 29 
Amino acids are actively transported by proton-powered transporters embedded in 
lysosomal membranes [68] [69], and it is less clear how other building blocks are 
released and recycled. As mentioned previously, mTORC1, the master regulator of 
autophagy, is localised to the surface of lysosomes in response to amino acid 
release. The redistribution of mTORC1 to the lysosomes is essential for mTORC1 
activation and subsequent inhibition of autophagy [27] [70]. This feedback 
mechanism avoids over-activation of autophagy, which can be detrimental to the 
cells.  
 
During nutrient replete conditions, the cellular pool of amino acids is mainly 
mediated by the proteasomes [71].  Inhibition of proteasome leads to shortage of 
amino acids in the cells and an up-regulation of autophagy activities [72]. During 
starvation, autophagy is up-regulated as an adaptive mechanism and is thought to be 
the main source of amino acids. It was reported that during starvation, amino acid 
levels decrease in the absence of autophagy [73] [74].  
 
Macroautophagy involving the formation of autophagosomes can also take place in 
an Atg5/Atg7 independent way [75]. Atg5/Atg7 independent autophagosomes differ 
from conventional autophagosomes, and they orginate from the membranes of 
trans-Golgi and late endosomes [75]. This alternative macroautophagy pathway is 
activated by metabolic stress and is found to play a role in erythrocyte development 
[75]. It may have a role in other physiological processes. It is not completely 
understood how Atg5/Atg7 independent autophagy is regulated or its relative 
importance in different organs. It remains to be determined what is the relative 
contribution of bulk protein degradation through this pathway in the cells.  
 
It has been 20 years since the process of autophagy was first characterised in yeast 
[76]. Since then a wide range of physiological functions of autophagy have been 
discovered and it has been found to be linked with human aging and disease.  
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1.3 The importance of autophagy in human aging and disease. 
  
Considering the important role of autophagy in maintaining cellular homeostasis 
and integrity, it is not surprising that loss of autophagy would perturb this balance 
and result in human diseases. Autophagy plays a role in a number of physiological 
aspects and it has been implicated in a spectrum of pathological conditions 
including neurodegenerative disorders, infections, autoimmune diseases, diabetes,  
muscular diseases and cancer [50]. It is also found to play a role in human aging. A 
summary of the role of autophagy is shown in table 1.  
 
 
 
Health and 
diseases 
Pro or against 
diseases 
Mechanisms 
Aging Pro Autophagy plays a role in the clearance of 
damaged proteins and organelles [77] . 
Against 
 
Exact mechanism unknown. Up-regulation 
of autophagy has been linked to pre-mature 
aging in mouse models [78]. 
Autoimmune 
diseases 
Against 
 
Autophagy is involved in MHCII 
presentation and it maintains T cell and B 
cell homeostasis.  
Cancer Pro Autophagy can be utilised by cancer cells 
to promote cell survival. See Chapter 1.4 
Against 
 
Autophagy maintains cellular homeostasis 
through the removal of damaged proteins 
and organelles. See Chapter 1.4 
Diabetes Pro Fatty acids can up-regulate autophagy 
which contributes to pancreatic β-cell death 
[79]. 
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Against 
 
 Atophagy protects against diabetes-
induced cellular stresses in  β-cells (As 
reviewed in [80]). 
Infections Pro Certain microbes have even evolved 
mechanisms that utilize components of the 
autophagic machinery to facilitate viral 
maturation [81] 
Against Infectious agents are recognized and 
engulfed by autophagosomes which are 
then fused with lysosomes [82]. 
Muscular 
diseases 
Pro Excessive levels of autophagy can lead to 
muscle wasting and myopathies [83].  
Against 
 
Autophagy maintains cellular homeostasis 
through the removal of damaged proteins 
and organelles [83]. 
Neurodegenerat
ive disorders, 
Pro Abnormal clearance of β-amyloid proteins 
through autophagy generate disease 
promoting peptides [84]. 
Against 
 
Autophagy maintains cellular homeostasis 
through the removal of damaged proteins, 
protein aggregates and organelles [83]. 
 
Table 1 Summary of the role of autophagy in disease. 
 
Cells have developed precise mechanisms to rapidly remove misfolded or damaged 
proteins; this is mediated by the proteasome and autophagic pathways. If these 
proteins are not cleared and accumulate in cells, they can lead to increasing 
oxidative stress and cellular toxicity. In general, proteasomes degrade smaller 
proteins which are normally specifically recognised by E3 ligases. Autophagy, on 
the other hand, degrades bulky proteins and aggregates. In general, autophagy 
substrates are less specific, though a number of specific autophagy targets have 
been identified, such as p62 and NBR1. Autophagy is also capable of the 
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degradation of insoluble protein aggregates which can not access the catalytic 
cavity buried within the proteasome structures.  
  
In response to unfolded or misfolded proteins in the ER, mammalian cells are able 
to activate the ER stress response where chaperones are activated to carry out ER-
associated degradation. Autophagic pathways are also up-regulated by ER stress 
activating in parallel with ER stress chaperones [85]. Cells become more sensitive 
to ER stress and display increased cell death upon inhibition of autophagy [85]. 
Misfolded proteins result in neuronal inclusions or plaques in the brain, which are 
responsible for a number of neurodegenerative conditions [86] [87]. Autophagy 
deletion in mouse models has been linked to protein inclusion bodies in the brain 
and neurodegeneration [88] and autophagy has been found to be a crucial factor for 
neuronal development and homeostasis. Autophagy pathways have been linked to 
Alzheimer's disease [89], Huntington's disease [90], Parkinson's disease [91] and 
Creutzfeldt-Jakob disease [92]. These conditions often result from inheritable 
mutations, which lead to protein misfolding and aggregate formation. Autophagy 
plays a protective role against these orders.  A range of small molecule activators of 
autophagy have shown therapeutic potential in mouse models of Huntington’s 
disease [47].  
 
Ageing is a complex and unavoidable process influenced by a number of signalling 
mechanisms and environmental factors. In ageing cells, the accumulation of 
damaged organelles such as mitochondria and proteins is a common feature. Since 
autophagy is a housekeeping process that mediates the degradation of aberrant 
cytosolic proteins and organelles, it is not surprising that it plays a part in the ageing 
process. Genetic studies provide evidence that in Caenorhabditis elegans and 
Drosophila models, elevation of basal autophagy decreases the rate of ageing in 
cells and increases lifespan [93].  
 
Although autophagy is a mechanism of self-digestion, autophagic pathways have 
been utilized as a defense mechanism by mammalian cells. It takes part in the 
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removal of invading microorganisms such as bacteria, viruses, protozoa and 
parasites [94] [95] [96]. Autophagy has been found to be up-regulated during 
infections. Infectious agents are recognized and engulfed by autophagosomes which 
are then fused with lysosomes. For example, when inside cells, the bacterium 
Legionella pneumophila which is responsible for Legionnaires' disease forms 
vacuoles, the vacuoles are recognized and ubiquitinated [82]. The vacuoles then 
bind to specific autophagy adaptor protein p62/SQSTM1 and are engulfed [82]. 
However, under selective pressure, certain bacteria and viruses have developed 
strategies to antagonize autophagy functions to avoid removal. The Bacterium 
Shigella flexneri avoids recognition by autophagic pathways and hence removal by 
expressing modified surface proteins [97].  Some microbes have even evolved 
mechanisms that utilize components of the autophagic machinery to facilitate viral 
maturation [81]. A better understanding of the roles of autophagy in infection would 
be beneficial to the studies of autophagy in other diseases such as cancer and also to 
the development of anti-bacterial or anti-viral therapies. 
 
Aberrant autophagy activity has been linked to the pathogenesis of autoimmune 
diseases such as multiple sclerosis (MS) [98] and lupus [99]. These autoimmune 
diseases are characterized by deregulated immune responses against the body’s own 
cells or tissues. Rapamycin, which activates autophagy through inhibition of 
mTORC1, displays immunosuppressant properties. It has shown therapeutic 
potential to treat lupus in pre-clinical studies [100].    
 
A number of mouse models, especially genetic knockout models, have been 
established to investigate the roles of autophagy in human pathology. Studies in 
mouse models have confirmed the links between autophagy and these diseases 
described above. Targeted deletion of autophagy essential genes 
Atg5 or Atg7 in mice lead to an accumulation of poly-ubiquitinated proteins in 
neurons and in turn lead to neuro-degeneration. Rapamycin, an autophagy inducer, 
has been found to prolong the lifespan of mice. Female mice have been found to 
live longer by 14% and male 9% when rapamycin administration starts at 600 days 
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of age [101]. p62 knockout mice also presented accelerated aging, and defective 
mitochondrial functions and increased oxidative stress were detected in these mice 
[102]. Studies in mouse models have also confirmed that autophagy is crucial for T 
cell and B cell survival. Mice with Atg5 or Atg7 deficiency have elavated amount 
of mitochrondria in T cells which lead to cell death [103]. Targeted deletion of Atg5 
in B cells also lead to increased B cell death [104]. Targeted ablation of Atg7 in 
muscle result in smaller myofiber in mice and the degenerative phenotype is 
manifested with age [105]. Moreover, GFP-LC3 transgenic mice have been 
generated by Mizushima and colleagues, the detectable LC3 punctate corresponds 
to autophagic activities [106].  
 
Since the first genetic link was established between autophagy and cancer in 1999, 
when Beclin 1 gene was found to be frequently deleted in human cancers [56], there 
has been an explosion in autophagy research in the context of cancer. Like most 
areas of scientific exploration, the more knowledge we gain in the field, the more 
we realize how much work remains to gain full understanding of the role autophagy 
plays in cancer.  
 
1.4 The complex role autophagy plays in tumourigenesis  
 
The functions and outcome of autophagy in cancer are highly context specific; 
paradoxically it can either promote cancer cell survival [107] or cancer cell death 
[108]. For this reason, reports have referred to autophagy as ‘a double edged sword’ 
or ‘janus-faced’ [109, 110]. Understanding the exact role of autophagy in cancer 
under each context has now become a priority.  
 
Cancer development is a highly complicated, multi-step process where normal cells 
go through a series of aberrant transformations that involve a global change in gene 
expression, into malignant cells that proliferate uncontrollably and invade into other 
parts of the body [111]. Cancer itself is a diverse group of diseases, and there are 
more than 100 distinct types of cancer [7].  The carcinogenesis of each cancer is 
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varied; only 10% of all cancers are due to germline mutations such as in genes such 
as TP53 or BRCA1/2 genes, the majority of cancers resulting from somatic 
mutations [112]. Oncogenesis is a multifactorial process; cancer epidemiology 
studies have revealed a number of risk factors such as ethnicity, diet, hormones, 
infections, weight, and radiation. Each type of cancer has a different set of risk 
factors.  
 
Cancer in general can be divided into three critical stages: initiation, promotion and 
progression. To become neoplastic, normal cells first acquire insensitivity to growth 
suppressors and undergo uncontrolled over-growth [7]. Tumour cells are able to 
evade programmed cell death and achieve replicative immortality. Primary tumours 
can migrate from the site of origination and invade into a secondary part of the body. 
Metastatic cancer can establish itself by recruiting blood supply and modify 
surrounding cells to form a tumour microenvironment [111]. As summarized in 
Figure 1.4, autophagy, being an important catabolic adaptive mechanism, plays 
important and complex roles in nearly all aspects of carcinogenesis.    
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Figure 1.4 Autophagy plays important and paradoxical role in every stage of 
carcinogenesis 
 
Autophagy is active constitutively at basal levels to maintain cellular homeostasis 
and limit genomic damage. These autophagic functions are thought to inhibit 
primary tumour formation. In order for tumour cells to invade into a secondary 
location, cancer cells need to detach from the primary tumour. Anoikis, which is a 
type of programmed cell death activated when cells are detached from the 
extracellular matrix (ECM), can occur. Autophagy has been found to promote 
cancer cell survival against anoikis. Paradoxically, autophagy inhibits angiogenesis 
which is needed by a solid tumour to recruit increased blood supply. Finally, 
autophagy can be a pro-survival mechanism for cancer cells to deal with metabolic 
stress especially in regions where blood supply is limited.  
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1.4.1 Autophagy plays a role of tumour suppressor during oncogenesis  
 
Autophagy was first linked with cancer through genetic studies. It was found that a 
number of autophagy genes are frequently lost in certain types of cancers. For 
example, human BECN1 (a gene encoding beclin 1) is hemizygously-deleted in 
around 50% of breast, ovarian and prostate cancers [113] [56]. Autophagy and 
apoptosis share certain upstream signals and Beclin 1 is thought to be one of the 
major convergence molecules for the two processes. Monoallelic deletion of beclin 
1 in mice increased the incidence of cancer including hepatocellular carcinoma, 
lung carcinoma and lymphoma [114]. When beclin 1 was stably transfected into 
MCF-7 cells, autophagy activities were up-regulated [56]. The tumourigenesis of 
these cells was decreased after injection in nude mice [56].  
 
A number of autophagy executor genes, ATG2B, ATG5, ATG9B and ATG12 have 
also been linked to carcinogenesis [115]. It was discovered that frame-shift 
mutations in these ATG genes with mononucleotide repeats are common in gastric 
and colorectal carcinomas with microsatellite instability [115]. Tumour suppressor 
genes prevent the cells from progressing to cancer, and pre-malignant cells with 
genetic instability frequently develop loss-of-function mutations in these genes. The 
fact that a number of autophagy genes are lost in cancers indicates that autophagy 
can act as a tumour suppressor.  
 
Several genetic studies in mouse models also show that autophagy can prevent 
tumour formation. For example, the lack of certain autophagy genes such as BECN1 
[114] can lead to cancer. In contrast, Beclin 1 over-expression, which leads to up-
regulation of autophagy, can inhibit tumour development [56]. Also, mice form 
benign liver adenomas after either mosaic deletion of Atg7 specific in the liver or 
mosaic deletion of Atg5 [116].   
 
Autophagy can inhibit the initiation of tumourigenesis through limiting genomic 
instability and inflammation [107]. Defective proteins and mitochondria generate 
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excessive free radicals that saturate the cells ability to scavenge them and these free 
radicals lead to reactive oxygen species and oxidative stress. Free radicals can 
attack DNA molecules, leading to structural lesions. If unrepaired, these DNA 
lesions result in genetic mutations which may eventually contribute to genetic 
instability [117]. Normal cells undergo a series of genetic changes to become 
transformed cancer cells and genetic instability is one of the most important factors 
for carcinogenesis. For pre-malignant cells, genetic instability enables them to 
diversify, evolve and finally to acquire mechanisms to reach malignancy [7].  
 
A few mechanisms have been proposed to explain how autophagy acts as a tumour 
suppressor. Autophagy mediates the degradation of mitochondria in a process 
referred to as mitophagy, accumulation of defective mitochondria contributes 
towards increased oxidative stress and carcinogenesis [118]. Autophagy regulates 
p62 levels in the cells and loss of autophagy leads to p62 accumulation, which 
contributes to tumourigenesis [119]. Autophagy also limits inflammation and 
mediates oncogene-induced senescence [119].  
 
Mitochondria in the cells are specifically turned over by autophagy as a way of 
controlling the amount of mitochondria and also to remove damaged ones. The 
selective engulfment of mitochondria by autophagy is refered to as mitophagy.  
Parkin is a ubiquitously expressed E3 ligase that plays a role in Parkinson’s disease. 
It is activated and recruited to damaged mitochondria by PINK1 (PTEN-induced 
putative kinase protein 1) protein [120]. The outer layer of the mitochondrial 
membrane is ubiquitinated by Parkin and p62 is also recruited to mitochondria to 
mediate mitophagy [121]. The expression levels of parkin have been found to be 
down-regulated or ablated in a number of cancers including ovarian and breast 
cancers and leukemia [122].  It should be noted that the tumour suppressive role of 
parkin may also be due to its role in the regulation of glucose metabolism. The loss 
of parkin up-regulates glycolysis and inhibits mitochondrial respiration, resulting in 
the Warburg effect [123]. Defective mitophagy is directly linked to tumourigenesis 
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in mouse models [124]. ROS accumulates in mitophagy deficient cells and in turn 
this promotes genetic instability and cancer.  
 
p62, also known as sequestosome-1 or SQSTM1 is a cytoplasmic protein with 
multiple functions. It contains a ubiquitin binding domain and an LC3 binding 
domain [125]. In general autophagy is a bulk degradation process that non-
selectively engulfs organelles and cytoplasm. p62 is a autophagy receptor molecule 
that can mediate selective autophagy [125]. It can act as a ubiquitin-binding 
chaperone that recognises and sequesters specific ubiquitinated cargoes destined to 
be degraded by autophagy. For example, p62 has been found to surround mutant 
huntingtin aggregates and reduce the cytotoxicity of protein aggregates by 
promoting their autophagic degradation [126]. p62 is also a regulator of 
mitochondrial dynamics and functions [127] [128]. The degradation of p62 itself is 
mediated by autophagy, and the lack of autophagy leads to accumulation of p62 in 
the cells [129]. dIn healthy cells, p62 serves as a protective scavenger, removing 
potentially toxic protein waste (e.g. misfolded proteins) from the cells through 
autophagic degradation; however the beneficial role of p62 is reversed when there 
are elevated levels of p62 in the cells. Excessive intracellular p62 due to loss of 
autophagy has been found to have a number of detrimental effects on the cells. It 
has been found to be responsible for the formation of ubiquitin-positive protein 
aggregates in the cells, which correlate closely with neurodegeneration, liver injury 
and hepatocellular carcinoma [130]. Accumulation of p62 has also been linked with 
increased ROS production which promotes endoplasmic reticulum (ER) stress and 
accumulation of DNA damage [119].  
 
Nrf2 is ( nuclear factor-erythroid 2-related factor-2) is a transcription factor that 
plays dual roles in tumourigensis. It can reduce ROS levels and protect the cells 
from oxidative damages, but it also assists cancer cell survival and progression [131] 
[132] [133]. Nrf2 protein is constitutively turned over in the proteasomes, by 
binding to an adaptor protein of the ubiquitin ligase complex - Keap1 (kelch-like 
ECH-associated protein 1) [134]. p62 interacts with Keap1 through Nrf2-binding 
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site,  excessive p62 disrupts the interactions between Keap1 and Nrf2, leading to the 
stabilization of Nrf2 [131]. Over activation of Nrf2 proteins, through inactivation of 
Keap1 or over-expression of p62, have been reported in a number of human cancers 
[135].  
 
Moreover, p62 is often found to be up-regulated in human cancers and this is 
thought to promote tumorigenesis [119]. In this regard, the link between p62 
accumulation from defective autophagy and oncogenesis was also shown in a study 
where p62 knock-out mice were found to be protected from Ras oncogene-induced 
lung carcinomas relative to Atg7f/f counterparts [136].  
 
The lack of autophagy leads to increased inflammation. Inflammation is a localized 
protective mechanism in tissues of higher eukaryotes in response to irritation, injury 
or infection. During inflammation, blood vessels are dilated and the rate of blood 
flow increased. Leukocytes and macrophages migrate through the blood vessels into 
areas of inflammation in order to clear away injured tissues or infections. 
Inflammation is now thought to play important roles during the multiple stages of 
carcinogenesis [112][111]. Chronic inflammation caused by bacterial infections, 
viral infections, tobacco smoking [137] and obesity increases cancer risk [138, 139]. 
Multiple kinds of innate immune cells are often found in tumours. These immune 
cells produce cytokines, chemokines, growth factors and ROS, which contribute to 
uncontrolled cell growth and genetic instability and hence promote tumour 
progression. One of the hallmarks of cancer is its ability to evade recognition by 
immune cells [7] and it is generally accepted that in more established tumours, the 
inflammation and immune responses are more pro-tumourigenic.  In an 
inflammatory microenvironment cancer cells have increased growth rate and 
mutation rates [140]. 
 
Autophagy may protect against tumorigenesis by limiting chronic necrosis and 
inflammation. Hepatocellular tumours due to disruption of the BECN 1 gene display 
increased inflammation which is thought to promote tumourigenesis [114]. In the 
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context of cancer, autophagy plays a role in inflammation through at least two 
mechanisms.  
 
Firstly, cells undergoing apoptosis are cleared efficiently by phagocytes in normal 
tissues, without the activation of the immune systems [141]. If these apoptotic 
corpses remain un-cleared, they can potentially lead to necrosis. Necrotic cells  
release signals to recruit inflammatory cells of the immune system and this 
increases tumour-promoting potential [112]. Autophagy plays a role in the 
engulfment of the apoptotic corpse, thereby limiting inflammation. Secondly, 
tumour cells often acquire defective apoptotic pathways to evade cell death. If 
autophagy is down regulated in these cells, it also leads to necrosis [142].  In mice 
with Atg5 deletions, their retinas and lungs display infiltration of inflammatory 
cells due to a defect in apoptotic corpse clearance [143]. Autophagy pathways are 
required for the release of signals by apoptotic cells to attract engulfment, a process 
which limits inflammation. The autophagy pathway has also been reported to 
negatively regulate inflammatory signalling, for example, caspase 1 activity and IL-
1β production, both of which are pro-inflammatory signals that can be regulated by 
autophagy [144-146].  
 
Autophagy’s role in innate and adaptive immune responses is implicated in 
immuno-surveillance for pre-malignant cells. Immuno-deficient mice are prone to 
spontaneous and chemically induced cancers [147]. Patients with prolonged 
treatment of immunosuppressant drugs after transplant operations have a markedly 
higher chance of developing cancer [148]. Autophagy is crucial for T cell 
development, proliferation and differentiation [149], and is important in 
macrophage functions [150]. Autophagy is also required for antigen presentation on 
MHC II (major histo-compatibility complex class II) molecules.  
 
Additionally, autophagy contributes towards tumour suppression by playing a role 
in inducing senescence. Senescence is a phenomenon where diploid cells withdraw 
from cell cycle progression and cease proliferation. Alongside programmed cell 
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death, cellular senescence acts as a barrier to oncogenesis [151]. Senescence can be 
triggered by DNA damage or the activation of oncogenic signals, and autophagy is 
found to mediate the establishment of oncogene-induced senescence [152].  
 
All studies described above provide both genetic and mechanistic evidence that 
autophagy can act as a tumour suppressor, especially in the initial stages of 
tumourigenesis. As mentioned before, constitutively active autophagy functions to 
provide cells with nutrients and removes defective proteins and organelles, assisting 
cells to deal with stressful metabolic environments. Therefore it is not surprising 
that autophagy plays a role in promoting tumour formation. There are studies 
providing evidence that autophagy pathways can be utilized by cancer cells to 
promote survival and establish malignancy, as reviewed in the following paragraphs 
(Chapter 1.4.2).   
1.4.2 Autophagy can also promote tumour progression 
 
During the initial stages of oncogenesis, cancer cells undergo uncontrolled 
proliferation and avoid programmed cell death; solid tumours frequently encounter 
harsh environments such as hypoxia and the lack of nutrients. Autophagy is 
frequently up-regulated in solid tumours, especially in the core region of the tumour. 
In less perfused areas, there is limited availability of nutrients (growth factors, 
amino acids etc) and oxygen [153]. Autophagy is thought to maintain energy 
metabolism and help cancer cells deal with the harsh conditions until the 
environment is improved. In this regard autophagy can act as a survival mechanism 
promoting cancer cell survival and propagation [154].   
 
Certain cancer cell lines display higher basal autophagic activities to maintain their 
energy balance. When these cells encounter stressful environments, they often fail 
to elevate autophagy activities much further. They are described to be addicted to 
autophagy pathways [155]. For example, pancreatic cancers have constitutively 
high levels of autophagy and they require autophagy to survive and progress. These 
pancreatic cancer cells are exquisitely sensitive to autophagy inhibition [156]. RAS 
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is a well characterised oncogene that promotes cancer growth; RAS signalling also 
activates autophagy and cancer cells driven by mutant RAS depend on autophagy to 
promote oncogensis.  There is a synthetic lethal situation when autophagy is 
inhibited in cancer cells with RAS hyper-activation [157].  
 
Cancers do not progress and metastasize in isolation; they require the appropriate   
tumour microenvrioment which is characterized by the presence of a variety of 
factors including immune cells, endothelial cells, fibroblasts and ECM (Extra 
Cellular Matrix) [158]. Tumour microenvironment plays a decisive role in cancer 
prognosis and responses to therapeutics. Autophagy has been found to influence 
nearly every aspect of the tumour microenvironment:  Autophagy in endothelial 
cells is found to mediate hypoxia induced angiogenesis [159]. It acts as a mediator 
in both adaptive and innate immune responses [160]. Autophagy limits 
inflammatory responses and necrosis (Chapter 1.5.1), however it is found that 
autophagy can act as an alternative secretary pathway for inflammatory molecules 
(e.g. chemokines and cytokines) and ECM modulators, in a process termed 
‘autosecretion’ [161] [162]. Autophagy-mediated cancer cell senescence limits 
oncogenic potential; however, the autophagy-senescence transition in cancer-
associated fibroblasts has been found to promote tumour growth [163]. These 
fibroblasts undergo constitutively active mitophagy and they undergo elevated 
aerobic glycosis producing and secreting ketone bodies, lactic acid and fatty acids 
that fuel neighbouring cancer cell growth [164]. 
 
The oncogenic role autophagy plays is supported by several genetic studies. For 
example, depletion of FIP200, a gene essential for autophagy, inhibits RAS 
oncogene-driven mammary carcinogenesis [165]. As mentioned previously, mice 
with mosaic deletion of Atg5 or deletion of Atg7 in the liver leads to benign 
tumours. It should be noted that these tumours do not progress into malignant 
adenocarcinoma or acquire the capacity to metastasize. This indicates that cancer 
cells may require autophagy to become more established and achieve malignancy 
[116]. 
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1.4.3 Autophagy promotes metastasis  
 
Metastatic cancer is the main cause of lethality in cancer patients [166]. A number 
of studies have demonstrated that autophagy plays a role in metastasis. For example, 
recent work from our lab using a 3D organotypic model demonstrated that the 
inhibition of autophagy in cancer cells impairs their invasiveness [167].  DRAM1, a 
p53 target gene that regulate autophagy and p62, a selective autophagy substrate 
have been demonstrated to regulate cell motility and invasions in glioblastoma stem 
cells [168].  
 
TNF-related Apoptosis Inducing Ligand (TRAIL) mediates death-ligand-induced 
apoptosis in cells and it is found to be crucial for the suppression of metastasis 
[169]. Autophagy contributes to the resistance to TRAIL mediated cell death in 
cancer cells [170].  
 
In order to metastasize, cancer cells from primary tumours need to detach from 
extracellular matrix (ECM), migrate through blood vessels and invade into 
secondary tissues, where they can settle, expand and colonize. When normal cells 
are detached from the ECM, they undergo a type of apoptosis termed anoikis [171]. 
Cancer cells acquire the capacity to evade anoikis and achieve anchorage-
independent growth. A number of pathways have been identified to be involved in 
this critical step of tumourigenesis, including aberrance in Ras and PI3K cell 
proliferation signal pathways [171]. Autophagy is not only able to assist cancer cell 
survival in the blood stream by maintaining energy balance; it also has been found 
to be activated during anoikis and it is thought to be one of the mechanisms that are 
utilized by cancer cells to promote metastasis [172]. Isolated metastasising cancer 
cells eventually establish interaction with ECM in a distant organ.  
 
Some cancer patients can develop recurrent metastatic cancer after a dormancy 
period that can last from years to decades. The cause of this can be explained by 
tumour cell dormancy [173]. Primary tumour cells can metastasize to distant 
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secondary sites and enter a dormancy period before resuming malignancy. These 
cells are difficult to detect and can evade conventional anti-cancer therapies that 
target rapidly growing cancer cells [174]. Autophagy has been shown as a pro-
survival mechanism for cancer cells in dormancy [175].  
 
In summary, autophagy limits tumour initiation by maintaining cellular homeostasis, 
limiting genetic instability and inflammation; however it promotes tumour 
establishment and progression by enabling cancer cells to cope with the harsh 
environment during cancer development and to evade cell death [176].  
 
1.5 The role of autophagy in cancer therapeutics 
 
1.5.1 Autophagy is frequently up-regulated by cancer therapeutic drugs. 
 
The important role autophagy plays in carcinogenesis provides the possibility that 
autophagy may be targeted for cancer therapy. However, the role of autophagy in 
cancer therapeutics is also highly context dependent. It may be a pathway induced 
by cancer therapeutics to achieve drug efficacy or it may be a pro-survival 
mechanism promoting drug resistance.  
 
A variety of cancer therapeutic treatments have been shown to up-regulate 
autophagy in cancer cells (Fig. 1.5).  
 
These autophagy inducing treatments include conventional DNA damaging agents 
such as IR [177], etoposide and camptothecin [178]; novel targeted drugs such as 
the estrogen receptor inhibitor taxomifen, anti HER2 receptor antibodies, tyrosine 
kinase inhibtors and proteasome inhibitors [179]. In some cases, autophagy levels 
are elevated as a secondary adaptive mechanism struggling cancer cells use to 
promote survivial. Increasing number of novel anti-cancer drugs up-regulates 
autophagy by targeting the PI3K/Akt/mTOR pathways [180] and this is an 
undesired effect that enables cancer cells to cope with stressful environment. 
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Figure 1.5 Anti-cancer treatments frequently lead to autophagy activation. 
 
(Information from this figure was compiled from references [177-179]). The 
diagram illustrates that current anti-tumour drugs are developed against a number of 
pathways. Through various anti-cancer mechanisms, these anti-cancer drugs (In 
green circles) frequently up-regulate autophagic activities. Generally it is thought 
that autophagy in this context was induced by cancer cells to deal with the toxicity 
and promote cell survival. Cancer cells have been found to be hyper-sensitive to 
autophagy inhibitors such as chloroquine (CQ) and 3-Methyladenine (3-MA) (In 
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red circles) in combination with other anti-cancer drugs. CQ has been selected to 
enter clinical trials as part of anti-cancer therapy.   
1.5.2 Certain cancer therapies require autophagy to achieve maximal efficacy  
 
Autophagy can assist cells to cope with cytotoxicity until the environment has 
improved but it does not maintain cell viability in a sustainable way. Autophagy is a 
catabolic mechanism that recycles energy and cellular building blocks through self-
eating. Over stimulation of autophagy can lead to cell death. The pro-death 
properties of autophagy are thought to play a positive role in anti-cancer treatments. 
As mentioned previously, many cancer cells develop defects in apoptotic pathways 
to evade cell death during their transformation. Autophagy induced by anti-cancer 
treatments can serve as an alternative mechanism to elicit cell death in cancer cells 
[9]. For example, triptolide, an agent that efficiently inhibits pancreatic cancer cell 
growth, is found to destroy cancer cells through the induction of autophagy [8].   
 
Cancer therapies induce cell death, and the dying cells may act as signals that 
recruit the immune system to target residual tumour cells [181]. Certain drugs such 
as anthracyclines and oxaliplatin are found to induce immunogenic cell death and 
these agents require the immune system to be effective [182]. ATP is released by 
dying cancer cells following cancer treatment, and it is critical for chemotherapy 
induced immune response against cancer cells [183]. Autophagy in cancer cells has 
been found to be a crucial factor for their immunogenicity [6]. A study by Guido 
Kroemer and colleagues demonstrated that only autophagy proficient cancer cells 
can release ATP when they undergo cell death and autophagy deficient cancer cells 
fail to attract dendritic cells and lymphocytes into the tumour [6].  
 
Rapamycin (and its derivatives) have shown promising therapeutic potential for 
cancer treatment because of their anti- proliferation and immunosuppressant 
properties [184]. Rapamycin leads to up-regulation of autophagic activities through 
mTOR inhibition; a number of recent studies have shown that autophagy is in fact a 
 48 
critical factor for the anti-tumour effects of rapamycin [185] [186]. Cytotoxicity 
inflicted by rapamycin in cancer cells is attenuated when autophagy is inhibited.   
 
In summary, autophagy is up-regulated by a number of chemotherapeutic drugs and 
certain drugs require autophagy to achieve maximal efficacy. A screening study 
carried out in Kroemer’s team tested for autophagy, apoptosis and necrosis 
induction of chemotherapeutic drugs. 59 out of 1400 drugs potently activate 
autophagy in cancer cells, however none of these drugs kill cancer cells via 
autophagy [187]. The study indicates that in most cases, autophagy may be a cyto-
protective mechanism. It may be postulated that inhibition of autophagy in 
combination with these drugs would not reduce drug efficacy during in 
chemotherapy and actually may enhance synergistic killing of cancer cells.  
 
1.5.3 Autophagy as a cytoprotective mechanism promoting cancer survival 
during cancer treatment  
 
Cancer cells have a resilient nature and can develop drug resistance through a 
number of pathways, and autophagy overall is a pro-survival response that assists 
cells to deal with a range of cytotoxic insults. In some cases autophagy is induced 
as a pro-cancerous mechanism during cancer treatments, and it can be exploited by 
tumour cells to promote survival and recovery against cancer therapeutic drugs 
[188].  
 
There has been compelling evidence that inhibition of autophagy promotes cancer 
cell sensitivity to certain cancer therapeutic treatments such as IR, tyrosine kinase 
inhibitors [189] and Src kinase inhibitors [190]. Moreover, although autophagy can 
inhibit tumour initiation, it promotes tumour progression and metastasis. These 
observations underscore the use of autophagy inhibitors as adjuvant anti-cancer 
therapies.  
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3-MA (3-methyladenine) and wortmannin are PI3K kinase inhibitors which block 
autophagy initiation. These agents have been evaluated in pre-clinical studies and 
have been found to potentiate the sensitivity of cancer cell lines to drugs such as 5-
FU and cisplatin [191] [192]. However these agents also affect other physiological 
processes and have a relatively high cytotoxicity at clinically relevant 
concentrations.  
 
Chloroquine is a drug that has been widely used to treat malaria and it is also used 
as an anti-inflammatory agent against rheumatoid arthritis and lupus. It is is well 
tolerated by non-transformed cells. Because autophagy is utilised by cancer cells as 
a survival mechanism and many current cancer therapies have been found to 
activate autophagy, the inhibition of autophagy may be beneficial to cancer patients. 
In fact, a correlation study carried out in the late 80s revealed that the use of anti-
malarial chloroquine was associated with lowered incidence of Burkitt lymphoma, 
which was an endemic in Africa around that time [193].  
 
There is increasing amount of evidence that chloroquitin has potentials as a death-
sensitising agent when used in combination with other cancer therapies [194]. A 
number of clinical trials have been carried out or in progress using the lysosomal 
inhibitor hydroxychloroquine (a derivative of chloroquine) as a part of cancer 
treatment (Details available at ClinicalTrials.gov). So far chloroquine is thought to 
be promising as a novel anti-cancer treatment [195]. For example, a randomised, 
and double blind trial revealed that chloroquine when used as combination therapy 
for glioblastoma multiforme, the patients survival time is doubled comparing to 
placebo control [195]. Since chloroquine inhibits all lysosomal functions and also 
has other functions in the cells such as activation of ATM and immnosuppression. 
The exact mechanism of anti-cancer properties of chloroquine is unknown but one 
likely mechanism is through autophagy inhibition. Whether the central anti-tumour 
action of chloroquine is due to the inhibition of autophagy or other functions of 
chloroquine remains to be determined.  
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In summary (Fig. 1.4), autophagy is frequently up-regulated by anti-cancer 
therapeutics and can assist drug resistance in cancer cells. Autophagy inhibiting 
drugs have shown promising effects in clinical trials. However in some scenarios, 
autophagy facilitates efficient killing by anti-cancer drugs. Therefore it is important 
to investigate the role autophagy plays during cancer treatment in a context 
dependent way, and to inhibit autophagy only when it is playing a pro-survival role.  
 
Because of its importance in tumourigenesis as well as cancer therapeutics, a better 
understanding of the functions of autophagy under specific contexts is of great 
importance. This is becoming one of the main areas for cancer research. Another 
critical area of cancer research is the DNA damage response. DNA damage 
response pathways are frequently altered in cancer cells and a great proportion of 
current drugs used to treat cancer are DNA damaging agents. Studies of DNA 
damage response not only helps to understand the carcinogenesis process, but may 
reveal additional therapeutic approaches in cancer treatment.   
 
Autophagy is a cytoplasmic process, whereas DNA damage and repair take place in 
the nucleus. There is an increasing amount of evidence that the two processes are 
closely linked. Under normal circumstances, autophagy is found to play a role in the 
maintenance of genomic integrity. It has been reported that depletion of autophagy 
leads to increased DNA damage in the cells. Cells lacking Atg7, a gene essential for 
autophagy, is reported to accumulate DNA aberrations including increased double 
strand breaks, polyploid nuclei and gene amplification [1] [2]. When the cells are 
challenged with DNA damaging agents, such as chemotherapeutic drugs, autophagy 
is frequently reported to be up-regulated [196]. As mentioned previously, inhibition 
of autophagy potentiates cancer cell sensitivity to DNA damaging drugs.  
 
The exact mechanisms how loss of certain autophagy genes such as Beclin1, Atg5 
and Atg7 lead to tumours remain to be determined. Because autophagy 
constitutively removes damaged proteins and organelles to minimise the production 
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of ROS in the cells, it is speculated that lack of autophagy leads to an increased 
incidence of DNA damage.  
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1.6 DNA damage response and cancer genetics  
 
Genomic integrity is crucial for higher life forms, since genetic mutations or 
chromosomal instabilities can lead to diseases which can be inheritable. One of the 
most distinctive traits of cancer cells is genetic instability, and the genetic alteration 
enables tumour cells to acquire a series of functions. These gain of functions are 
referred to as ‘the hallmarks of cancer’ [111]. Genetic instability is driven by a 
number of factors such as DNA damage accumulation, defective DNA repair 
machinery, and failure to prevent mitotic entry where DNA lesions get passed to 
daughter cells.     
 
In our body, genomic integrity is constantly being challenged. As each cell acquires 
1000 to 1,000,000 DNA lesions every day [197]. These lesions can block 
replication fork formation during DNA synthesis and can block transcription in the 
short term. If left unrepaired, these lesions induce genomic mutations and 
aberrations [198]. Some of the lesions are due to environmental factors such as 
untra-violet radiation (UV) and heavy metals. Some lesions are caused by 
physiological processes, for example, DNA replication apparatus such as DNA 
polymerases occasionally mismatch nucleotides during replication, and reactive 
oxygen species produced during the oxidative respiration chain can cause damage 
to the DNA as well. Luckily for most of us, most of this DNA damage is repaired 
efficiently by our complex DNA repair pathways. For difficult to resolve lesions, 
the cell can alternatively activate programmed cell death pathways. Occasionally, 
some DNA lesions escape being identified by DNA repair mechanisms and result in 
mutations. Humans have a mutation rate of around 1x10
-4
 - 1x10
-6
 per gamete for a 
given gene [199].  
 
The links between DNA damage accumulation and carcinogenesis have long been 
established. Two notable examples are skin cancer from over-exposure to the sun 
and lung cancer from tobacco smoking. UV radiation from the sun [200] causes 
mainly two types of lesions - cyclobutane pyrimidine dimers and 6-4 photoproducts. 
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Both of these are bulky in size and can lead to distortions in the helical DNA 
structure, hindering transcription and replication [201]. Carcinogens from tobacco 
such as polycyclic aromatic hydrocarbons and aromatic amines are able to react 
with DNA molecules directly or through intermediate metabolites [202].     
 
Defects in the DNA damage response (DDR) are responsible for certain human 
genetic disorders and people with these genetic traits are commonly pre-disposed to 
cancer. Notable disorders include ataxia-telangiectasia (AT), a neuro-degenerative 
motor disease due to the cell’s failure to resolve oxidative damage in the brain. 
Patients with AT mutations have defective ATM protein (more details will be 
covered in the next section). Xeroderma pigmentosum (XP), a condition 
characterized by extreme sensitivity to sunlight is due to a deficiency in the ability 
to repair damage caused by ultraviolet (UV) damage in the skin. People with AT 
have a 25% higher chance of developing cancer in their life [203] and fewer than 
40% of people with XP survive beyond the age of 20 [204]. Malignant melanoma 
and squamous cell carcinoma are the two most common causes of death in XP 
patients [204]. Besides the genetic disorders outlined above, a number of cancer 
specific susceptibility genes have been identified. Tumour suppressor gene TP53 
which encodes p53 is mutated or lost in a large proportion of human tumours [205]. 
People with mutations in BRCA genes are predisposed to various forms of cancers, 
especially breast cancer and ovarian cancer. BRCA 1 and 2 (Breast Cancer 1 and 2) 
are tumour suppressor proteins involved in the process of homologous 
recombination DNA repair process [206].  
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1.6 DNA damage response network  
 
Mammalian cells have evolved a complex set of DNA repair machinery dealing 
with the high incidence of lesion formations. There are three main aspects of DNA 
damage response; DNA repair, cell cycle arrest and apoptosis. They are tightly 
coordinated to minimise the amount of heritable mutations. Defects in these 
pathways can lead to human diseases including cancer, as discussed in the previous 
section.    
 
In the event of DNA damage, cells activate their cell cycle checkpoints to prevent 
DNA replication and also to provide an opportunity for the cells to repair the 
lesions. If the lesions fail to be repaired, programmed cell death can be activated. 
Checkpoint pathways share many common components with DNA repair response. 
Two master kinases, ATM and ATR are responsible for downstream signalling 
cascades that eventually lead to cell cycle arrest and DNA damage repair.  
1.6.1 Cell Cycle Checkpoints   
 
The cell cycle is tightly controlled in mammalian cells to ensure correct cell 
division and genomic integrity. If disrupted, potentially harmful genetic defects 
may be passed on to daughter cells.  A series of tightly regulated signalling events 
take place to arrest the cell cycle upon DNA damage, as illustrated in Fig. 1.6.  
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Figure 1.6 Cell cycle checkpoints in response to double strand breaks are 
mediated by ATM-Chk2, ATR-Chk1 and p53 pathways. 
 
(Adapted from [207]) Double strand breaks on DNA molecules trigger a series of 
signalling events leading to activation of cell cycle checkpoints.  
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ATM is one of the first molecules to be activated in response to double strand DNA 
breaks. Under normal conditions, ATM kinase is in its inactive dimer form. It can 
rapidly sense double strand breaks and auto-phosphorylate at Ser1981, which 
causes structural changes and promotes dimer dissociation into active monomeric 
ATM [208]. Scaffolding complex MRN (MRE11, Rad50 and NBS1) functions as a 
docking site for ATM to the site of double strand breaks (DSB) [209] . ATM kinase 
has multiple substrates including histone H2AX, Chk2 and p53. In terms of cell 
cycle arrest, ATM activates the p53 tumour suppressor protein by phosphorylation 
at multiple sites (Ser15, Ser46 and Ser9) [210]. p53 protein level is normally kept 
low in a healthy cell, through constitutive degradation by MDM2 [211]. 
Phosphorylation of p53 stabilises the protein [212] and p53 level is rapidly elevated 
in response to ATM activation [213]. p53 transcriptionally activates p21, which 
arrests cell cycle transition from G1 to S [214, 215]. The cell cycle functions of p53 
are of particular importance if DSBs take place during the G1 phase of the cell 
cycle [216].  
 
When DNA damage occurs after the G1 phase, ATM is able to arrest the cell cycle 
before mitosis through an alternative mechanism. ATM phosphorylates and 
activates Chk2 (check point protein 2) which signals to activate G2 and intra-S 
checkpoints [217]. Moreover, Chk2 is also able to phosphorylate p53, at Ser15 
[218]. Besides cell cycle arrest, p53 plays a central role in programmed cell death. 
The choices between cell cycle arrest or apoptosis depends on a variety of factors 
including the degree of DNA damage, the types of lesions, the protein levels of p53, 
and the presence of other pro-death or pro-survival signals [219] .   
 
Both ATM and ATR are serine-threonine kinases containing similar functional 
domains. The two molecules were historically thought to act in parallel with 
overlapping functions [220]. They both mediate cell cycle arrest and DNA damage 
repair. Recent studies have shown that ATM is required for ATR activation in 
response to double strand breaks [207], with some exceptions.   
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Once activated and recruited to the site of double strand breaks, ATM kinase 
phosphorylates and activates a number of substrates including CtIP, which forms a 
complex with BRCA1 protein. The complex is a crucial component for Exo1 
nuclease mediated strand resection [221]. Strand resection is controlled in a cell-
cycle dependent manner. Strand resection is mainly observed in S-phase cells where 
most spontaneous damage occurs [222]. The determination of which repair pathway 
to undertake depends on the cell cycle (See Chapt. 1.6.2). During strand resection, 
3’ single strand DNA (ssDNA) overhangs are generated on each end of DNA 
breaks. ssDNA is readily coated with Replication Protein A (RPA) proteins. ATR 
protein is recruited, docking to ssDNA region via adaptor protein ATRIP (ATR-
Interacting Protein). ATR activates the Chk1 mediator Claspin via phosphorylation. 
Active Clapsin recruits Chk1 to the site of damage where Chk1 is also 
phosphorylated by ATR at Ser317 and S345 sites, which are crucial for Chk1 
functions [223]. Activated Chk1 is then dissociated from the complex, interacting 
with its substrates both in the nucleus and cytoplasm [224]. Similar to the function 
of Chk2 in cell cycle regulation, Chk1 also contributes to G2 and intra-S checkpoint 
activation.   
 
The ATR-Chk1 pathway is activated in the presence of single strand DNA. Since 
ATM mediates strand resection during blunt end double strand breaks, ATM is 
required for ATR activation [225] [226]. ATR can also be activated without ATM, 
when there are single-stand DNA overhangs caused by replication arrest for 
example. RPA (Replication protein A) is a small protein that binds to single strand 
DNA, it stimulates the binding of ATRIP which recruits ATR to the site of DNA 
damage [227]. 
 
Chk1 and Chk2 are able to phosphorylate the Cdc25 protein family [228], and this 
in turn inhibits CDK (cyclin dependant kinase) functions. 14-3-3 protein promotes 
CDK1-cyclin B and mitotic entry. Phosphorylated Cdc25 binds and sequesters 14-
3-3 protein in the cytoplasm. In summary, ATM-Chk2 and ATR-Chk1 pathways 
sense and mediate cell cycle arrest upon double strand breaks.  
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1.6.2 Repair of double strand breaks   
 
During cell cycle arrest, the cells are given the opportunity to repair the damage. 
The cells have complex mechanisms to deal with different types of DNA damage. 
There is base excision repair (BER) for damaged bases, single strand break or 
abasic sites, nucleotide excision repair (NER) pathways remove and repair bulky 
lesions or dimerisation, and DNA mismatched repair (MMR) for mismatched bases. 
These lesions are efficiently recognised and regularly repaired in the cells [229]. 
Among all types of DNA damage, double strand breaks (DSBs) are especially 
difficult to repair. This type of damage is highly hazardous because it can lead to 
loss of genetic information; and chromosomal re-arrangements. If two breaks are 
wrongly joined onto different chromosomes. Tumour suppressor inactivation and 
oncogene activation can take place in the process. Defects in double strand break 
repair lead to genetic instability and a higher probability of carcinogenesis [230].  
 
A number of DNA damaging agents cause double strand DNA breaks, such as 
ionising irradiation (IR), etoposide and doxorubicin. These agents have also been 
used in cancer therapeutics that target rapidly proliferating cells with defective 
DNA repair mechanisms. Natural causes of DSBs include free radicals produced by 
oxidative metabolism, and replication fork collapse when polymerase encounters a 
single brand break.  
 
DSBs take place in our cells at a frequency of 10 times per cell per day [231]. Cells 
can repair DNA double-strand breaks by two principle mechanisms - non-
homologous end-joining (NHEJ) and homologous recombination (HR). The choice 
of pathway depends on the cell-cycle phase and the type of DSB ends. ATM and 
ATR, the two master cell-cycle regulators during DNA damage, are also implicated 
in DNA damage repair. Both ATM and ATR are required for HR pathways. The 
key catalytic protein that mediates NHEJ is another serine/threonine kinase called 
DNA-PKcs (DNA protein kinase catalysing subunit). ATM, ATR and DNA-PKcs 
all belong to phosphatidylinositol-3 kinase related protein kinases (PIKKs) family. 
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They are well conserved large proteins and they share similar functional catalytic 
domains [232]. 
 
The process of mammalian NHEJ is illustrated in Fig. 1.7. During NHEJ, the first 
protein that binds the DNA ends is thought to be KU protein complex, which has 
high affinity for the ends of DSBs [233]. It is a heterodimer consisting of KU70 and 
KU80 proteins and provides scaffolding for other NHEJ components. Two KU 
complexes bind to each broken strand and each interacts with a molecule of DNA-
PK protein.  The two DNA termini are joined in three steps. DSBs are rarely blunt 
ended and they frequently contain overhangs and phosphate groups [234]. Firstly, 
DNA-PK protein forms a complex with nuclease Artemis which mediates broken 
ends processing. Nucleotides are removed from the broken ends to create blunt ends. 
Then DNA polymerases are recruited to the complex and fill in the gaps at NHEJ 
junctions. Finally, Ligase IV/XRCC4 complex joins the ends. Since short sequences 
are sometimes removed by nucleases and this can lead to loss of genetic 
information, the NHEJ process is considered to be an error-prone process. 
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Figure 1.7 Non-Homologous End-Joining (NHEJ) repair mechanism in 
mammalian cells in response to double strand DNA breaks. 
 
(Adapted from [207]) KU heterodimetric complex recognises the double strand 
breaks and bind to the ends. Downstream NHEJ factors including Artemis, DNA-
PK, LIG4, XRCC4 and XLF are recruited forming a complex. Nucleotides are 
added and/or removed at the end of breaks and the ends are joined.  
 61 
In contrast to NHEJ, HR is more or less error-free, as a homologous chromosome is 
used as a repair template. The process of HR is demonstrated in figure 1.8. During 
HR, strand resection takes place along the site of damage from 5’ to 3’. This 
process is carried out by Exo1 exonuclease and facilitated by a few protein 
mediators including BRCA1-CtIP, MRN complex and BRCA2. Nearly all single 
strand DNA in the cells is coated with RPA molecules [235], which prevents 
ssDNA forming secondary structures. Rad51 is a crucial factor for HR DNA repair 
pathways, promoting homology match on a different chromosome and DNA strand 
invasion – a process where the broken single strand DNA pairs with an intact DNA 
molecule through homology. Once activated, Rad51 replaces RPA on the ssDNA 
[236], which is paired with a complementary strand by homology on a different, 
undamaged chromosome. DNA polymerases fill in the gaps using the partner 
chromosome as a template. Finally a Holliday junction is formed to resolve the 
DNA structure, giving rise to two intact DNA molecules.  
 
Mediated by the two master kinases ATM and ATM, cell cycle checkpoints occur 
in parallel with DNA damage repair pathways. Cell cycle checkpoints are important 
for two main reasons. When there is DNA damage, the cells cease to grow and 
proliferate; otherwise it could potentially lead to inheritable mutations. Also, during 
cell cycle arrest, the cells are given a period of time to repair the DNA lesions.  
 
In the case of heavily damaged DNA where the cells cannot resolve the lesions, 
activated p53 induces programmed cell death [237].  
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Figure 1.8  Homologous recombination DNA repair is activated when there are 
double strand DNA breaks or when there is DNA replication fork collapse. 
 
ATM and ATR are the two master kinases that get activated, forming a core for 
signalling hubs at sites of damage and mediate downstream signalling events that 
complete the repair.  
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There is a significant amount of cross-talking in DNA damage response networks. 
In recent years, it has been discovered that in addition to cell cycle regulations, 
checkpoint proteins Chk1 and Chk2 can also regulate DNA damage repair. Chk2 is 
reported to phosphorylate BRCA1 [238] and Chk1 is found to phosphorylate 
BRCA2 [239] and Rad51 [240]. These molecules are important components of 
HRR pathways. The cell cycle mediator protein Chk1 has been reported to be a 
crucial factor for HR DNA repair pathways [240]. In the study lead by Thomas 
Helleday, Chk1 is found to activate Rad51 through phosphorylation on Thr 309 site, 
which is a key molecule for homologous recombination. Cells depleted of Chk1 and 
cells with T309A inactivation mutant fail to form Rad51 nuclear foci in response to 
DNA damage [240].  
 
Although HR is error-free and NHEJ is error-prone, HR can only take place after 
DNA replication because of its requirement for a sister chromatid. NHEJ can take 
place throughout the cell cycle. During S phase, HR is the predominant repair 
mechanism for DSBs. During G0 and G1 phases, NHEJ is the main pathway. Both 
processes are thought to be crucial and defects in either pathway lead to diseases 
and even lethality.  
 
1.7 cancer therapeutics and synthetic lethality  
 
The trait of defective DNA repair mechanisms in cancer cells has been exploited in 
cancer treatments such as conventional chemotherapy and radiotherapy. Platinum-
containing compounds such as carboplatin and cisplatin are DNA damaging agents 
that intercalate in DNA structure, resulting in distortive DNA lesions. Specific 
inhibitors of DDR components have been developed and used effectively to treat 
cancers, for instance, etoposide and irinotecan are agents that inhibit topoisomerase, 
an enzyme that unwinds DNA by breaking and rejoining the phosphodiester bonds 
on the DNA backbone in order for transcription or replication to take place. Double 
strand breaks occur wherever topoisomerase is inhibited. Thanks to the robust DNA 
repair response in mammalian cells; these lesions are repaired in most of the normal 
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cells in the body. On the other hand, cancer cells with a defective DNA repair 
mechanism may not be able to resolve the damage and this leads to cell death. 
Moreover, cancer cells are often insensitive to signals suppressing growth and they 
generally proliferate more rapidly than non-transformed cells. DNA molecules are 
synthesized at a faster rate; therefore cancer cells are more sensitive to these DNA 
damaging agents. However, one of the major problems of these conventional killing 
strategies is not tumour specific, these agents frequently lead to cell death in non-
transformed cells, especially those with fast proliferation rates. Therefore these 
drugs have a limited therapeutic window. Patients frequently suffer from a wide 
range of side effects including hair loss, diarrhea and immuno-suppression.  
 
Clearly, development of targeted therapies is much needed; utilizing synthetic 
lethality in strategies of cancer therapy is becoming a focus of cancer research. Due 
to genetic instability, cancer cells develop gain-of-function mutations and they also 
harbour many non-lethal loss-of-function genetic defects. Novel cancer therapies 
have been developed to specifically target gain-of-function cancer mutations. For 
example, anti-HER2 antibodies have been used to treat breast cancers that over-
express HER2 receptor [241]. However, loss-of-function defects can not be easily 
reversed [242]. Synthetic lethality is a situation where two non-lethal genetic 
defects are not compatible with each other. The combination of the two defects lead 
to cell death [243].  
 
The multiple pathways in DDR functionally complement each other and there is 
some redundancy to certain degree. The tumour cells can be viable after loss of 
certain pathways. A number of DDR synthetic lethal situations have been identified. 
For example, cancer cells with dysfunctional BRCA are hypersensitive to PARP 
inhibitors [244]. Cancer cells with loss of BRCA1 or BRCA2 display defect in HR 
repairs, inhibition of PARP leads to increased single strand DNA breaks that 
become double strand breaks with overhangs. These damages can only be repaired 
by HR pathways [245]. A better understanding of synthetic lethal relationships in 
cancer genetics will potentially lead to breakthroughs in targeted cancer therapies.     
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1.8 Aim of project - to investigate the role of autophagy in DNA damage repair 
 
The current understanding on the relationships between autophagy and DNA 
damage is that loss of autophagy leads to accumulation of DNA damage. Eileen 
White and colleagues discovered that defective autophagy leads to DNA damage 
response both in vitro and in mammary cancer cells in vivo, and increased γH2AX 
foci was observed in autophagy deficient cells [1]. Increased DNA damage was also 
observed. Gene amplification, aneuploidy (A state of cells which have more or less 
numbers of chromosomes than normal.) and eventually genomic instability take 
place which contribute towards tumourigenesis [2].  
 
There is also other links recently discovered between autophagy and DNA damage. 
Protein acetylation and deacetylation are post-translational modifications that are 
implicated in gene activation/silencing, chromatin dynamics, DNA damage 
responses [246] and protein stability. Certain acetylated proteins are reported to be 
degraded through autophagy [247]. Thomas Robert and colleagues showed that 
yeast sae2 (human CtIP), a recombination protein involved in strand resection is 
acetylated and degraded by autophagy [248]. The cells possibly use this mechanism 
to keep levels of HR repair proteins low, especially during cell cycle phases when 
HR is inactive. FIP200 is a gene essential for autophagy activities, since cells with 
FIP200 (200 kDa FAK-family interacting protein) depletion are hypersensitive to 
DNA damaging agents and show deficient DNA damage repair. [249].  
 
The exact mechanism of how autophagy regulates the DNA damage response is still 
unknown. Since autophagy deficient cells have an accumulation of DNA damage 
[2], which could be either due to increased incidences of DNA damage occurrences, 
or due to certain defects in DNA damage response pathways. DNA damage 
response is a multi-step process and it involves a complex network of molecules. 
The main aim of this project is to dissect the pathways and investigate the exact role 
of autophagy in this process.  
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Chapter 2: Materials and methods 
 
2.1 Composition of routinely used solutions and media 
 
Phosphate 
Buffered Saline 
(PBS) 
170 mM NaCl, 3.3 mM KCl, 1.8 mM Na2HPO4, 10.6 mM 
KH2PO4 
PBS-Teen (PBT)  0.5% BSA, 0.1% Tween 20 in PBS 
5x RIPA 0.75M NaCl, 5% NP40, 2.5% Sodium Deoxycholate, 0.5% 
SDS, 0.25M Tris pH8.0  
SDS Running 
Buffer: 
0.1% SDS, 192 mM glycine, 25 mM Tris pH8.3 
Stripping Buffer 
for Western Blots 
0.2M Glycine, 1%SDS and pH adjusted to 2.5 with HCl  
Tris-acetate-
EDTA (TAE): 
40 mM Tris, 0.1% glaciel acetic acid, 1 mM EDTA 
Transfer Buffer: 192 mM glycine, 25 mM Tris, 20% methanol, 0.01% SDS 
Tris-Buffered 
Saline (TBS): 
25 mM Tris-HCl, pH 7.4, 137 mM NaCl, 5 mM KCl 
Tris-EDTA (TE): 10 mM Tris-HCl, pH 8.0, 1 mM EDTA 
TBST TBS + 0.1% Tween-20 
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2 x Western 
Sample Buffer 
100 mM Tris, pH 6.8, 2% SDS, 5% ß- mercaptoethanol, 15% 
glycerol, bromophenol blue 
5 x Western 
Sample Buffer 
60 mM Tris-HCL, pH 6.8, 2% SDS, 4 mM ß-
mercaptoethanol, 25% glycerol, 0.1% bromophenol blue 
 
Table 2 Composition of routinely used solutions and media 
 
2.2 Cell culture and treatments 
 
2.2.1 Cell culture 
 
Mouse Embryo Fibroblast (MEF) cells were grown at 37°C in Dulbecco's modified 
Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal calf serum 
(FCS), 2 mM L-glutamine (Invitrogen), 60 μg/ml penicillin (Sigma) and 100 μg/ml 
streptomycin (Sigma). Cells were routinely grown in a humidified atmosphere 
containing 5% CO2 at 37°C. Cell culture was performed in a Class II hood, using 
aseptic technique and sterile equipment and reagents. 
 
Cells were passaged at a frequency of every 2-3 days. After media was aspirated 
from the flask or culture dishes, 10ml of PBS was added to the cells to wash the 
cells and it was then aspirated. 3ml 0.25% trypsin in PE buffer was added to the 
flask/dish for approximately 3 minutes at 37°C to detach the cells. Following 
trypsinisation pre-warmed fresh media was immediately added to the dissociated 
cells to neutralise trypsin reactions. The cell suspension was then transferred into a 
fresh flask/dish at a ratio of 1:2 to 1:3.  
 
Cryo-freezing was routinely used for long term deposit of cell lines. Cells were 
trypsinised and centrifuged at 1000g for 5 minutes at room temperature. The 
medium/trypsin solution was removed and the cell pellet was resuspended in a 
solution consist of 90% FCS, 10% dimethylsulphoxide (DMSO). Cells were 
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aliquotted into cryo-tubes and frozen at -80°C. For longer term storage, the cryotubs 
were then transferred to liquid Nitrogen tanks which held the cells at -180°C.  
 
Thawing of cells was carried out by placing cryo-tubes in a 37°C water bath at until 
just thawed. Cells were then mixed with 10ml pre-warmed fresh media, centrifuged 
at 1000g for 5 minutes and the supernatant was removed to eliminate DMSO from 
cell freezing medium. The cell pellet was finally resuspened in 10% FCS DMEM. 
 
2.2.2 Cell number counting  
 
The number of cells in suspension was determined using the automated Casy® Cell 
Counter system (Innovatis). Following trypsinisasion and resuspension in a small 
amount of medium, the cells were diluted by 50 fold with PBS in a cell counting 
cup. The cell number was automatically determined by the machine which also 
provides information about the viability in cell population. For growth curve 
measurements the cells were counted in triplicate.  
 
2.2.3 Growth Curve construction 
 
Cells from sub-confluent cultured flasks or dishes were trypsinised and diluted in 
10% FCS medium. 10
6
 cells were plated onto each 10mm dishes and the cells were 
harvested and counted. For each data point, triplicate of dishes were used and the 
errors were calculated as standard deviation.  
 
2.2.4 Primary MEF cell isolation 
 
13 – 14 days after female plugging was noticed, the pregnant female was culled and 
immersed in 500ml deionised water with one Presept tablet dissolved in it. The 
carcass was sprayed with 70% Ethanol and the uterus containing embryos was 
excised using sterile dissection tools. The uterus was rinsed in a 15cm tissue culture 
dish containing 50ml 33ug/ml gentamycin (Invitrogen) in PBS. Once transferred to 
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a Class II hood, the embryos were freed from the uterus using fine forceps and 
decapitated using scalpels. Red internal embryonic organs were removed and 
discarded. The remaining tissues were torn into small pieces using forceps and 
transferred into a falcon tube with 10ml 0.05% trypsin in PE buffer. The tube was 
then incubated at 37°C for 30 minutes with gentle shaking every 10 minutes before 
800μl of 2.5% trypsin was added to the tube for a further 10 minutes. At the end of 
the incubation, the cells were seeded into 15cm tissue culture dishes containing 
40ml pre-warmed medium at a density of 2-embryo-equivalence of cells per dish.   
 
2.2.5 Transient transfection of plasmid DNA using Calcium Phosphate 
Precipitation.  
 
Cells to be transfected were seeded onto 100 mm tissue culture plates the day prior 
to transfection. A total of 20 μg DNA plasmid was diluted in 440 μl distilled H20 
(Invitrogen), the DNA was mixed with 500 μl 2 x HBS thoroughly. Finally 60μl of 
2 M CaCl2 solution was rapidly added to the mixture which was then vigorous 
mixed. DNA calcium phosphate precipitate was allowed to form for 20 minutes at 
37°C then added drop-wise to tissue culture plates. The plates were incubated at 
37°C in a humidified incubator for 16h – 18h when plasmid DNA was introduced 
into the cells through the calcium phosphate precipitate. The medium was then was 
removed after 16 hours before fresh 10% FBS DMEM added.  
 
2.2.6 Eletroporation transfection of primary MEFs.  
 
1x10
6
 cells MEFs in exponential growth phase were trypsinised centrifuged at room 
temperature. The supernatant was removed and the pellet was washed with 10ml 
PBS. The pellet was re-suspended in100μl Nucleofector® Solution (Lonza).The 
cells were then transferred to an electro-curvette (Lonza) where 10μg DNA plasmid 
was added. The mixture was electroporated using T20 program. The cells were then 
rapidly placed in a dish containing 10% FBS DMEM.  Transfected cells were 
incubated in a 37°C/5% CO2 environment until analysis.  
 70 
 
2.2.7 Retroviral infections 
 
Retroviral infections were carried out using phoenix-eco retroviral packaging cells 
which produce retrovirus that targets mouse cells. 1.5x10
6
 phoenix-eco cells were 
plated in a 100 mm dish the day before, and 20 μg retroviral DNA plasmid was 
transfected into each plate using Calcium Phosphate Precipitation method as 
described above. The supernatant containing retrovirus in 20% FBS DMEM was 
collected and added to target MEF cells three times within two days. 5 μg/ml final 
concentration of polybrene (hexadimethrine bromide; Sigma) was added to the 
supernatant. The MEF cells were plated the day before infection at 0.8 x10
6
 
/100mm. The supernatants containing retrovirus were filtered through 0.45 μm 
filters to remove any phoenix eco cells and it was then added to the MEFs cultures. 
24h after the last round of infection, MEF cells were selected for three days in 2.5 
μg/ml puromycin (sigma) containing 10% FCS DMEM. 
 
2.2.8 Generation of primary Atg7-/- cell lines.  
 
Primary MEF cell lines with stable deletion of Atg7 were generated using Phoenix-
eco as a packaging cell line. Retroviral infection with a control plasmid and a 
plasmid containing cre-recombinase was performed in primary Atg7flox/flox MEFs.  
 
2.2.9 Establishment of cell lines for detecting HR capacity.   
 
Atg7
flox/flox 
MEFs were transfected with 0.5µg of HR reporter constructs from Kevin 
Hiom, University of Dundee. Puromycin, at 2.5μg/ml, was added to the media 1 
day post-transfection. Colonies were isolated after 8–10 days on selection. Genomic 
DNA was then extracted and analyzed by Southern blotting to confirm that the cell 
lines contained a single integrated copy of the reporter cassettes, this was carried 
out by supervisor Kevin Ryan. Subsequently several colonies were picked and 
infected with cre recombinase retrovirus to remove Atg7 gene. By following the 
 71 
steps above, Atg7f/f and Atg7-/- cells with stable genomic insert of HR reporter 
construct were established.   
 
2.2.10 γ –ray ionizing Irradiation (IR) of cells 
 
IR treatment is a method of damaging DNA by causing double strand breaks. The 
cells to be irradiated were plated the day before on 10mm dishes. The dishes with 
adherent cells were irradiated using Alcyon II Cobalt-60 Teletherapy Unit. 
Depending on the half life of cobalt element, length of treatment was calculated 
according to dose rates that varied between 2-10 Gymin-1. The dishes were placed 
underneath the cobalt source and irradiated. Control cells were also brought to the 
Co-60 source at the same time without being irradiated.  
 
2.3 Molecular cloning 
 
2.3.1 Restriction digests 
 
Restriction Digests were carried out with enzymes and buffers from New England 
Biolabs (NEB). Five to ten-fold unit excess of enzyme was incubated with 10μg 
plasmid DNA in the appropriate NEB buffer overnight at for 1 hour 37ºC. After 
digestion, cleaved vector plasmid was incubated for a further 30 minutes at 37ºC 
with 5U Shrimp Alkaline Phosphatase (NEB). Finally digested DNA was purified 
to remove enzymes using Qiagen PCR purification kit and resuspended in Tris-
EDTA (TE) buffer.  
 
2.3.2 Ligation 
 
DNA fragments following restriction enzyme treatment were purified before 
ligation reactions. The fragments were separated by gel electrophoresis followed by 
excision using a Qiagen Gel Band Purification Kit. Ligations were carried out at 
room temperature overnight using Rapid DNA Ligation Kit (Roche). An 
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approximate twice the amount of the insert fragment over the vector plasmid was 
combined in a final volume of 10μl DNA Dilution Buffer. 10 μl T4 DNA Ligation 
buffer was then added along with 5U T4 DNA ligase. 
 
2.3.3 Transformation of competent cells 
 
E.Coli DH5α supercompetent cells (Stratagene) were transformed for plasmid 
preparation. The cells were aliquoted into 50μl volumn and stored at -80ºC. For 
each plasmid, one aliquot was thawed on ice before 10-20 ng of plasmid DNA (in 
1ul TE or water) was gently added into supercompetent cells. The cells were 
incubated for 15 minutes on ice before heat shock treatment at 42ºC for 30 seconds. 
The tubes were then rapidly transferred to ice, where 250 μl of 37ºC LB broth was 
added. The competent cells were incubated in suspension for 45 minutes on an 
orbital shaker (225-250 rpm). 150 μl of the transformation mixture was then added 
to and spread on LB agar plates containing 50 μg/ml ampicillin or kanamycin. The 
plates were incubated at 37ºC overnight in order for colony-formation of the 
transformed cells. 
 
2.3.4 Screening of transformants – minipreps 
 
Single colonies were isolated from the transformation plates. They were grown 
overnight at 37ºC in 10ml LB medium with 50 μg/ml ampicillin/kanamycin. 
Plasmid DNA miniprep were performed using QIAprep Spin Miniprep Kits 
(Qiagen #27104) (Routinely carried out by Molecular Technology Service, Beatson 
Laboratories). Analytical restriction digests were performed with appropriate 
enzymes and buffers and resolved by agarose gel eletrophoresis to validate 
successful insert of DNA fragments. DNA plasmids with inserts were subsequently 
sequenced (Carried out by Central Services).  
 
2.3.5 Preparation of plasmid DNA – maxipreps 
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Maxipreps were carried out for large scale plasmid DNA preparation. After the 
DNA plasmid was transformed into competent cells, a single bacterial colony was 
isolated from the bacteria plate and inoculated into 4 ml LB medium containing 
50μg/ml ampicillin/kanamycin. The mini culture was incubated for 4 hours with 
vigorous shaking at 37ºC. The culture was then transferred to a conical flask 
containing 200 ml LB containing 50μg/ml ampicillin/kanamycin. Following an 
overnight incubation at 37ºC on an orbital shaker (300 rpm), cells were pelleted by 
centrifugation at 3000g for 20 minutes at 4ºC and plasmid DNA retrieved using the 
Qiagen Plasmid Maxi Kit following kit instructions (routinely performed by 
Molecular Technology Service in the institute).  
 
2.3.6 Agarose gel electrophoresis 
 
1% - 2% agarose gel was prepared by adding agarose (Sigma) to 200ml TAE buffer, 
before microwave heated to dissolve the agarose. Ethidium Bromide was added to 
give a final concentration of 0.5μg/ml in the agarose solution. Agarose was poured 
into a gel tray with combs inserted and allowed to solidify for at least 45 minutes. 
Samples for electrophoresis were prepared by the addition of 5 x gel loading buffer 
(30% glycerol, bromophenol blue) and electrophoresed at 120V for approximately 
1h in TAE gel running buffer. DNA bands were visualised using a UV 
transilluminator. 
 
2.4 RNA/cDNA techniques 
 
2.4.1 Preparation of total cellular RNA 
 
Total cellular RNA was isolated from sub-confluent growing cells using Qiagen 
RNeasy Spin Column kit, in accordance with the manufacturer’s instructions. 
Before the cells were lysed in RLT buffer, Media was aspirated from 6-well plates 
or 100 mm plates and the cells were rinsed with PBS once.  After RNA isolation, 
the concentration was determined by UV spectrophotometry. A ratio of absorbance 
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at 260 nm to 280 nm in the range of 1.8-2.0 indicated the RNA samples were 
relatively free from DNA or protein contamination.  
 
2.4.2 Preparation of cDNAs from RNA using reverse transcriptase 
 
Template RNA was isolated from whole cell lysate as described above. cDNAs 
were prepared using using DyNAmo™ SYBR® Green 2-Step qRT-PCR kits 
(Finnzymes), in accordance with manufacturers instructions. 20 μl reaction mix was 
prepared by mixing 1μg RNA, 10μl RT buffer 1μl Random Hexamers (300 ng/μl) 
and 2 μl M-MuLV Rnase H+ reverse transcriptase. 
 
Reverse transcriptase reactions were carried out using a Peltier Thermal Cycler (MJ 
research, Helena Bioscience) under the following parameters: 25ºC for 15min, 37ºC 
for 30min and 85ºC for 5min. cDNAs were then stored at -20ºC. 
 
2.4.3 Quantitative Real Time Polymerase chain reaction (qRT-PCR) 
 
Prior to analysis, a bulk preparation of serially diluted total RNA from genetically 
unmodified MEFs was made, aliquoted and stored at -20ºC. The RNA was used as 
stardards in each qRT-PCR reactions.  
 
qRT-PCR was carried out with 2 μl of cDNA, 10 μl 2x qPCR master mix provided 
in DyNAmo™ SYBR® Green 2-Step qRT-PCR kits (Finnzymes), 5.5 μl H2O and 
2.5 μl designed primers as indicated (QuantiTect Primer Assays – Qiagen) for gene 
of interest.  
 
The reaction mix was pipetted into 96 well optical plate (BioRad) with an optically 
clear flat cap strips (BioRad). qPCR was carried out under the following cycling 
parameters using MJ Opticon Moniter Analysis Software version 3.1, on a Peltier 
Thermal Cycler (MJ Research) with a Chromo 4 continuous fluorescence detector. 
Data analysed using MJ Opticon Moniter Analysis Software version 3.1 
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PCR reaction were carried out using cDNA template prepared as described 
previously under the following cycling parameters: 95°C for 15min, [94°C 10 sec, 
55°C 30 sec, 72°C 30 sec] 40 cycles, 72°C 10 min. Expression levels of genes 
analysed by qPCR were normalized relative to levels of 18S rRNA. 
The following Primers were used 
 
Primers for Atg7:  
5′-ATGCCAGGACACCCTGTGAACTTC-3′  
5′-ACATCATTGCAGAAGTAGCAGCCA-3′. 
 
Atg5:  
5’-AAGTCTGTCCTTCCGCAG-3’  
3’-TGAAGAAAGTTATCTGGGTAG-5’ 
 
Mouse 18S primers were from Qiagen (QT01036875). 
 
2.5 Protein immunoblotting (Western Blotting) 
 
2.5.1 Cell lysis and protein extraction  
 
Immediately prior to use, 10ml 1x RIPA was prepared and kept on ice by diluting 
5x RIPA buffer in deionised water, 1 protease inhibitor tablet and 200μL Na3VO4 
was added to the buffer to inhibit proteolysis and dephosphorylation after cell lysis.   
 
Plates to be harvested were washed twice with ice cold PBS, 400μL RIPA lysis 
buffer was added to each 100mm dish. Lysates were collected from plates and 
transferred to 1.5mL eppendorf tubes, which were incubated on ice for 45 minutes. 
Subsequently, the whole cell lysates were centrifuged at maximum speed in a 
desktop minicentrifuge (21,000g) for 10mins at 4°C to pellet DNA and debris. The 
supernatants were transferred to fresh eppendorf tubes and stored at -20°C until use. 
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2.5.2 Separation of proteins by polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Protein lysates in RIPA buffer was diluated with 2x western sample buffer. Prior to 
loading on denaturing polyacrylamide gels, the samples were boiled on a 100°C 
heat block for 5 minutes. 20μL of protein samples were loaded into a Nupage® 
Novex® Bis-Tris 4-12% (Invitrogen) gradient gel or a homemade 10% - 15% gel. 
8μL of Pre-stained protein standard (Thermo PageRuler®) was loaded into a well 
so as to determine the molecular weight of the proteins within the samples. Gels 
were run in 1X NuPAGE® MOPS SDS running buffer for the precast gels, or 
homemade 1X running buffer for the homemade gels, at 150V in an Invitrogen 
XCell SureLock
TM
 mini-cell electrophoresis system. The voltage was terminated 
when the blue dye front had reached the bottom of the gel. For gels to be probes 
with antibodies recognizing small proteins such as LC3 or H2AX, the voltage was 
stopped before the dye front had reached the bottom.  
Depending on the molecular weight of the protein to be probed and detected, the 
homemade 10-15% gels were made with from 30% stock acrylamide solution 
(37.5:1 acrylamide:bis acrylamide) Severn Biotech Ltd) and constituted 375mM 
Tris-HCl, pH8.8, 0.1% SDS, polymerised with 0.05% ammonium persulphate (APS) 
(Sigma), 0.1% TEMED (Sigma). Stacking gel was 4% acrylamide and with 125mM 
Tris-HCl, pH 6.8 , 0.1% SDS, polymerised with 0.05% ammonium persulphate, 
0.1% TEMED. 
 
2.5.3 Western blotting 
 
Electrophoretic transfer of separated proteins resolved by SDS-PAGE gels to 
nitrocellulose (Amersham Biosciences) or PVDF membranes was achieved using 
Invitrogen XCell SureLockTM mini-cell tanks. An extra step applied for PVDF 
membranes, they were activated by soaking in methanol for 2min before soacking 
in transfer buffer for 2 min until uniformly opaque. SDS Gels were blotted onto 
membranes in a sandwich with sponge and 2 sheets of Whatman 3MM paper, all 
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pre-soaked in transfer buffer, the gel faces cathode side of the sandwich and the 
membrane anode. Gel transfer was carried out in Transfer Buffer at 0.4 Amps for 
1.5 hours in an XCell IITM blot module. After transfer, ponceau-S (Sigma) staining 
was performed to assess transfer fidelity. 0.1%. The ponceau S stained membrane 
was subsequently detained by 2 washes with dH2O and 1 wash in TBST. A list of 
antibodies used for western blotting analysis and FACs analysis was presented as in 
table 2.  
   
Antibody Dilution Company 
   
actin (clone 1A4) 1:10,000 Sigma 
BrdU  1:200 Dako 
Claspin H300 1:1000 Santa Cruz 
S345 p-Chk1 1:1000 Cell Signalling 
total Chk1 G4  1:1000 Santa Cruz 
ERK p42 1:1000 Santa Cruz 
γ-H2AX 1:1000 millipore 
S10-Phospho-
Histone-3  
1:100 Santa Cruz 
LC3B 1:1000 Cell Signalling 
Wip1 1:1000 Santa Cruz 
Anti mouse IgG HRP 
linked 
1:3000 Cell Signalling 
Anti rabbit IgG HRP 
linked 
1:3000 Cell Signalling 
 
Table 3  List of antibodies used for western blotting and flow cytometry analysis.  
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2.5.4 Probing and signal detection  
 
After electrophoric transfer, membranes were blocked in TBST milk blocking 
buffer (TBST + 5% skimmed milk powder (Marvel) for 30 min at room temperature 
on with gentle shaking on a rocker. Membranes were then were incubated with 
primary antibodies typically a 1:1000 dilution in 5% BSA in TBST with gentle 
rotation overnight at 4°C.  
 
After incubation in primary antibody, the membranes were washed 3 times with 
TBST for 15 minutes each time and incubated with for horseradish peroxidase-
conjugated secondary antibody for 1 hour at room temperature with gentle rotation. 
The blots were then washed 3 times for 15 minutes with TBST before protein 
signals were activated using enhanced chemiluminescence reagents (ECL 
Amersham), in accordance with manufacturer’s instructions.  X-ray films (Fuji 
Medical X-ray film) were used to capture the signals and developed in an X-ray 
processor (AGFA).  
 
2.5.5 Stripping of Western Blots  
 
In order to detect a different protein band on the same membrane, the membrane 
was incubated in stripping buffer for 30 min at 50°C with constant agitation, to 
remove bound primary antibodies without removing transferred proteins. The 
membranes were then washed twice in TBST and incubated in 5% milk in TBST 
blocking buffer for 30 min at room temperature.  
 
2.6 Flow Cytometry Assays  
 
2.6.1 Sample collection for flow cytometry analysis 
 
Cells were grown on 10mm or 6-well dishes and treated accordingly. At time of 
sample collection, media that includes floating cells was collected into a 15ml 
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Falcon tube. The cells were washed with 2ml PBS which was also transferred into 
the same tube. 2ml of 0.25% trypsin in TE buffer was added to the cells to detach 
the cells and the cell suspension was combined in the tube. The tubes were 
centrifuged at 1000g for 5min and the supernatant was aspirated and discarded. 
Cells were re-suspended in 500 μl PBS by pipetting up and down a few times. 5ml 
ice cold methanol was added to the cells while vortexting which helped to avoid 
clumping. The cells were incubated in fixative methanol for a minimum of 2 hours 
before further sample processing.   
 
2.6.2 Cell Cycle profile assessment with propodium iodide (PI) staining 
 
Prior to FACS analysis, the cells in methanol fixation pelleted by centrifugation and 
re-suspended in 400 μl PBS, 20 μl 1 mg/ml PI (Sigma) and 0.2 μl RNase (100 
mg/ml). The samples were incubated for 30 min at room temperature in the dark to 
allow for PI incorporation. The cells were then sorted for and analysed for DNA 
content by measurement of fluorescent signals in the FL2 channel. The percentage 
of cells with sub-G1 DNA content was taken as a measure of the percentage of 
apoptotic cells in the cell population. The flow cytometry assays were performed on 
a Becton Dickinson FACS machine and the acquired data was subsequently 
analysed using FlowJo software. 
 
2.6.3 S-phase analysis 
 
To determine the percentage of actively proliferating cells in the cell population, the 
capacity of cells to incorporate either the synthetic thymidine analogue 5-bromo-2’-
deoxyuridine (BrdU) into their DNA was tested. Before the cells were harvested 
and fixed in methanol, 25μM BrdU was added into cell culture medium for the 
appropriate length of time.  
 
For BrdU flow cytometry analysis, the cells were centrifuged at 1000g for 5 min 
and the methanol was removed. The cell pellets were re-suspended in 2ml of PBS 
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before 1ml of 4M Hydrochloric acid (HCl) was added. The samples were incubated 
at room temperature for 15 min to in order to denature the DNA structures, which 
allow BrdU epitopes to be exposed and recognized by subsequent antibodies. The 
cells were washed with 5ml PBS and then with PBT solution. The cells were 
centrifuged and the pellet was re-suspended in 300μl of PBT containing a 1:200 
dilution of the anti-BrdU antibody (Dako). The samples were then incubated at 
room temperature for 30min in the dark. After the incubation, the cells were washed 
with 2ml PBT to remove excess primary antibody and re-suspended in 300μl PBT 
containing a 1:300 dilution of the Alexa 488 conjugated anti-mouse antibody and 
incubated for 30 minutes in the dark. The excess secondary antibodies were 
removed by washing with 2ml PBT. Finally the pellet was re-suspended in 400 μl 
PBS, 20 μl 1 mg/ml PI (Sigma) and 0.2 μl RNase (100 mg/ml). The flow cytometry 
assays were performed on a Becton Dickinson FACS machine and the acquired data 
was subsequently analysed using FlowJo software. 
 
2.6.4 Mitosis determinations  
 
The percentage of mitotic cells was determined by detection of cells with 
phosphorylated Histone H3 protein at ser10. pS10 Histone H3 is a mitotic marker 
commonly used in flow cytometry analysis or immunofluorescence microscopy. 
Cell were treated accordingly, fixed and stored as described above.  
 
Prior to analysis, the cells were centrifuged at 1000g for 5min and the fixative was 
removed. The cells were re-suspended in 2ml of 0.3% Triton-X-100 in PBS and 
incubated on ice for 15 min. The cells were then pelleted and Triton-X-100 in PBS 
was aspirated and discarded. The pellet was re-suspended in 200μl of PBT (0.5% 
BSA, 0.1% Tween 20 in PBS) containing 1:100 dilution of anti-pS10 H3 antibody 
(Santa Cruz). The samples were incubated for 1 hour at room temperature. The cells 
were then washed with 5ml PBT and pelleted. The cell pellet was re-suspended in 
200μl of PBT containing a 1:100 dilution of the FITC conjugated anti-rabbit 
antibody for 30 min in the dark. Excess secondary antibodies were removed by 
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washing with 5ml PBS. The samples were finally pelleted and re-suspended in 400 
μl PBS, 20 μl 1 mg/ml PI (Sigma) and 0.2 μl RNase (100 mg/ml). The flow 
cytometry assays were performed on a Becton Dickinson FACS machine and the 
acquired data was subsequently analysed using FlowJo software. 
 
2.6.5 Detection of homologous recombination  
 
Plasmid encoding restriction enzyme I-Sce I was transfected into Atg7
f/f
 and Atg7
-/-
 
cell lines that contain stable insert of HR plamid as described in Chapter 2.2.9. 48 
hours after I-Sce I transfection using electroporation method, Atg7
flox/flox 
and Atg7
-/-
 
cells were analysed by flow cytometry in a FL1 versus FL2 dot plot with 20% FL2 
– FL1 compensation. GFP positive cell population appears off the autofluorescence 
diagonal towards FL1. They represented cells that were capable of carrying out HR.  
 
2.6.6 Detection of Non-homologous End-joining (NHEJ)  
 
Plasmids to tests HNEJ activity were kindy provided by Vera Gurbunova and have 
been previously described [250].  NHEJ reporter plasmid was linearised with 
HindIII restriction enzyme and purified with Qiagen Spin Column. 10μg of the 
plasmid was tranfected by electroporation (Amaxa MEF2 Nucleofector Kit by 
Lonza) together with an RFP-expressing plasmid (2μg) to control for transfection 
efficiency. 48 hours after transfection, 
/flox 
and Atg7
-/-
 cells were analysed by flow 
cytometry.  Atg7
flox/flox 
and Atg7
-/-
 cells were analysed by flow cytometry in 610 
(red channel) versus 530 (green channel) dot plot.  
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2.7  Immunofluorescence microscopy  
 
2.7.1 Cell fixation on coverslips  
 
16mm Coverslips (VWR) were autoclave-treated to achieve sterilization before use. 
Each coverslip was placed in a well in a six-well plate. 20,000 cells were added to 
each well in 2ml medium. The plates were agitated slowly to ensure even 
distribution of cells on the coverlips. The cells were incubated in a tissue culture 
incubator at 37°C/5%CO2 overnight. Following treatment, the medium was 
removed from the six-well plate and the cells were washed once with PBS to 
remove excess medium. Fixative solution was freshly prepared; it contained 4% 
paraformaldehyde (PFA) (Electron Microscopy Sciences) in PBS.  2 ml fixation 
solution was added to each well and incubated at room temperature for 15 min. The 
solution was aspirated and discarded, 2ml PBS was added to each well and the 
plates were stored at 4°C before permealibisation step. PFA fixation method was 
routinely performed for most antibodies. For RPA and CtIP immunocytochemistry, 
cells were fixed first with PFA and then treated with 70% ethanol in PBS at −20°C. 
For ATR, pATR and ATRIP immunocytochemistry, cells were fixed in ice cold 
acetone/methanol (1:1) for 15 min at room temperature.  
 
2.7.2 Permeabilisation and blocking  
 
To permeabilise the cells, the coverslips with adhered cells were incubated in 2ml 
of 0.3% Triton-X-100 in PBS solution per well for 10min at room temperature. The 
coverslips were then washed with PBS and blocking solution (3% BSA, 10% FBS, 
and 5%milk in PBS) was added to the wells. The plates were blocked at room 
temperature with gentle agitation for 1.5h.  
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2.7.3 Probing with primary and secondary antibodies 
 
Following blocking, the coverslips were washed 3 times with blocking buffer 
without milk (3% BSA and 10% FBS in PBS) before incubation in primary 
antibodies. The antibodies were diluted in blocking buffer without milk as indicated 
(table 3). For each coverslip, 20μl primary antibody solution was dropped onto 
parafilm (Pechiney Plastic Packaging Company) which was placed in a light-
shielded square dish. The coverslips were placed onto the droplets of primary 
antibody solutions, with the side with adhered cells covered by the solutions. The 
dish was placed at 37°C for 1 hour in a tissue culture incubator. Meanwhile, three 
flasks each containing 100ml of 0.1% Triton-X-100 in PBS solution was prepared. 
At the end of incubation in primary antibody, the coverlips were washed by dipping 
three times in each of the three flasks. The coverslips were than incubated in 
secondary antibodies against the appropriate species in the same manner and 
washed by the dipping methods.  
 
The coverlips were fixed onto microscope slides using VECTASHIELD® 
mounting medium with DAPI. 2 drops the mounting medium were placed on the 
slides and the coverslips were placed onto the droplets, with the side with cells 
facing the solution. The edge of coverlips was sealed with clear nail varnish.   
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Antibody Dilution  Company  
   
S1981 p-ATM 1:500 Cell signaling 
ATR  1:100 Santa Cruz 
ATRIP  1:100 Bethyl Laboratory 
p-ATR  1:100 Santa Cruz 
CtIP  1:100 Santa Cruz  
H2AX  1:250 Millipore 
KU-70  1:100 Santa Cruz 
Rad51  1:1000 Calbiochem 
γRPA  1:200 EMD 
Alexa Fluor® 488  1:200 Invitrogen 
Texas Red 1:200  Invitrogen 
 
Table 4 List of antibodies used in immunofluorescent microscopy.  
 
2.7.4 Visualization  
 
Fluorecent microscope images were acquired using a laser scanning confocal 
microscope (A1R [Nikon]; or FV1000 [Olympus]) using either a Plan-Apochromat 
VC60× NA 1.40 oil immersion lens or UPLSAPO 60× NA 1.35 oil objective 
together with NIS-Elements AR (Nikon) or Fluoview version 1.7c (Olympus) 
software, respectively. 
 
2.7.5 EdU detection with immunofluorescence microscopy 
 
After sedding on glass coverslips MEF cells were treated as required and 1 hour 
before fixation, 25μM EdU (Invitrogen) was added to cell culture medium. The 
cells were then fixed with 4% PFA for 15 minutes at room temperature and washed 
twice with 3% BSA in PBS. The cells were permeabilised with 0.5% triton X-100 
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in PBS for 20 minutes at RT. Following fixation and peameabilisation, the cells 
were then washed twice with 3% BSA in PBS. EdU reaction buffer (Click-iT 
reaction buffer, CuSO4, Alexa Fluor 488 azide and 10x reaction buffer additive) 
(Invitrogen) was added according to manufacturer’s instructions and incubated at 
for 30 min in the dark at room temperature. The excess reaction buffer was removed 
and the cells were washed twice with 2ml of 3% BSA in PBS. Fixed cells were then 
blocked in 3% BSA in PBS for 30 min before incubation in required primary and 
secondary antibodies as described above.  
 
2.7.6 Statistical Analyses 
 
Image analysis of Rad51 foci was undertaken using an Image J/Fiji Macro to detect 
enhanced fluorescence (foci) within nuclei.  At least 50 cells were examined in each 
population and the foci density calculated as the foci area of a nucleus relative to 
total nuclear area (as assessed by DAPI stain).   
 
Statistical analysis of the results obtained using Image J/Fiji Macro assessment of 
Rad51 foci formation following γ-irradiation was via a Student’s t-test (2-sides with 
unequal variance). 
 
2.8 Analysis of proteasome activity 
 
The proteasome assays were performed in primary Atg7
f/f
 and Atg7
-/-
 cells. The 
assayw were also performed after treatment of Atg7f/f MEFs with 100nM 
Bafilomycin A1 for 16 hours, and/or with Lactacystin (10μM) for 3 hours where 
indicated. The medium was removed from the adherent cells plated in 10mm dishes 
the day before. The cells were detached with 2ml of 0.25% trypsin in PE buffer and 
diluted with 8ml room temperature medium, they were then transferred to a 15ml 
falcon tube. The cells were washed carefully with PBS 3 times to remove traces of 
trypsin which could affect experimental results. The final pellet was resuspended in 
room temperature medium and plated into 96 well plates at 10,000 cell per well. 
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Proteasome-Glo™ Cell-Based Reagents (Promega Bioscience) were prepared in 
accordance with manufacturer’s instructions. The cells were equilibrated at room 
temperature (approximately 22°C), before 100μl reagents was added to the cells in 
each well. Luminescence generated from each reaction condition was detected with 
a Veritas Microplate luminometer according the manufacturer's instruction.  
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Chapter 3. Investigating whether autophagy deficiency leads to 
DNA damage accumulation 
 
3.1 Primary Atg7
flox/flox 
and Atg7
-/-
 MEF cell lines were established.  
 
As described in Chapt 1, Atg7 is a gene essential for autophagy. Atg7 protein is 
required for both ubiquitin-like conjugation systems that form the Atg12-Atg5-
Atg16 complex and lipid bound LC3-II, and these two are crucial for phagophore 
formation.  
 
Mice with whole body Atg7 deletion are born with a normal frequency but they can 
not survive the neonatal starvation period (48 hours after birth) [74]. Genetically 
modified mice containing Atg7 gene flanked by loxP sites are commonly used as an 
experimental model. The loxP sites can be targeted for recombination by Cre 
recombinase and Atg7 can be deleted in this system [251]. Atg7
flox/flox
 embryos 
were isolated from pregnant mice at 13 to 14 days after the plug was detected. 
Primary MEF cell lines were established from the embryos and the cells were 
pooled. Retroviral vectors with Cre recombinase (pBabe-puro-Cre) were used to 
induce conditional deletion of Atg7 in these MEFs in vitro. Empty vector with 
selection marker was used as a control. Comparing to Atg7
flox/lox 
(hereafter referred 
to as Atg7f/f ) and Atg7
-/-
 MEFs isolated from different embryos, the use of cre-
mediated in-vitro Atg7 deletion also avoids potential artifacts due to genetic 
variability between different individuals. 
 
After 3 days of selection in puromycin (2.5μg/ml) for infected cells, Atg7 levels 
were assessed by qPCR (Fig.3.1). It was revealed that Atg7 mRNA is significantly 
lower in cre recombinase expressing Atg7
flox/flox
 MEFs. The depletion of Atg7 
mRNA occurred within 5 days (Fig. 3.1).   
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Figure 3.1 Atg7
flox/flox 
locus is efficiently recombined by retroviral Cre 
recombinase.   
 
Relative mRNA expression of Atg7 was measured by RT-qPCR in Atg7
flox/flox 
cells 
which were retrovirally infected with either pBabe-Puro or pBabe-Puro-Cre. The 
experiment was carried out in various batches of MEFs and done at least three times 
overall.   
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Atg7 is a long-lived protein that has a half-life of about one week [251]. Three days 
following the antibiotic selection period, western blotting for Atg7 protein was 
carried out. Complete Atg7 depletion at the protein level was verified as shown in 
Fig. 3.2, and the depletion is sustained for at least two weeks after infection.     
   
Atg7 is an E1 like enzyme that is essential for the conversion of LC3-I to LC3-II 
(Figure 1.3), which is embedded on the inner and outer membrane of the 
autophagosome. The amount of LC3-II is proportional to the number of 
autophagosomes [252]. LC3-I (19kD) to LC-II (17kD) conversion on western blots 
has been used to determine autophagic flux and is a general indicator of autophagy 
activity. Figure 3.2a shows that both LC3-I and LC3-II were detectable in Atg7f/f  
cells (Atg7
flox/flox
), indicating that there is constitutively active autophagy in these 
cells. As expected, LC3-II band is absent in Atg7
-/-
 cells, and there is no significant 
difference in LC3-I between Atg7f/f  and Atg7
-/-
 cells.    
 
Autophagy is generally thought to be a non-selective process that bulk degrades 
proteins and organelles. However several selective autophagy substrates have been 
identified. p62/SQSTM1,  a well characterized autophagy substrate, is a 
cytoplasmic chaperone-like protein associated with polyubiquitinated protein 
cargoes that are destined for degradation via the autophagic machinery. The 
molecular structure of p62 contains an LC3 binding domain and a ubiquitin binding 
domain [125]. The LC3 binding domain on p62 allows its association with 
autophagosomes and therefore selective degradation via autophagy. Under normal 
conditions, basal autophagy continuously clears p62 and associated cargo (such as 
toxic aggregate-prone proteins) from the cytoplasm. It is generally accepted that, 
with a few exceptions, inhibition of autophagy is correlated with increased levels of 
p62 at protein levels [129]. The levels of p62/SQSTM1 were examined in cre 
recombinase treated Atg7
flox/flox
 cells. It was revealed that the p62 level was 
elevated significantly in Atg7
-/-
 cells a week after selection and the up-regulation 
persisted for at least two weeks (Figure 3.2b).  
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Figure 3.2 Loss of Atg7 depletes LC3-II conversion and leads to p62 up-
regulation. 
 
(a) Atg7 level and LC3-I to LC3 conversion were assessed by Western blotting after 
Atg7
flox/flox
 cells were infected with cre recombinase containing retrovirus. (b) The 
sustainability of Atg7 depletion and p62 upregulation were examined by western 
blot analysis. The experiment was carried out at least three times for different 
batches of MEFs to ensure Atg7 protein was depleted in cre treated Atg7flox/flox 
cells. 
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To summarise, Atg7 is completely deleted in cre recombinase infected Atg7
flox/flox
 
cells as verified by qPCR and western blotting. Loss of Atg7 leads to failure of 
LC3-I – LC3-II conversion and accumulation of p62.  
 
3.2 Investigation of the effect of loss of autophagy on DNA damage repair.  
 
Mammalian cells have a complex set of DNA damage responses which are finely 
coordinated in order to maintain genomic integrity and limit oncogenic 
transformation. Primary MEF cells were used to dissect the role of autophagy in 
DNA damage response, because transformed cells frequently harbour genetic 
defects in DNA damage repair pathways leading to genetic instability and immortal 
transformation.  
 
A number of molecular components are known to be localised at the sites of DNA 
damage in the nucleus, forming nuclear foci when visualised by 
immunofluorescence [253]. Histone protein H2AX is one of the first proteins that 
become activated via phosphorylation following DNA damage and it is reported 
that focus formation occurs within 3 minutes [254] [255]. Phospho-H2AX is 
commonly referred to as γ - H2AX because it was first discovered in cells exposed 
to γ rays, and can be phosphorylated by ATM, ATR and DNA-PKcs. H2AX 
facilitates ATM recruitment to the site of DNA breaks [256]  and ATM is 
considered to be the main modulator of H2AX activity [208]. Some of the DNA 
damage response molecules form foci during certain stages of the cell cycle, 
whereas γ - H2AX foci formation can take place at any stage of the cell cycle [257]. 
γ-H2AX focus formation in the nucleus has been used as a cellular marker for DNA 
damage, especially double strand breaks. Each focus formation covers megabases 
on the chromatin and represents a repair center for damaged DNA [255].   
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Figure 3.3 Double strand breaks after DNA damage are repaired in Atg7f/f and 
Atg7-/- cells at similar rates.   
 
Atg7f/f and Atg7-/- cells were irradiated (10Gy) and parameters of DNA repair 
monitored over time.  (a) Analysis of the accumulation of γ-H2AX by 
immunofluorescence microscopy was carried out to detect focus formation 1h and 
8h after ionizing radiation (IR, 10Gy).  (b) γ-H2AX was detected by western 
blotting at the indicated times following ionizing radiation (IR, 10Gy). *The experiment 
was carried out at least three times and a representative figure is presented here. 
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To investigate how the loss of autophagy affects DNA repair, wild-type and Atg7
-/-
 
cells were exposed to 10 Gy IR to induce DSBs and γ-H2AX foci formation was 
monitored (Fig.3.3a).  
 
As shown in Fig. 3.3a, no detectable difference in γ-H2AX nuclear foci was 
observed at resting state between Atg7f/f and Atg7
-/-
 cells. Comparable levels of 
focus accumulation were observed in the nucleus for the two cell lines 1 hour after 
IR, indicating a significant amount of double strand breaks were induced by 
irradiation.  The foci were no longer visible after 8 hours by immunofluorescence in 
both cell lines. These observations indicate that autophagy deficient cells are able to 
resolve IR-induced DSBs. Western blotting for γ-H2AX provides a more 
quantitative assessment of DSB repair (Fig. 3.3b), revealing that  Atg7-/- cells are 
able to repair IR-induced double strand DNA breaks, at a similar rate to Atg7f/f  
cells. These images also demonstrate the cells can repair damaged DNA fairly 
efficiently, the repair rate varies across different cell lines and is dependent on the 
proliferation speed of the cells. For example Fast growing neuroblastoma cells can 
repair most DNA damage 2 hours after 10Gy IR [258]. We found that in freshly 
isolated MEFs, most of γ-H2AX foci disappear 8 hours after 10Gy IR.   
 
As described in chapter 1, there are multiple pathways for DNA damage repair; 
sometimes these mechanisms buffer each other’s functions. Double strand breaks 
are mainly repaired by HR and NHEJ pathways, with less characterized pathways 
such as microhomology-mediated end joining also able to mediate the repair of 
DSBs [259]. Assays for γ-H2AX provide evidence that Atg7-/- cells repair DSBs 
but did not reveal how these lesions were resolved. Further assays examining the 
activation of downstream parameters the DNA damage response network were 
performed.  
 
Assessment of the activation of ATM and ATR, the two master kinases for double 
strand break DNA responses was carried out using immunofluorescence 
microscopy (Fig. 3.4 and Fig. 3.5). Comparable nuclear foci formation of p-ATM 
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(S1981), ATR, p-ATR and ATRIP were detected in Atg7f/f  and Atg7
-/-
 cells after 
10Gy IR. CtIP is an important strand resection protein activated by ATM, and it is 
also important for ATR activation in response to IR-induced double strand breaks. 
Equivalent amounts of RPA protein foci, which mark the presence of single strand 
DNA, were observed in Atg7f/f  and Atg7-/- cells.  This indicates that there was a 
comparable extent of strand resection after IR in autophagy deficient cells.  It was 
also revealed that equivalent amounts of CtIP foci were formed in the two cell lines. 
Immunofluorescence microscopy images for ATR, p-ATR, ATRIP and CtIP were 
performed by Naihan Xu.   
 
These results (Fig. 3.3 – Fig. 3.5) indicate that autophagy deficient cells are able to 
sense IR-induced DNA damage, which mainly consists of double strand breaks. 
ATM and its downstream targets all appear to be efficiently activated upon DNA 
damage. These DSB ends are efficiently processed and strand resection was able to 
take place. Strand resection after IR-induced DSB is necessary for the activation of 
ATR. ATR kinase also was found to be efficiently recruited to the site of damage in 
the absence of autophagy.  
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Figure 3.4 Equivalent levels of ATM activation were detected in Atg7f/f and 
Atg7
-/- 
cells.   
 
Activation of ATM in Atg7f/f  and Atg7
-/-
 cells was assessed by the measurement of 
phospho-ATM (Ser1981) nuclear foci using immunofluoresence microscopy, 
before and 1h after 10Gy IR. DAPI was used to stain the nucleus.  
*The experiment was carried out at least three times and a representative blot is presented here. 
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Figure 3.5 Autophagy deficient cells appear to have intact strand resection 
machinery during DNA damage response. 
 
(Experiments performed by Naihan Xu, a former BICR member). (a) The 
levels of ATR, ATRIP and phospho-ATR nuclear foci were assessed by 
immunofluorescence 1h after irradiation (IR, 10Gy) in wild-type and Atg7
-/-
 cells. 
(b) The sub-cellular localization of CtIP and RPA was assessed by 
immunofluorescence 1h after irradiation (IR, 10Gy) in wild-type and Atg7
-/-
 cells. 
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Chk1 phosphorylation is considered to be the main functional readout for ATR 
kinase activities [260]. Chk1 is one of the key molecules in the DNA damage 
response and it activates different cell cycle checkpoints – G1/S, the intra-S, G2-M 
and the mitotic spindle checkpoint [207]. In response to genotoxic stress, Chk1 is 
activated by ATR and initiates a signalling relay that eventually arrests the cell 
cycle. This provides an opportunity for the cell to repair the DNA damage. Both IR 
and etoposide are able to induce double strand breaks [261]. Thus we examined 
Chk1 activation after exposure to IR or etoposide-induced DNA damage. It was 
revealed that phosphorylation of Chk1 at serine 345, a site phosphorylated by ATR, 
was greatly impaired in autophagy deficient cells in response to these DNA 
damaging agents (Fig. 3.6).   
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Figure 3.6 Atg7 null cells have a deficiency in Chk1 activation. 
 
(a,b) Phosphorylation of Chk1 at S345 was measured by Western blotting in wild-
type and Atg7
-/-
 cells at the indicated times following exposure to 10Gy IR (a) or 
25μM etoposide (b). *The experiment was carried out at least three times and a representative blot is presented here. 
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3.3 Investigation of the mechanisms through which Chk1 is de-regulated.  
 
Chk1 activation is tightly modulated by a number of pathways, such as Claspin and 
WIP1. Claspin is an adaptor protein for Chk1 and it is also a target of ATR kinase. 
The phosphorylation of Claspin in the Chk1 binding domain promotes its 
association with Chk1 [262]. Claspin facilitates Chk1 phorphorylation by ATR and 
is required for Chk1 activation. Claspin protein levels are known to be modulated 
during cell cycle progression and also during the DNA damage response [263]. 
Claspin is normally degraded by the ubiquitin-proteasome system, and the 
degradation of Claspin is thought to terminate Chk1 activation and promote cell 
cycle progression [264]. In order to investigate whether the claspin level was 
affected in autophagy deficient cells, leading to Chk1 deficiency, western blotting 
analysis was carried out.  The same levels of claspin protein were detected in 
Atg7f/f  and Atg7-/- cells (see Fig. 3.7a).  
 
WIP1/PPM1D is a phosphatase that dephosphorylates Chk1 at Ser345 [265]. 
Similar to the functions of Claspin, WIP1 is thought to inactivate DNA damage 
response signalling after the lesion is repaired. WIP1 protein level is also tightly 
regulated in the cells [266]. If WIP1 for some reason is up-regulated in autophagy 
deficient cells, this would lead to decreased levels of phosphorylated Chk1. 
However identical levels of WIP1 were observed in Atg7f/f  and autophagy 
deficient cells (Fig. 3.7b).  
 
In fact, Analysis of Chk1 by western blot showed that both phospho- and total Chk1 
levels were diminished at a later time point (e.g. after 2 weeks) following loss of 
autophagy (Fig. 3.8).  
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Figure 3.7 Levels of Chk1 modulators Claspin and WIP1 were unchanged after 
loss of autophagy. 
 
(a,b) Levels of Claspin (a) and WIP1 (b) were measured by Western blotting in 
Atg7
flox/flox   
and Atg7
-/-
 cells following treatment with ionising irradiation (10Gy). 
*The experiment was carried out at least three times and a representative blot is presented here. 
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Figure 3.8 Total Chk1 protein level diminishes at later time points in autophagy-
deficient cells. 
 
Levels of phoshorylated Chk1 and total Chk1 were assessed by Western blotting in 
Atg7
flox/flox 
  and Atg7
-/-
 cells 2 weeks after recombination following 10Gy of 
ionising irradiation. *The experiment was carried out at least three times and a representative blot is presented here. 
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To summarise the findings so far, autophagy deficient cells appeared to be able to 
resolve IR induced DNA damage. They can activate molecules upstream of Chk1 
upon the induction of DSBs and no obvious defects were observed. However cells 
lacking autophagy displayed defective Chk1 activation. Less phosphorylated Chk1, 
and at a later time point lower levels of total Chk1 were observed in autophagy 
deficient cells. The decrease in phosphorylated Chk1 was observed after induction 
of DSBs; and the decrease in total protein level was observed in the absence or 
presence of DNA damaging agents. Chk1 activities are not only regulated by 
adaptor protein Claspin and phosphatase WIP1, the activation of Chk1 is actually 
coupled to its own degradation [267]. The phosphorylation of Chk1 at Ser345 
facilitates its proteasome mediated degradation [267].  
 
Our observations that impaired phosphorylation of Chk1 followed by deceased total 
protein levels could be explained by activation mediated degradation of Chk1.  It is 
generally accepted that autophagy deficient cells, which cannot efficiently remove 
damaged mitochondria and proteins, generate more reactive oxygen species (ROS) 
leading to more DNA damage [268]. ROS can act as signalling molecules at 
physiological levels in the cells, and they are produced in the mitochondria where 
oxygen metabolism occurs [269]. At elevated levels, ROS can cause oxidative 
damage to DNA molecules and accumulation of DNA damage leads to genomic 
instability and contributes to tumourigenesis. Mitochondria, as the main source of 
ROS in the cells are dynamic structures that are cleared by autophagy, and the 
process is referred to as mitophagy. Mitophagy constitutively degrades damaged or 
unwanted mitochondria. Mitophagy-deficient cells have de-regulated ROS levels 
which can cause damage to DNA, protein and lipids [270].   
 
Since DNA damage leads to activation of Chk1 and there’s increased DNA damage 
in autophagy deficient cells, it was reasoned that possibly the regulation of Chk1 
activation by upstream kinases, adaptor protein Claspsin or phosphotase WIP1 is 
not perturbed, but that Chk1 is constitutively activated in autophagy deficient cells 
due to the increased incidences of DNA damage. Activation of Chk1 leads to its 
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degradation and over time it would then have an impact on the total pool of Chk1. 
More mechanistic details on how the degradation occurs will be covered in chapter 
5. 
 
A different system, without the use of retroviruses was utilized to investigate the 
role of autophagy in Chk1 activation. Atg7
flox/flox 
mice were crossed with B6 CAG-
Cre-ER mice, which express a Cre recombinase targeted deletion system that can be 
induced by tamoxifen treatment. In contrast to in-vitro infection with cre 
recombinase, the tamoxifen -ER system does not require three rounds of infections 
and sequential selection. It was found that 6 days after the cells were first exposed 
to 4-hydroxytamoxifen (TAM), Atg7 was successfully removed, as assessed by 
western blotting shown in Fig. 3.9. Total Chk1 was also diminished in the absence 
of Atg7 (Fig. 3.9). In Atg7f/f  cells, Chk1 was activated 1h after IR, as assessed by 
western blotting for Ser345 p-Chk1; in Atg7
-/-
 cells, less phosphorylation-activation 
was observed in response to DNA damage. It can also be seen that the basal 
phosphorylation of Chk1 in Atg7
-/-
 is higher than that of Atg7f/f  cells.        
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Figure 3.9 Tamoxifen induced deletion of Atg7 in CAG-Cre MEFs also leads to 
decreased total Chk1 level.  
 
MEFs isolated from Atg7flox/flox – CAG-Cre embryos were treated with 2μM 4-
hydroxytamoxifen (TAM) for 48h, and incubated in TAM free medium for a further 
96h. The cells were harvested for western blotting 1h after 10Gy IR. *The experiment was 
carried out at least three times and a representative blot is presented here. 
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Both in-vitro infection of Atg7flox/flox MEFs and the Tamoxifen mediated Atg7 
deletion method involves the use of cre recombinase, which has been reported to 
have DNA damaging effects in cells without the LoxP site. Cre recombinase is an 
enzymatic protein originally found in P1 Bacteriophage and it catalyses site specific 
recombination between its specific recognition sites on the DNA, termed loxP sites 
[271]. Cre recombinase is a widely used tool in molecular biology to knock in/out 
specific genes. DNA flanked between two same-orientation loxP sites is excised 
[272]. Although being a powerful tool, the use of cre recombinase has raised 
concerns due to its associated toxicity. Naturally occurring sequences with high 
homology to loxP have been discovered in mammalian cells [273]. These pseudo-
LoxP sites can undergo cre-mediated recombination. Cre expression in mammalian 
cells in the absence of loxP sites have been reported to cause accumulated DNA 
damage and apoptosis [274] [275]. Therefore it was important to find out whether 
Chk1 deficiency after loss of autophagy was due to an off-target effect by cre-
recombinase, before any further characterization on the effect of autophagy loss on 
Chk1.  To test this, wild type primary MEFs were isolated from day 13-14 embryos 
with B6 background. These MEF cells were infected with cre-transgene-containing 
retrovirus and selected with puromycin for 3 days. Western blotting was carried out, 
and it was revealed that there was no difference in Chk1, either the activated Chk1 
or total Chk1 protein level, in cre treated Atg7f/f MEFs (Fig. 3.10).   
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Figure 3.10 WT MEFs treated with cre plasmid do not impede Chk1 activation 
or decreased Chk1 levels. 
 
Western blotting analysis showing the effect of Cre recombinase on Chk1 
phosphorylation (S345) in genetically unmodified (wild-type) primary MEFs. *The 
experiment was carried out at least three times and a representative blot is presented here. 
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Chapter 4. Investigating the downstream effect of Chk1 
deregulation in autophagy deficient cells  
 
Chk1 is one of the key molecules in the DNA damage response (either DNA strand 
breaks or blocked replication fork) and it activates different cell cycle checkpoints – 
G1/S, the intra-S, G2-M and the mitotic spindle checkpoint. Chk1 deletion in mouse 
models is embryonic lethal [276]. As early as the blastocyst stage before embryo 
formation, nuclear aberrations and apoptotic cell death can be detected. Chk1 is 
considered to be essential for cell survival and growth [276]. Chk1 and Chk2 are the 
two main cell cycle mediators, Chk is from checkpoint kinase, like their name 
suggests, Chk1 and Chk2 are proteins that play central roles in the crossroads 
between DNA damage response and cell cycle checkpoints. Once activated by 
stimuli such as genotoxic stress, the two checkpoint proteins trigger downstream 
signalling responses leading to cell cycle arrest. Although Chk1 and Chk2 are not 
structurally related to each other, they are functionally similar and share common 
substrates including Cdc25A and Cdc25C which are cell cycle checkpoint 
mediators. In recent years, it was found that the two kinases do not have complete 
overlapping functions and Chk1 may play a more essential role than Chk2 in the 
cells. Homozygous Chk1 deletion in mouse is embryonic lethal; however Chk2 
knockout mice are viable and fertile without any obvious defects [277], Chk2 
deficient mouse cells display normal cell cycle profiles, in contrary to findings in 
human immortalized cell lines [278], Chk2 was found to be insignificant in damage 
induced cell cycle checkpoint in mice [279] [280].  
 
As described in the previous chapter, soon after loss of Atg7, Chk1 activation is 
impaired in autophagy deficient cells; and at later times both total Chk1 protein 
levels and phosphorylated Chk1 are depleted in Atg7
-/-
 cells. These phenomena lead 
us to ask the question whether cell cycle regulation is abnormal in autophagy 
deficient cells, and whether these cells show abrogation in cell survival or 
proliferation.  
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4.1 Analysis of cell cycle checkpoints in response to DNA damaging 
agents in Atg7f/f  and Atg7-/- cells.  
 
Both mammalian and chicken somatic cells with complete Chk1 depletion are 
viable but they display significant checkpoint defects. Chk1 was found to be crucial 
for the DNA damage induced G2 checkpoint [276] [281]. Cells lacking Chk1 are 
expected have a de-regulated cell cycle. We therefore examined the cell cycle 
checkpoints in Atg7-/- cells in response to the genotoxic agent etoposide. Etoposide 
is a topoisomerase II inhibitor and cells undergo G2/M arrest upon treatment with 
etoposide [282]. The cell cycle arrest gives the cells some time to repair the double 
stand breaks caused by etoposide before entry into mitosis.    
 
Cell cycle distribution in Atg7f/f  and Atg7
-/-
 MEF cells before and after etoposide 
treatment was assessed. Equivalent cell cycle distribution was observed in the two 
cell lines before DNA damage challenge. After etoposide treatment, both cell lines 
displayed S phase and G2 arrest to a similar extent (Fig. 4.1). The results indicate 
that autophagy deficient cells, though appearing to have deficiency in Chk1 activity, 
have an intact G2 checkpoint.  
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Figure 4.1 Autophagy deficient cells have equivalent cell cycle distribution to 
Atg7f/f  cells prior to and after DNA damage. 
 
Atg7
flox/flox 
and Atg7
-/-
 cells were treated with 25μM etoposide for 8h after which 
cell-cycle analysis was undertaken by flow cytometry.  *The experiment was carried out at least 
three times and a representative figure is presented here. 
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During mitosis and meiosis, histone protein H3 becomes phosphorylated at ser10 
and this facilitates chromosomal condensation [283]. Mitosis occurs rapidly in the 
cells and at any given time only a small fraction of cells are pH3 positive. 
Nocodazole is an agent that inhibits the polymerization of microtubules. Cells 
treated with nocodazole fail to form metaphase spindles and the cell cycle cannot 
progress beyond the mitosis stage. The use of nocodazole allows the quantification 
of the percentage of cells that are going through mitosis.  
 
Checkpoint activities were examined in Atg7f/f  and Atg7
-/-
 cells. It was revealed 
that both cell lines efficiently undergo cell cycle arrest upon treatment with 
etoposide and neither cell line progresses into mitosis (Fig. 4.2). Results as shown 
in Fig.4.1 and Fig.4.2 indicate that the G2/M checkpoint is intact in Atg7
-/-
 cells.  
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Figure 4.211 deficient cells have intact G2/M checkpoints. 
 
The ability of cells to promote entry into mitosis or undergo G2/M cell cycle arrest 
was scored by detection of phosphorylated Ser 10 in histone H3 (pH3). Etoposide 
(25μM) and/or Nocodazole (100nM, to arrest cells in mitosis) was added to the cells 
for 8 hours where indicated.  *The experiment was carried out at least three times and a representative figure  is 
presented here. 
 112 
Serum starvation induces reversible G1 cell cycle arrest [284, 285]. Atg7f/f  and 
Atg7
-/-
 cells were synchronized in G1 phase by incubation in serum free medium for 
16 hours.  Final concentrations of 10% serum or/and etoposide (25μM) were added 
for a further 8 hours before the cells were harvested for flow cytometry analysis.  It 
was found that there were comparable G1 checkpoint activities between the two 
cells lines (Fig. 4.3). In nutrient replete conditions, around half of the cell 
population was detected as BrdU positive, indicating that they had been going 
through S-phase. After starvation, the cells were arrested in G1 phase and did not 
progress into S-phase. When serum was added back to starved cells, both wild-type 
and Atg7
-/-
 cells resumed their cell cycle progression and entered S-phase, as 
indicated by BrdU incorporation. When etoposide was added together with serum, 
neither of the two cell lines progressed into S-phase, indicating that autophagy 
deficient cells have an intact DNA-damage mediated G1 checkpoint.  
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Figure 4.3 Autophagy deficient cells have intact G1 checkpoints. 
 
 
The ability of Atg7
flox/flox 
and Atg7
-/-
 cells to promote entry into S phase or undergo 
G1 cell cycle arrest was determined by BrdU incorporation. Where indicated, cells 
were synchronized via incubation in serum free medium for 16 hours prior to 
addition of serum or/and etoposide (25μM).  *The experiment was carried out at least three times and a 
representative figure is presented here. 
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No obvious aberrations in DNA-damage-induced cell cycle controls were observed 
in Atg7-/- cells. Chk1 mediates cell cycle arrest through downsteam molecules such 
as Cdc25A and CDK1. Cdc25A is a phosphatase that drives G2/M phase transition 
by removing the inhibitory phosphorylation (Thr14 and Tyr15) on Cdk1 so Cdk1 
can form a complex with cyclin B [286]. Human Cdc25A activity is inhibited by 
Chk1 via phosophorylation and the protein is rapidly targeted for degradation [287]. 
Levels of Cdc25A and phosphorylation of CDK1 (Tyr15) in response to IR were 
examined (Fig. 4.4). Cdc25A levels were found to be constant before or after IR 
treatment and also there was no difference in the phosphorylation of CDK1. 
Cdc25A levels were not perturbed in the absence of autophagy, where Chk1 was 
de-regulated.  
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Figure 4.4 Loss of autophagy has no effect on Chk1 downstream molecules 
Cdc25A and pCDK1. 
 
(a) Levels of Cdc25A were assessed by western blotting prior to, 1h and 2h after 
10Gy IR. (b) p-CDK1 (Tyr 15) levels were examined in a similar manner. *The 
experiment was carried out at least three times and a representative blot is presented here. 
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4.2 Investigation of the effect of autophagy-deficiency on DNA 
repair of double strand breaks.  
 
Besides cell cycle control, Chk1 is also an important regulator of DNA damage 
repair [288]. It is found to phosphorylate Rad51 at Thr309, a nuclear protein that 
mediates homologous recombination during DNA damage repair [240]. Rad51 
normally displays a defuse pattern in the nucleus. The phosphorylation of Thr309 is 
crucial for Rad51 function, and Rad51 fails to form nuclear foci in Chk1 deficient 
cells (Sorensen et al., 2005). Once activated, Rad51 rapidly replaces RPA on single 
stranded DNA, and initiates homologous recombination.      
 
Because Chk1 is de-regulated in Atg7
-/-
 cells, we examined Rad51 foci formation in 
the nucleus after the cells were exposed to IR. Rad51 localises to sites of double 
strand breaks and forms microscopically detectable foci when cells are challenged 
with DNA damaging agents such as etoposide or IR [289]. In healthy growing cells, 
Rad51 foci are also frequently detected during the S-phase of the cell cycle, where 
most spontaneous double strand breaks occur due to stalled or collapsed replication 
forks [290]. To differentiate Rad51 focus formation caused by exogenous agents 
and spontaneous DSBs, proliferation marker EdU (5-ethynyl-2´-deoxyuridine) was 
used to identify S-phase cells. EdU is a modified nucleoside, an analogue of 
thymidine that can be incorporated into the DNA. It is similar to BrdU, but 
detection of EdU does not require DNA denaturation. It was revealed that Rad51 
fails to form foci in Atg7
-/-
 cells after DNA damage, whether they are in S-phase or 
not (Fig 4.5).  Nuclear foci formation was further quantified using an Image J/Fiji 
Macro to detect enhanced fluorescence (foci) within the nuclei.  At least 50 cells 
were examined in each population and the foci density calculated as the foci area of 
a nucleus relative to total nuclear area (as assessed by DAPI stain). The macro used 
for data analysis was built by Dave Strachan (BICR). 
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Figure 4.5 Rad51 focus formation does not occur in Atg7
-/-
 cells after DNA 
damage. 
 
(a) Rad51 nuclear focus formation (IR) was examined by immunofluorescence in 
wild-type and Atg7
-/-
 cells, 1h after exposure to 10Gy IR. Where indicated in each 
panel, DAPI was used to stain DNA. (b) The graph represents Rad51 positive 
nuclear area (foci) normalised against total nuclear area in Atg7f/f  and Atg7
-/-
 cells. 
*The experiment was carried out at least three times and a representative figure  is presented here. 
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The difference in Rad51 foci between Atg7f/f and Atg7-/- cells was visibly small; 
this was because of the limitations of the antibody available to us. The use of a 
macro quantifying (Rad51 Foci / Nuclear area) of the cells was able to reveal the 
difference and its significance, as presented in Fig 4.5(b).  
  
It is important to note that  Rad51 expression level is cell cycle dependent, the 
protein level is lowest during G1 phase, and it increases during S-phase and peaks 
during G2-M phase [291]. The expression levels coincide with the availability of 
sister chromatid as a template for HR. As shown in Fig. 4.1, the cell cycle 
distribution is comparable between Atg7f/f and Atg7-/- cells therefore the 
difference in foci formation was not due to a difference in cell cycle distribution.  
 
As mentioned previously, Rad51 is a central player in HR DNA repair, Rad51 
nucleofilament mediates homology search on an adjacent chromosome and 
stimulates DNA strand exchange process. To determine the effect of loss of 
autophagy on HR repair pathways, GFP-plasmid-based flow-cytometry assays were 
performed to quantify HR capacities in Atg7f/f and Atg7-/- cells.  
 
Atg7f/f  and Atg7-/- cells lines that contain stably inserted HR substrate reporter 
plasmid were established as described in Chapter 2.2.9. The primary structure of the 
recombination reporter substrate was shown in Fig 4.6a. The reporter has two 
consecutive copies of modified and inactive GFP (Green Fluorescence Protein) 
genes. The first copy of GFP gene was modified to contain a restriction enzyme site 
for I-SceI, an endonuclease which recognises 18bp sequence and cut the sequence 
leaving 4 base pair overhangs [292].  The second copy of GFP is truncated at 3’ end 
and is also inactive. When I-SceI is introduced into the HR reporter expressing cells, 
double strand breaks with overhangs were generated by the enzyme, and these 
lesions can only be fully resolved through HR pathways. NHEJ pathway may be 
able to repair such lesions; however nucleosides may be added or deleted at 
breakage ends randomly, resulting in a mutant GFP that is inactive. 48 hours after I-
SceI transfection using electroporation method, Atg7
flox/flox 
and Atg7
-/-
 cells were 
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analysed by flow cytometry in a FL1 versus FL2 dot plot with 20% FL2 – FL1 
compensation. GFP positive cell population has a higher FL1 signal relative to that 
autofluorescence diagonal, as shown in Fig. 4.6b. They represented cells that were 
capable of carrying out HR.  
 
 
Figure 4.6 recombination is impaired in autophagy-deficient cells. 
 
(a) (Adapted from [293]) The plasmid used in reporter HR assays encodes two 
copies inactive GFP proteins. When restriction enzyme I-SceI introduces double 
strand breaks with overhangs, HR takes place to repair the breaks using sequence 
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information from the second copy of GFP, located on a sister chromatin. (b) 
Plasmid-based assays were used to measure HR activity in wild-type and Atg7-null 
cells. (c) The results of 3 repeated experiments were quantified as represented graph. 
*The experiment was carried out at least three times and a representative figure is presented here. 
Results from flow cytometry assays as in Fig. 4.6 showed that Atg7-/- cells have 
diminished capacity to carry out HR relative to Atg7f/f  cells. This finding is 
supported by the fact that Rad51 fails to form foci in autophagy deficient cells.  
 
The two main ways of repairing DSBs are HR and NHEJ. HR appeared to be 
defective in autophagy deficient cells. Since DNA damaging pathways frequently 
buffer each other’s functions, i.e. NHEJ can be up-regulated when HR is inhibited 
and vice versa. The next step in this study was to investigate whether there was any 
irregularity in NHEJ pathways.   
 
The first step of NHEJ involves Ku complex recognizing and assembling at each 
end of DSBs (Figure in Intro). Ku is a heterodimeric protein complex consisting of 
two subunits Ku70 and Ku80. Once bound to DNA, it recruits downstream catalytic 
proteins such as DNA Protein kinase and DNA ligase IV. Identical amounts of 
Ku70 foci formation were observed in Atg7f/f  and Atg7-/- cells in response to IR 
(Fig 4.7). This would indicate NHEJ is carried out to the same extent in the 
presence or absence of autophagy.  
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Figure 4.7 Atg7
-/-
 cells have comparable levels of KU positive foci relative to 
Atg7f/f  cells as assessed by immunofluorescence. KU70 nuclear foci formation 
was monitored in Atg7f/f and Atg7-/- cells 1h after 10Gy IR treatment. DAPI was 
used to stain the nucleus.  
*The experiment was carried out at least three times and a representative figure is presented here. 
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A more definitive measurement of NHEJ is to use a GFP-readout plasmid-rejoining 
assay. It was revealed that there are equivalent NHEJ capacities in Atg7f/f and 
Atg7-/- cells, as measured by the plasmid-based assay (Fig. 4.8).    
 
The use of NHEJ substrate plasmid pEGFP-Peml-Ad2 was first published by 
Gorbunova lab [250]. The plasmid encodes a GFP sequence which has an inserted 
adenoviral exon flanked by two introns. The GFP is inactive because of the 
additional exon. Both introns contain a restriction site for HindIII enzyme, which 
generates compatible ends for NHEJ. Following treatment with HindIII, NHEJ 
causes end-joining of the DNA break resulting an active GFP, as illustrated in Fig 
4.8 (a).  
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Figure 4.8 Non-Homologous End-Joining is unaffected in autophagy-deficient 
cells as assessed by flow cytometry assays. 
 (a) (Adapted from [250]) GFP sequence in reporter substrate (pEGFP-Peml-Ad2) 
has an artificially inserted adeno-exon flanked by two introns, both of which 
contain restriction sites for HindIII. The GFP is inactive until the plasmid is 
digested by HindIII enzyme and rejoined through NHEJ pathways. (b) Plasmid-
based assays were used to measure NHEJ activity in wild-type and Atg7-null cells. 
(c) The graph represents the quantification of repeated experiments.  
*The experiment was carried out at least three times and a representative figure is presented here. 
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The results above show that autophagy deficient cells have defects in HR pathways 
but they appear to have intact NHEJ pathways.  
 
It has been reported that defects in HR pathways can lead to an accumulation of 
chromosomal breaks and promote genomic instability [294]. Cells lacking HR 
components such as Rad51 or BRCA1 are often viable but they accumulate 
spontaneous damage and are hypersensitive to DNA damaging agents such as IR or 
UV [295]. Mouse cells lacking critical HR mediators such as Rad51 or Xrcc2 have 
chromosomal re-arrangement and aneuploidy and knocking out these genes in mice 
leads to embryonic lethality [296] [297].  
 
Because of their importance in guarding genomic integrity, it is not surprising that 
these HR mediator genes are frequently found to be mutated in cancer. Defects in 
DNA repair pathways promote neoplasmic transformation [298]. Cancer cells 
lacking HR capacity have been found to be more dependent on alternative repair 
mechanisms including NHEJ, base excision repair and other less-defined 
mechanisms [299] [300]. This property of tumour cells has been utilized in 
synthetic lethal anti-cancer therapeutics. For example, breast cancer cells lacking 
BRCA1/2 have been found to be hypersensitive to PARP (poly ADP ribose 
polymerase) inhibitors [301], which is an important mediator for base excision 
repair pathways, and PARP is frequently found to be up-regulated in cancer cells 
[302].  
 
Alternative pathways to HR are more error prone because they are not homology-
based and they often involve loss of genetic information at the sites of breakage. 
HR is the predominant repair pathway for cells that have finished DNA synthesis 
and before they divide into two daughter cells [303]. The lack of HR during these 
scenarios can potentially contribute to neoplastic transformation. For example, 
chromosomal re-arrangement can occur if the ends from different chromatids are 
wrongly joined together [299].   
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4.3 Characterisation and quantification of genetic instability in autophagy 
deficient cells.  
 
The profound genetic instability due to loss of HR capacity promotes cancer cell 
transformation, yet in most cases; cell death is induced when there is an 
accumulation of chromosomal breakage [294]. Sub-G1 DNA content is a reliable 
measure of apoptotic cell death. To investigate whether autophagy deficient MEFs 
have more spontaneous cell deaths, Sub-G1 DNA contents over a period of 3 weeks 
were monitored in Atg7f/f and Atg7-/- cells. At any given time, Atg7-/- cells 
displayed increased basal cell death relative to Atg7f/f cells. During the first three 
weeks after Atg7 recombination, Atg7-/- cells displayed twice the amount of cells 
going through spontaneous cell death relative to Atg7f/f cells. By the end of 3 
weeks, Atg7-/- MEFs entered crisis and had a drastic portion of apoptotic cells (Fig 
4.9). 
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Figure 4.9  Autophagy deficient cells have increased spontaneous cell death. 
 
Sub-G1 DNA content was measured by flow cytometry analysis in Atg7f/f and 
Atg7
-/-
 cells at the indicated time points after Atg7 recombination. 
*The experiment was carried out twice and a representative figure is presented here. 
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Before Atg7
-/-
 entered crisis point at the end of the three-weeks after recombination, 
the absolute percentages of cells going through spontaneous cell death were 
relatively low (around 2-4% in Atg7f/f cells and 4-8% for Atg7-/- cells). It was 
expected that increased spontaneous cell death would manifest as defects in cell 
growth, therefore cell proliferation rates of Atg7f/f and Atg7
-/-
 cells were monitored 
over a period of 4 weeks. Growth curve analysis revealed that autophagy deficient 
cells had a significant slower rate of growth (Fig. 4.10). Crystal violet staining 
assay was also used to detect the difference in growth rates between Atg7f/f and 
Atg7
-/-
 cells. 10
6
 cells were seeded onto 10mm dishes and incubated in a humidified 
5% CO2 incubator, after 48h, the dishes were stained with crystal violet solutions. 
Crystal violet is a chemical that binds sugar containing molecules such as DNA, 
and it can be easily visualized. The intensity of purple colour is generally 
correlative to the amount of cells on the dishes. Results as shown in Fig. 4.10b 
revealed that there was significant less of Atg7
-/-
 cells on the dishes and hence that 
they grow at a slower rate.   
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Figure 4.10 Atg7
-/-
 have a significant longer doubling time relative to Atg7f/f 
cells.  
 
(a) The difference in cell proliferation rate between Atg7
flox/flox 
and Atg7
-/-
 cells was 
monitored over a time course of 4 weeks. (b) 10
6
 Cells were plated onto 10mm 
dishes on day one and the dishes containing adherent cells were stained with crystal 
violet dye on day 3. *The experiment was carried out twice and a representative figure is presented here. 
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Micronuclei formation is commonly used as a biomarker to quantify chromosomal 
damage, especially damage related to double strand breaks [304]. A micronucleus is 
an irregular small nucleus that is formed during mitosis. Micronuclei are commonly 
seen in cancer, as a result of chromosomal instability [305]. It contains 
chromosomal fragments or a whole chromosome that fails to be segregated into a 
daughter cell. It can be easily visualized using DAPI, which is a dye binding to 
DNA. Micronuclei can form through multiple mechanisms. Deficiency in HR 
pathways such as BRCA or Rad51 results in micronuclei accumulation in the cells 
[306] [307]. It was considered that HR deficient cells become hyper-dependent on 
NHEJ. NHEJ is an error-prone way of repairing DSBs and is more likely to form 
dicentric chromosomes (chromosomes attached to two centromeres) and acentric 
chromosomal fragments (chromosomes unattached to centromere) [305]. These 
chromosomal aberrations eventually manifest as micronuclei formation.  
 
It was observed that there was increased micronuclei formation in autophagy 
deficient cells and the difference was quantified (Fig. 4.11). This observation 
supports that autophagy deficient cells have increased genetic instability, and is 
possibly due to the fact that HR pathways are defective in autophagy deficient cells.  
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Figure 4.11 Loss of autophagy leads to micronuclei accumulation. 
 
Occurrence of micronuclei was examined and quantified in Atg7f/f and Atg7
-/-
 cells 
at the indicated time points after Atg7 recombination. *The experiment was carried out at three 
times and a representative figure is presented here. 
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4.4 Investigation of synthetic lethal effects due to HR defect in autophagy 
deficient cells.   
 
Most of DSBs are repaired by NHEJ which is available throughout the cell 
cycle[303]. Both HR and NHEJ pathways are crucial for the cells to maintain 
genetic stability; the two pathways can not replace each other and mutations in 
either pathway leads to diseases including cancer [298]. If one of the two pathways 
is lacking in the cells, the other pathway can be up-regulated to mediate the repair 
of DSBs. This plasticity has been demonstrated by several studies. For instance, HR 
is up-regulated in cells that have defective NHEJ pathways [308]. NU7441 is potent 
specific DNA-PK inhibitor [309], it has been shown to inhibit NHEJ and increase 
dependence on HR pathways in cancer cell lines [310].  
 
Autophagy deficient cells have defective HR pathways and intact NHEJ pathways. 
NHEJ does not appear to be up-regulated by the loss of autophagy. To investigate 
whether cells became hyper-dependent on NHEJ pathways after the loss of 
autophagy, Atg7f/f and Atg7
-/-
 cells were treated with DNA-PK inhibitor NU7441 
following exposure to 10 Gy IR. Our results, as shown in Fig. 4.12, indicated that 
Atg7f/f cells were able to repair IR induced DSBs after 30 hours in the absence or 
presence of DNA-PKi. In Atg7-/- cells where HR was found to be defective, 
treatment of DNA-PK inhibitor lead to persistence of DNA damage, as marked by 
γ-H2AX staining, 30 hours following DSB inducing IR treatment (Fig 4.12).  
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Figure 4.12 DNA double strand breaks persist in autophagy deficient cells 
following inhibition of DNA-PK.  
 
Immunofluoresent microscopy analysis for the persistence of γ-H2AX foci 30h 
after 10Gy irradiation (IR) in control and ATG7
-/-
 cells was assessed either in the 
absence or presence of 10μM DNA-PKcs inhibitor, NU7441 (DNA-PKi).  DAPI 
was used to stain DNA in the nucleus. *The experiment was carried out at twice and a representative 
figure is presented here. 
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The accumulation of un-repaired DSBs leads to cell cycle arrest and eventually 
programmed cell death is activated [311]. As Atg7-/- cells displayed persistent 
DNA damage after inhibition of NHEJ pathways, cell death analysis was carried out 
to investigate whether the loss of autophagy leads to increased cell death in 
response to DSB inducing agents in combination with an NHEJ inhibitor (Fig. 4.13). 
Atg7f/f and Atg7
-/-
 cells were exposed to 10Gy IR, followed by 48h incubation with 
or without 10μM NU7441 (DNA-PKi). The cells were harvested for flow cytometry 
analysis and it was revealed that loss of autophagy leads to hypersensitivity to IR in 
combination with DNA-PKi.  
 
Higher does of IR (25Gy) led to higher percentage of cell death in autophagy 
deficient cells (Fig. 4.14). There was limited amount of apoptosis (< 5%) in lower 
dose IR (10Gy) treated cells, in the absence or presence of autophagy. Inhibition of 
DNA-PK and therefore NHEJ pathways did not appear to affect cell viability after 
DNA damaging treatment in Atg7f/f cells. However, in Atg7
-/-
 cells there was a 
marked increase in  cell death in DNA-PKi treated cells after DNA damage induced 
by 10Gy IR (Fig. 4.13).  
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Figure 4.13 Atg7
-/-
 cells are dependent on DNA-PK/NHEJ following treatment 
with IR.  
 
Sub-G1 DNA contents were analysed by flow cytometry in Atg7f/f and Atg7
-/-
 cells 
48h following 10Gy IR in the absence or presence of 10μM DNA-PKcs inhibitor, 
NU7441 (DNA-PKi).  *The experiment was carried out at least three times and a representative figure is presented 
here. 
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Numerous studies have shown that the loss of HR capacities in non-transformed or 
cancer cell lines leads to hypersensitivity to IR, as reviewed in [312]. Results as 
presented in Fig. 4.13 showed that autophagy deficient cells did not display any 
radio-sensitivity when exposed to 10Gy IR. However, when cells were treated with 
25Gy IR, there was an increase in cell death for cells lacking autophagy (Fig. 4.14). 
There was increased spontaneous cell death in Atg7
-/-
 cells and upon 25Gy IR, the 
death was further increased. Atg7f/f primary cells did not display any increase in 
cell death following IR.  
 
Etoposide is a commonly used chemotherapeutic drug that induces double strand 
breaks. Etoposide also induces double strand breaks through the inhibition of 
topoisomerase II [261]. Similar to the synergy in cell death observed with IR and 
DNA-PKi, Atg7
-/-
 cells were also found to be hypersensitive to etoposide (25μM) in 
combination with treatment with DNA-PKi (10μM) (4.15).  
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Figure 4.14  Higher dose of IR leads to increased cell death in autophagy 
deficient cells.  
 
Atg7f/f and Atg7-/- cells were exposed to 25Gy IR and harvested for flow 
cytometry analysis 48h later. Sub-G1 DNA contents were analysed. *The 
experiment was carried out at least three times and a representative figure is presented here. 
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Figure 4.15 Atg7
-/-
 cells are hypersensitive to DNA-PKi (10μM) after treatment 
with Etoposide. 
 
Sub-G1 DNA contents were analysed by flow cytometry in Atg7f/f and Atg7
-/-
 cells 
48h following 25μM Etoposide in the absence or presence of 10μM DNA-PKcs 
inhibitor, NU7441 (DNA-PKi).  *The experiment was carried out at least three times and a representative 
figure is presented here. 
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To test whether autophagy deficient cells were intrinsically hypersensitive to 
etoposide, Atg7f/f and Atg7
-/-
 cells were treated with titrating concentrations of 
etoposide of up to 60μM. It was found that loss of autophagy had no effect on 
apoptosis after treatment with etoposide (Fig 4.16).    
 
It has been reported that loss of autophagy is linked to hypersensitivity to 
chemotherapeutic drug camptothecin (CPT). FIP200 is an autophagy essential gene. 
Camptothecin does not have a great impact on cell viability in Atg7f/f cells, while 
FIP200 knockout MEFs have greatly diminished cell viability [249]. In breast 
cancer cell line MCF-7, inhibition of either Beclin1 or Atg7 leads to 
hypersensitivity to CPT [313].  
 
In order to test whether autophagy deficient MEFs are hypersensitive to CPT, 
Atg7f/f and Atg7
-/-
 cells were treated with titrating concentrations of CPT for 16 
hours and the cells were harvested for Sub-G1 DNA content analysis using flow 
cytometry. Autophagy deficient cells displayed marked sensitivity to CPT (Fig. 
4.17). 
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Figure 4.16 Loss of autophagy does not affect etoposide induced apoptosis.  
 
Sub-G1 DNA contents were analysed by flow cytometry in Atg7f/f and Atg7-/- 
cells 48h following treatment with 25μM etoposide as indicated.  *The experiment was 
carried out at least three times and a representative figure is presented here. 
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Figure 4.17 Atg7-/- cells are hypersensitive to Camptothecin.  
 
Wild-type and Atg7
-/-
 cells were treated with indicated concentrations of 
Camptothecin for 16 hours and cell death was accessed by flow cytometry analysis 
of sub-G1 DNA content.  *The experiment was carried out at least three times and a representative figure is 
presented here. 
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As shown in Fig 4.16 and 4.17, Atg7
-/-
 MEFs did not display increased sensitivity to 
etoposide however they are hypersensitive to CPT. Both CPT and etoposide are 
topoisomerase inhibitors, they form covalent complexes with cleaved DNA 
molecules and lead to DSBs [314, 315]. CPT is an inhibitor of DNA topoisomerase 
I, and etoposide of topoisomerase II. The types of DSBs they form are different and 
they exert different toxicity on cells. CPT leads to DSBs when the replication fork 
collides with CPT cleavage complex during S-phase [316]. Etoposide forms a 
cleavage complex with a long half life and eventually the single strand break turns 
into DSBs. DSBs by etoposide are repaired through HR and NHEJ [317]. The 
breakages created by CPT have overhangs of ssDNAs and resemble DNA ends 
after processed by strand resection mediators. DSBs mediated by CPT are primarily 
repaired with HR pathways [318, 319].  
 
Homologous recombination repair pathways involve DNA synthesis and stable 
cellular nucleotide levels are required to support DNA biogenesis. The lack of 
sufficient nucleotide pool in the cells leads to deficiency in DNA damage response 
and ultimately genetic instability [320]. Autophagy inhibition may limit the size of 
the cellular nucleotide pool, and so there is a possibility that the intrinsic sensitivity 
to CPT of Atg7
-/-
 cells was due to the lack of sufficient nucleotide. However, 
addition of exogenous nucleosides which elevate nucleotide pool did not reverse the 
effect (Fig 4.18).  
 
Atg7 is an E1-like enzyme crucial for autophagy process; a recent study reported 
that Atg7 can also form a complex with p53 protein both in the cytoplasm and the 
nucleus, playing a role in nutrient withdrawal induced cell cycle arrest [268]. It is 
unclear whether Atg7 plays a role in other pathways of DNA damage response. To 
ascertain whether the synergetic effects we observed were due to loss of autophagy 
or specifically Atg7 protein, Atg5
flox/flox
 MEFs were isolated and it was found that 
loss of Atg5 also leads to hypersensitivity to etoposide when treated with DNA-PKi 
(Fig 4.19).   
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Figure 4.18 Addition of exogenous nucleosides does not rescue CPT sensitivity in 
autophagy deficient cells. 
 
Apoptotic cell death was assessed 24h after treatment with Camptothecan (CPT) 
with or without nucleosides (10μM each of adenosine, guanosine, uracil and 
cytidine) as indicated. Total cell populations were collected and assessed for sub-
G1 DNA content by flow cytometry. *The experiment was carried out at least three times and a 
representative figure is presented here. 
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Figure 4.19 Atg5
-/-
 cells display synergy in cell death when treated with DNA PKi 
after DNA damage. 
 
Atg5
flox/flox 
MEFs were infected with Cre recombinase or empty retroviral vector as 
contol.  (a) Following antibiotic selection, cells were, where indicated, exposed to 
etoposide and/or DNA-PKi for 48h. Total cell populations were collected and 
assessed for sub-G1 DNA content by flow cytometry. (b) Relative mRNA 
expression of Atg5 was measured by qRT-PCR in ATG5
flox/flox 
cells which were 
retrovirally infected with either pBabe-Puro or pBabe-Puro-Cre. *The experiment was carried 
out at least three times and a representative figure is presented here. 
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Chapter 5. Investigating the Mechanisms through Which Chk1 
Level Is Down Regulated 
 
Protein degradation is a central process in the cells which is crucial for nearly all 
fundamental cellular activities including cell cycle progression, cell signalling, cell 
death, DNA transcription and DNA repair [321]. There are two main ways of 
degrading proteins and organelles in eukaryotic cells; they are the ubiquitin-
proteasome pathway and autophagy. The 26S proteasomes are large protein 
complexes found in all eukaryotic cells. They mainly degrade short-lived nuclear or 
cytosolic proteins [322]. Target proteins for proteasomal degradation are 
specifically marked by covalently attached ubiquitin molecules [323]. They are 
loaded into the catalytic cavity of proteasome complex where they are degraded. On 
the other hand, autophagy is a bulk degradation process that mainly degrades long-
lived proteins. Autophagy can also degrade bulkier proteins that otherwise do not fit 
in the barrel structure of proteasomes [324]. Both systems are important for the 
clearance of misfolded proteins and deficiency in either pathway can lead to various 
neurodegenerative conditions [325].  
 
Most ubiquitinated proteins are targeted for degradation in the proteasome. As 
described in Chapter 1, certain proteins, such as p62, NBR1 and HDAC6, can be 
ubiquitinated and specifically degraded via the autophagic machinery. Numerous 
proteins can be degraded by both proteasome and autophagy pathways, inhibition of 
either pathway can often lead to the up-regulation of the other [326] [327] [105]. 
There is also a study showing that the inhibition of autophagy can lead to 
suppression of proteasome mediated protein degradation through up-regulation of 
p62 [328]. Accumulation of p62, which contains a ubiquitin binding domain, is 
thought to delay the delivery of ubiquitinated proteins to the 26S proteasome. p62 
itself does not appear to have any effects on the proteasomal activities [328].  
 
Chk1 is a protein degraded by the proteasome. Chk1 protein is rapidly 
phosphorylated at multiple sites by ATR in response to genotoxic or replicative 
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stress. The phosphorylation of Ser345 site is thought to relieve the auto-inhibition 
of Chk1 and promote its kinase activities [329]. DNA damage responses consist of 
three main aspects: cell cycle arrest, DNA damage repair and programmed cell 
death. The three processes are finely coordinated and Chk1 is found to play a part in 
all three processes. The activation of Chk1 promotes cell cycle arrest and DNA 
repair. When the genotoxic stress is removed and DNA damage is repaired, Chk1 is 
inactivated and cell cycle resumes. A few mechanisms of Chk1 inactivation have 
been characterized to promote cell cycle recovery. Chk1 adaptor protein Claspin is 
regulated to modulate Chk1 activities [330] and phosphatase WIP1 specifically 
dephosphorylate Chk1 on a Ser345 [331]. Prolonged cellular stress leads to cell 
death and phosphorylated Chk1 is thought to be one of the intrinsic timers deciding 
cell fate. Activation of Chk1 facilitates its degradation. [332] [267]. 
Phosphorylation of Chk1 leads to its exposure to SCF E3 ligase, which mediates the 
ubiquitination and proteasomal degradation. Eventual depletion of Chk1 leads to 
permanent S phase arrest and subsequent cell death [333].  
 
5.1 Investigation of proteasomal activities in cells when autophagy is inhibited. 
 
Since p-Chk1 and later total Chk1 were diminished in autophagy deficient cells, it 
became apparent to test proteasomal activities in Atg7f/f and Atg7
-/-
 cells. The 
Proteasome-Glo™ Cell-Based Assays (Promega) was used to test proteasomal 
activities. The assay consists of artificially engineered substrates that can be 
recognised by the proteasome and cleaved by the chymotrypsin-like protease 
activities. The cleavage of the substrates leads to production of luciferin, which 
reacts with luciferase, producing luminescence signal. The strength of signal 
correlates with proteasomal activities.       
 
Proteasome activity luminescence assays were performed with Atg7f/f and Atg7
-/- 
cells (Fig. 5.1). Where indicated, 10μM lactacyctin was added to the cells 3h prior 
to harvest. Luminescence generated by proteasomal activities was measured and 
Atg7
-/-
 cells displayed nearly two fold of activity relative to Atg7f/f cells. The 
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signals are diminished after treatment with lactacystin, indicating that the signal is 
truly representative of proteolytic activity of the 26S proteasome complex. 
Lactacystin is a commonly used specific proteasome inhibitor. It is an compound 
first identified in bacteria streptomyces [334] , it binds covalently to the active site 
N-terminal threonine residue in beta-subunits of proteasome, inhibiting the catalysis. 
Lactacycstin was included in all proteasomal activity assays as a negative control.   
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Figure 5.1 Proteasomal activities are up-regulated in Atg7
-/-
 cells.  
 
Proteasomal activity was determined in wild-type and Atg7
-/-
 cells using a 
luciferase-based assay kit (Promega). Where indicated, lactacyctin (10μM) was 
added to the cells 3h prior to harvest. *The experiment was carried out at least three times and a 
representative figure is presented here. 
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As described previously (Fig. 3.4), there was less phosphorylated Chk1 in response 
to DNA damage in autophagy deficient cells soon after recombination, and later on 
there was decreased total Chk1 protein level in autophagy deficient cells (Fig. 3.8). 
No defects in Chk1 activation pathways were observed. Since activation of Chk1 
facilitates its proteasomal mediated degradation, we wanted to find out whether 
inhibition of proteasomal activities can reverse the effect on Chk1 after loss of 
autophagy. MG132 (carbobenzoxy-Leu-Leu-leucinal) is another commonly used 
proteasome inhibitor. While lactacystin inhibition involves covalent modification 
and is irreversible, MG132 is a potent and reversible peptide inhibitor that inhibits 
catalytic activities of the 26S proteasome complex [335]. 
 
It was found that the proteasomal inhibitor MG132 partially rescued 
phosphorylation of Chk1 at S345 in Atg7
-/-
 cells after irradiation. This is the case 
during early stages of recombination when only p-Chk1 is affected in Atg7-/- cells 
(Fig. 5.2) or when total Chk1 is also diminished at later times (Fig 5.3). Freshly 
recombined Atg7f/f and Atg7-/- cells were exposed to 10Gy IR and harvested for 
western blotting an hour later. The cells were treated with MG132 for 6h where 
indicated. In this case, total Chk1 levels were not noticeably diminished in Atg7
-/- 
cells, however there is decreased level of p-Chk1 (Ser345) after 10Gy IR in 
autophagy deficient cells (Fig. 5.2). In the presence of MG132, there were increased 
basal levels of p-Chk1 in both wild-type and Atg7-/- cells. Following treatment with 
MG132, Chk1 in Atg7
-/-
 cells was activated to a comparable extent as Atg7f/f cells.     
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Figure 5.2 Down-regulation of phosphorylated Chk1 in Atg7
-/-
 cells can be 
rescued by proteasomal inhibitors MG132. 
 
Chk1 phosphorylation at Ser345 and total protein levels in wild-type and Atg7
-/-
 
cells were examined 1h post 10Gy IR in either the absence or presence of 10μM 
MG132 for 6h. Actin was used as a loading control. *The experiment was carried out at least three 
times and a representative figure is presented here. 
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We were also interested to find out whether MG132 can rescue diminished total 
Chk1 protein in Atg7
-/-
 cells. Since Chk1 levels are not elevated after 6h of MG132 
treatment (Fig 5.2), in subsequent experiments, the treatment time was extended to 
16h (Fig. 5.3). After 16h MG132 treatment, there are higher levels of 
phosphorylated Chk1 in response to 10Gy IR in Atg7f/f and Atg7
-/-
 cells. 
Surprisingly, prolonged treatment with MG132 lead to the degradation of total 
Chk1 in Atg7f/f cells and did not raise the levels of total Chk1 in Atg7
-/-
 either. 
Since proteasomal activities are elevated in autophagy deficient cells, it remained a 
possibility that other proteasomal substrates were also degraded faster in these cells. 
In order to test this, protein levels of Mcl-1, a well characterized proteasomal 
substrate, were investigated in Atg7f/f and Atg7
-/-
 cells. Mcl-1 (myeloid leukemia 
cell differentiation protein) is a protein belongs to the Bcl-2 family; it is degraded 
by the ubiquitin-proteasome pathway and is known to have a very short half-live. 
Mcl-1 is rapidly turned over in the cells and the half life of Mcl-1 is around 3 hours 
[336]. Loss of autophagy does not affect levels of Mcl-1 at basal levels, this 
indicates that the up-regulation of proteasomal activities do not affect all short-lived 
proteins. After MG132 treatment, levels of Mcl-1 became elevated (Fig 5.3).   
 
A more definitive assay to test whether Chk1 is degraded faster in the absence of 
autophagy was carried out using Cycloheximide (CHX). Proteins in the cells are 
constantly recycled and renewed. The half life of a short-lived protein can be 
determined by western blotting analysis when protein synthesis is inhibited. CHX is 
a small molecule that blocks eukaryotic translation by binding to the ribosome and 
inhibits eEF2-mediated translocation [337]. It has been commonly used in assays to 
determine protein half life in eukaryotic cells. As shown in Fig. 5.4, Autophagy 
deficient cells were able to degrade Chk1 faster.  
 151 
 
 
Figure 5.3 Downregulation of p-Chk1 in Atg7-/- cells can be rescued by 
proteasomal inhibitors MG132 and long term MG132 treatment leads to Chk1 
degradation.  
 
Chk1 activation in wild-type and Atg7
-/-
 cells was examined 1h post 10Gy IR in 
either the absence or presence of 10μM MG132 for 16h.  *The experiment was carried out at 
least three times and a representative figure is presented here. 
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Figure 5.4 Loss of autophagy decreases Chk1 half life.  
 
(a) Endogenous Chk1 levels were determined by western blotting in Atg7
flox/flox 
and 
Atg7
-/-
 cells, after treated with cycloheximide (10μg) for various length of time as 
indicated. (b) Chk1 levels as shown in (a) were quantified using ImageJ software 
after normalisation to ERK/p42 loading controls. *The experiment was carried out at least three 
times and a representative figure is presented here. 
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In Cre mediated recombination system of Atg7
flox/flox 
MEFs where the procedure 
takes a week including selection with antibiotics, the deletion of autophagy activity 
is complete and the system is thought to have minimized off-target effects. 
However, it is difficult to find out how long exactly after infection with cre 
recombinase containing virus the cells start to lose autophagy. As shown in Fig. 5.1, 
Atg7-/- cells were found to have elevated levels of proteasomal activities. Cells 
with Atg7 depletion can not initiate autophagy and it remained a possibility that 
Atg7 has other functions in the cells independent of its E1 like enzyme activities. 
The use of a pharmacological inhibitor such as Bafilomycin A1 for autophagy 
would allow us to find out whether the up-regulation of proteasomal activities only 
occurred in Atg7
-/-
 cells or the effect is genuinely due to autophagy. Bafilomycin 
A1 is a natural compound first identified in the bacteria streptomyces griseus. It is a 
specific inhibitor of vacuolar-type hydrogen ATPase and can prevent the re-
acidification of lysosomes [338]. Bafilomycin hence inhibits the final step of 
autophagy when autophagosomes fuse with lysosome and the autophagic cargo is 
degraded.  
 
Atg7f/f primary MEFs were found to have elevated proteasomal activities after 
treatment with Bafilomycin A1 in a time-dependent manner. After 12 hours 
treatment, there was a detectable up-regulation. By 18 hours, the proteasome 
activity increased by three fold in Bafilomycin treated cells (Fig 5.5). This 
confirmed our findings in Atg7
-/-
 cells that loss of autophagy leads to increased 
proteasome activities. In response to dysfunctional lysosomes, the cells respond 
rapidly by up-regulating proteasomal activities as an adaptive mechanism.    
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Figure 5.5 Bafilomycin A1 up-regulates proteasomal activities in a time-
dependent manner.  
 
Proteasomal activity was determined in cells in the presence of absence of 
Bafilomycin A1 (100nM) for indicated length using a luciferase-based assay kit 
(Promega). Where indicated, lactacystin (10μM) was added to the cells 3h prior to 
harvest.  *The experiment was carried out at least three times and a representative figure is presented here. 
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To investigate whether short term autophagy inhibition has any effects on Chk1 
activation or total Chk1, cells were pre-treated with 100nM Bafilomycin A1 for 2 
hours where indicated before the addition of 25μM etoposide for indicated length of 
time. It was revealed that Chk1 is activated as assessed by p-Ser345 after 1 hour 
etoposide treatment to the same extent in the absence or presence of Bafilomycin. 
In accordance with published literature [333] [332] [267], Chk1 activation is not 
sustained in the presence of DNA damage agents, such as etoposide in this case. 
Comparing to 1h after etoposide treatment, there was decreased p-Chk1 signals in 
cells after 2h and 4h treatment in etoposide (Fig. 5.6). This is possibly because 
phosphorylated Chk1 is rapidly targeted for degradation. Total Chk1 protein levels 
were not affected by short-term Bafilomycin treatment. After 4h exposure to 
etoposide, Bafilomycin treated cells appeared to have a slightly weaker p-Chk1 
signal relative to cells without Bafilomycin.   
 
As shown in Fig 5.6, short term treatment (2 hours) with autophagy inhibitor 
Bafilomycin did not have any obvious effects on either total Chk1 or Chk1 
activation in response to DNA damaging agent etoposide. 2-hour Bafilomycin 
treatment itself also did not have any effect on Chk1 phosphorylation. However, 
longer term (12h) treatment of Bafilomycin appeared to have a differential effect on 
Chk1 activation depending on the presence of DNA damage inducing agent 
etoposide (Fig. 5.7). Treatment of Bafilomycin for 12 hours caused an increase in 
Chk1 activation (Fig. 5.7). In the presence of etoposide which creates double strand 
breaks, Bafilomycin failed to activate Chk1 further. In the presence of proteasome 
inhibitor MG132, Chk1 is strongly activated after etoposide treatment with or 
without Bafilomycin. This result indicated that loss of autophagy induced Chk1 
activation continuously and phosphorylated Chk1 is readily degraded by the 
ubiquitin-proteasome pathway. LC3 was probed as an indicator for autophagic 
activities. As Bafilomycin inhibits lysosomal functions, there was an accumulation 
of LC3-II in Bafilomycin treated samples.      
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Figure 5.6 Short term treatment of Bafilocymin does not have obvious effects on Chk1 activation 
in response to DNA damage.  
 
Phopho-Chk1 (S345) activation after Bafilomycin or/and Etoposide treatment was 
examined by western blotting. Cells were pre-treated with 100nM Bafilomycin for 
2h before addition of 25μM Etoposide where indicated. *The experiment was carried out at least 
three times and a representative figure is presented here. 
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Figure 5.7 Longer period of Bafilomycin treatment has differential impact on 
Chk1 phosphorylation in the absence or presence of DNA damaging agent.  
 
Levels of p-Chk1 (S345) were examined by Western Blotting in either the absence 
or presence of Bafilomycin A1 (100nM) for 12h and/or 10μM MG132 for 4h and/or 
Etoposide (25μM) for 4h where indicated. *The experiment was carried out at least three times and a 
representative figure is presented here. 
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5.2 Pharmacological Inhibitors of Autophagy Leads to Chk1 Activation, 
Followed by Chk1 degradation.   
 
To further explore the relationship between loss of autophagy and Chk1 functions, 
Atg7f/f primary MEFs were treated with either Bafilomycin or Chloroquine (CQ). 
Chk1 activations was then monitored over 8 hours (Fig 5.8 and 5.9). It was found 
that both Bafilomycin and CQ were able to activate Chk1 in a time-dependent 
manner, CQ also caused total Chk1 level to decrease within 8 hours (Fig 5.9).  
 
Similar to Bafilomycin, chloroquine (CQ) is an autophagy inhibitor that disrupts 
lysosomal functions. CQ is a basic molecule that enters lysosome and other acidic 
compartments in the cells where it becomes protonated in the vacuole and leads to 
less acidic environment. As previously described, Chloroquine has been 
traditionally used as an anti-malarial drug. In recent years it has shown potential as 
a promising anti-cancer agent. It has positive anti-tumour effects in a number of 
clinical trials [195]. The precise mechanism of the anti-tumour effect of CQ is 
unclear and it is thought that the effects are partially mediated by autophagy 
inhibition [339]. It should be noted that CQ has also additional effects besides 
autophagy inhibition [340]. CQ can cause chromatin structural changes that lead to 
ATM autophosphorylation at serine 1981, which results in the phosphorylation of 
Chk1 at serine 345 [208]. Therefore the p-Chk1 activation by CQ observed may be 
largely autophagy-independent. Indeed CQ mediated Chk1 activation (Fig. 5.9) is 
more pronounced than that of Bafilomycin (Fig. 5.7). CQ also caused Chk1 protein 
level to decrease within 8 hours, these observation further ties in with the fact that 
activation of Chk1 facilitates its degradation.      
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Figure 5.8 Short term Bafilomycin treatment leads to Chk1 activation. 
 
Primary MEFs were treated for the indicated time points with 100nM Bafilomycin 
A1. Cells were harvested and extracts were subjected to Western blotting with p-
Chk1 and total CHk1. Actin was used as a loading control.  *The experiment was carried out at 
least three times and a representative figure is presented here. 
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Figure 5.9 Short term Chloroquine (CQ) treatment leads to Chk1 activation.  
 
Primary MEFs were treated for the indicated time points with CQ (100μM). Cells 
were harvested and extracts were subjected to Western blotting with p-Chk1 and 
total Chk1.  *The experiment was carried out at least three times and a representative figure is presented here. 
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Since Bafilomycin and CQ activated Chk1 within hours and activation of Chk1 
leads to its degradation, this lead us to speculate that treatment with these agents for 
longer terms may lead to degradation of total Chk1 protein levels. Indeed, when the 
cells were treated with Bafilomycin for 18 hours, total Chk1 level was diminished 
(Fig 5.10). Chk1 fails to be activated in Bafilomycin treated cells, very likely due to 
the decrease of total Chk1 proteins.       
 
The down-regulation of Chk1 mediated by lysosomal inhibitor Bafilomycin can be 
rescued by MG132 or Lactacystin (Fig 5.11). MG132 treatment for 8h alone does 
not raise Chk1 level significantly but does appear to reverse the effect of 
Bafilomycin treatment on Chk1.    
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Figure 5.10 Bafilomycin treatment eventually leads to Chk1 degradation.   
 
Where indicated, primary MEFs were treated for 18 hours with Bafilomycin or/and 
exposed to 10Gy IR 1h before harvested. The cells were harvested and extracts 
were subjected to Western blotting with p-Chk1 and total Chk1.  *The experiment was 
carried out at least three times and a representative figure is presented here. 
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Figure 5.11 The effect of Bafilomycin on total Chk1 can be reversed by 
treatment of proteasomal inhibitors.  
 
Primary MEFs were treated with Bafilomycin for 16h; and with MG132 or 
Lactacystin for the indicated time points. Cells were harvested and extracts 
were subjected to Western blotting. *The experiment was carried out at least three times and a 
representative figure is presented here. 
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Chapter 6   Discussion  
 
6.1 Summary  
 
In this study, progress was made in dissecting the roles of autophagy in DNA 
damage responses.  It was found that the loss of autophagy leads to Chk1 de-
regulation. Soon following autophagy inhibition, the activation of Chk1 is impaired. 
Two weeks after Atg7 deletion, the total protein levels of Chk1 were down-
regulated. It was also observed that the inhibition of autophagy, with either genetic 
knockout or pharmacological inhibitors, led to an up-regulation of proteasomal 
activity in primary MEFs. It is known that phosphorylation and activation of Chk1 
facilitates its degradation [267]. Soon after loss of autophagy, Chk1 activation 
induced by DNA damage was found to be impaired. Our results indicated that this 
observation may be due to elevated proteasomal activity in Atg7
-/-
 cells.  
 
Prolonged autophagy inhibition leads to a decrease in total Chk1 levels and 
therefore the amount of Chk1 that could be activated in response to cellular stress. 
In either case, Chk1 activation was found to be impaired in autophagy deficient 
cells.  
 
Published studies have shown that Chk1 is a critical factor for HR repair [240] and 
autophagy deficient cells are more sensitive to CPT, a chemotherapeutic agent that 
causes double strand breaks that can only be repaired via HR [249]. Autophagy 
deficient cells accumulate more DNA damage [2] and also display a deficiency in 
the HR repair pathway as shown in Fig4.6. Atg7
-/-
 cells were however viable and 
appear to have intact cell cycle checkpoints. As shown in Fig. 6.1, HR and NHEJ 
are the two main pathways for DNA double strand break repair. The current study 
shows that Atg7-/- cells were hyper-dependent on the NHEJ pathways, since the 
inhibition of NHEJ with DNA-PKi increased etoposide or IR induced apoptosis in 
cells lacking autophagy. In other words, the inhibition of NHEJ pathway gives rise 
to a synthetic lethal situation when combined with autophagy deficiency.  
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Figure 6.1 Loss of autophagy leads to Chk1 deficiency and defective HR DNA 
repair pathway.  
 
Atg7
-/-
 cells were found to be hyper-dependent on NHEJ following DNA damaging 
agents, inhibition of which leads to increased cell death.  
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 6.2 Up-regulation of proteasomal activity following autophagy 
inhibition 
 
The two pathways have been traditionally thought to function in parallel to maintain 
cellular homeostasis under normal physiological conditions. In recent years there is 
emerging evidence that the two processes can cross talk. When one of the two 
pathways is altered, the other is subsequently perturbed. The interplay between the 
ubiquitin-proteasomal system and autophagy is complex and is not completely 
understood [341].  
 
There are several main steps in the ubiquitin-proteasome mediated degradation 
process – substrate recognition, ubiquitination, substrate delivery and degradation 
[64]. Autophagy possibly has multiple effects on the proteasomal degradation steps. 
p62 is frequently found to be up-regulated in autophagy deficient cells, where it has 
been found to inhibit the delivery of ubiquitinated substrates to the proteasome. As 
a result, there is an increased level of certain short-lived proteins such as p53 [328]. 
In contrast, our studies indicate that autophagy may be directly linked to 
proteasomal activity. The proteasome-Glo
TM
 cell based assay contains specific 
peptide substrates that can readily access protease sites within the cavity without 
interaction with E1, E2 and E3 ubiquitin delivery system.  The assay is a direct 
measurement of catalytic activity of the proteasome. It would be interesting to find 
out which of the two opposing effects – autophagy and proteasome dominates 
within the cell and whether the effects are cell-type dependent. Korolchuk and 
colleagues reported an accumulation of p53 as a result of inhibition of substrate 
protein delivery to the proteasomes [328]. We report here that the half life of Chk1 
protein decreases after loss of autophagy. Therefore it would also be interesting to 
find out whether proteasomal substrates are differentially affected by autophagy 
inhibition.  
 
Both the proteasome degradation system and autophagy are essential for the 
maintenence of cellular homeostasis. Proteasomes are thought to be the 
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predominant organelle that degrades proteins in an un-challenged state and short-
lived proteins. Autophagy on the other hand has been found to degrade 40% of all 
long lived proteins in the cells. [342].  A number of proteins have been identified to 
be degraded by both systems, such as as α-synuclein [343] and aggregate-prone 
proteins with polyglutamine and polyalanine expansions [344].  
 
Proteasomes in mammalian cells have relatively long half lives, approximately 1 
week in rat liver cells [345]. It is unclear how proteasomes are turned-over but 
autophagy possibly plays a role in it, since autophagy is thought to be the major 
mechanism through which large cellular structures are degraded. Proteasomes are 
largely abundant in the cells and they constitute around 1% of total soluble proteins 
[346]. When the cells encounter stressful conditions such as starvation, autophagy is 
up-regulated to degrade cytosolic proteins and organelles as an adaptive mechanism. 
Proteasomes are large structures and energetically costly for the cells to synthesize 
or degrade. It has been reported that instead of being degraded during cellular stress, 
proteasomes are sequestered into storage granules that evades autophagic 
degradation in yeast cells [347]. It is unclear whether mammalian cells adopt the 
same mechanism and it remains possible that autophagy inhibition leads to 
accumulation of proteasomes in MEF cells. One way of testing this is to assess the 
levels of proteasome subunits through western blotting in Atg7 knockout cells and 
in Bafilomycin A1 treated cells. In addition, mRNA assessment following 
autophagy inhibition may reveal any transcriptional regulation of autophagy on 
proteasome functions.  
 
One important question that remains to be answered is whether autophagy 
inhibition leads to proteasomal up-regulation in tumour cells and whether it occurs 
in vivo. Both proteasomal and autophagy inhibitors have shown potential in cancer 
therapeutics. Autophagy and proteasomes are the two main pathways of protein 
degradation; if inhibition of one pathway leads to the up-regulation of the other, one 
may expect that combinational use of the two inhibitors would have synergetic 
effects in cancer killing. The synergetic concept has been demonstrated in vitro 
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[348] but the feasibility of using the two inhibitors in combination therapies awaits 
further clinical investigation.   
 
Apart from cancer, autophagy disruption is implicated in a number of diseases such 
as autoimmune conditions and diabetes. It is unknown whether proteasomes in 
those diseased states are also affected.  
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6.3 Loss of autophagy, Chk1 activities and DNA damage response. 
 
Although Chk1 is generally thought to be a tumour suppressor that is crucial in the 
maintenance of genetic stability; however Chk1 mutations are very rare occurrences 
in either sporadic or hereditary cancers [349]. Recent studies have demonstrated 
that Chk1 inhibition. Cell cycle and cell death are two closely-related processes. A 
number of cancer treatments target specifically rapidly proliferating cells and some 
cancer cells can enter temporary growth arrest [350]. Because of the multiple cell 
cycle checkpoints, cancer cells lacking p53 fail to undergo G1 cell cycle arrest but 
instead arrest at G2/M mediated by Chk1. Tumour cells are thought to develop drug 
resistance by undergoing cell cycle arrest and protected from programmed cell 
death. Besides playing a role in cell cycle arrest, chk1 has also been shown to be 
required for cell cycle re-entry after stalled replication [351]. Chk1 has been found 
to be critical for cancer cell survival following anti-metabolite cancer treatments 
[352]. Chk1 inhibitors have shown promising chemo-sensitising effects in 
combinational cancer therapies and they are being developed for clinical use (as 
reviewed in [353]).  
 
Many cancer therapeutic drugs can up-regulate autophagy, which in response to 
many of those drugs is thought to be an adaptive mechanism that promotes drug 
resistance in cancer cells. Autophagy inhibitor CQ has shown promising clinical 
efficacy in cancer treatment, especially in combination therapies. It has not been 
explored whether autophagy inhibition leads to disruption of Chk1 functions in a 
tumour setting. It is also not known whether Chk1 is down regulated following CQ 
treatment in cancer cells. Both Chk1 and autophagy are thought to promote drug 
resistance in cancer cells. It would be of clinical importance to find out whether the 
synergy between autophagy inhibition and Chk1 deficiency exist in tumour settings. 
Further studies are needed to address these questions relevant to cancer therapies. 
 
Autophagy deficiency in primary MEFs leads to hypersensitivity to DNA-PK 
inhibitor NU7441 in combination with DNA damaging agents, as shown in Fig. 6.2. 
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NU7441 has shown promising potential as a part of cancer therapeutics in pre-
clinical evaluations [309]. DNA-PKcs share structural similarities in its kinase 
domains with PI3K family proteins and NU7441 is a structurally analogous to 
LY294002, a PI3K inhibitor. It has been reported that NU7441 also weakly inhibits 
PI3K [354]. Therefore it is possible that the chemo-sensitization of NU7441 on 
autophagy deficient cells may also be due to PI3K inhibition. MEFs from DNA-
PKcs knockout mice were isolated to address the question. DNA-PKcs knockout 
mice are more commonly known as SCID (severe combined immunodeficiency) 
mice because NHEJ pathways are critical for VDJ recombination during antibody 
maturation. Another member of our lab (Jim O’Prey) has found that SCID MEFs 
also display synergetic killing following autophagy inhibition with CQ and 
etoposide (data not shown here), confirming that inhibition of NHEJ pathway leads 
to increased apoptosis in autophagy deficient cells in response to DNA damage.  
 
Autophagy has been found to inhibit tumour onset, loss of autophagy accelerates 
tumour formation [116]. It would insightful to find out whether the effect of 
autophagy inhibition on Chk1 contributes towards the role autophagy plays in 
tumourigenesis. An initial experiment can be done to see whether loss of autophagy 
in vivo leads to Chk1 down-regulation. If it does, whether Chk1inhibition or Chk1 
knockdown can affect the outcome of tumourigenesis in wild type and autophagy 
deficient mice should be investigated.  
 
6.4 Loss of autophagy has differential effects on Chk1 functions   
 
It has long been established that complete Chk1 deficiency leads to severe 
proliferation defects and cell death [276]. Heterozygous Chk1 leads to defective S-
phase and mitotic checkpoint as well as DNA damage accumulation [355]. In this 
study, Chk1 functions are impaired in Atg7
-/-
 primary MEF cells, and these cells 
displayed growth defects. However they are viable for approximately one month 
before they enter crisis. Chk1 is important in cell cycle checkpoints [260] and HR 
DNA damage repair pathways [240]. Our assays demonstrated that Atg7
-/-
 cells 
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have intact G1 and G2/M cell cycle checkpoints but defective HR pathways. G1 
checkpoint is mediated by p53 upon DNA damage [356]. In contrast, Lee and 
colleagues previously discovered that Atg7
-/-
 cells have defective G1 checkpoint 
[268]. The differences in conclusions could be due to differed experimental 
strategies. While cell cycle arrest was assessed 3 hours after amino acid and serum 
withdrawal in their study; we examined cell cycle progression and found that both 
cell lines arrest their cell cycles after 16 hour serum starvation. There may be 
difference in the kinetics of cell cycle arrest between Atg7f/f and Atg7-/- cells and 
this remained to be determined. The reason we did not observe any defect in cell 
cycle arrest may be that the extent of Chk1 down-regulation was not sufficient to 
disturb cell cycles. To test this, Chk1 may be knocked-down to even lower levels in 
Atg7-/- cells and cell cycle analysis can then be carried out.  
 
Chk1 has been reported to be a haplo-insufficient tumour suppressor [260] and 
partial Chk1 inhibition is adequate to impair Chk1 functions in cell cycle controls 
and DNA damage repair [355]. Indeed, our data shows the HR repair pathway to be 
severely impaired in Atg7
-/-
 cells.  It was not expected that Atg7
-/-
 cells also 
displayed intact G2/M cell cycle checkpoint, as Chk1 activation was found to be 
down-regulated in Atg7
-/-
 cells and Chk1 has been shown to be a critical factor for 
G2/M arrest. Since CDC25A promotes cell cycle progression by activating CDKs 
[357], it was then reasoned that regulation of Cdc25A would provide mechanistic 
details of Chk1 function in cell cycle control. Studies in a number of human or 
immortalised MEF cell lines have shown that Cdc25A is degraded rapidly upon 
DNA damage treatments such as IR [286, 287]. In this report, it was found that 
Cdc25a levels did not change in either Atg7f/f or Atg7-/- cells following IR. This 
observation is consistent with Cann and Hick’s published study, Cdc25A does not 
get degraded following DNA damage in primary MEFs [358]. This indicates that 
MEF cells might have other Chk1 targets similar to Cdc25A regulating CDKs and 
cell cycle progression.  
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Though the HR pathways in Atg7-/- cells have been found to be defective, and it is 
established the defective HR repair is a disinctive trait for BRCA1/2 cells [244].  
The phenotype of Atg7-/- cells is different from BRCA1/2 KO cells, for example,  
Atg7-/- cells are not hyper-sensitive to etoposide or irradation  [359]. BRCA1/2 KO 
cells are embryonic lethal in mice and Atg7-/- mice can survival untill the neonatal 
starvation period [360]. Again, the difference could be because of the levels of 
depletion, Chk1 is reduced significantly in Atg7-/- cells and the remaining pool of 
Chk1 may be sufficient to mediate certain repairs.  
 
In Atg7f/f MEFs, Chk1 is strongly activated in response to DNA damaging agents 
such as etoposide and IR within 1 hour, and the signal intensity decreases over time, 
as shown in Fig 5.6 lysosomal inhibition also leads to the phosphorylation of Chk1 
at Ser345; but the response was weaker and slower than damage induced activation. 
It is unclear how lysosomal inhibition leads to Chk1 activation. One potential link 
may be that autophagy is required for the cells to clear damaged mitochondria. 
Since mitochondria are considered to be the main source of ROS production, the 
inhibition of autophagy leads to ROS accumulation and increased DNA damage. 
Studies from Eileen White’s group convincingly showed that autophagy plays an 
important role in regulating ROS and limiting genetic instability [2, 107, 153]. 
However it has been reported that lysosomes and/or autophagosomes are another 
major source of intracellular ROS besides mitochondria [361] [362], and the 
pharmacological inhibition of lysosome or autophagy actually decreases ROS 
production [362]. Therefore, more studies need to be carried out to determine the 
mechanism by which lysosomal inhibition up-regulate Chk1 activity. Assessment of 
DNA damage, ROS production and p62 levels can be performed to address this 
question.  
 
In general, cells were harvested one hour after treatment with etoposide or IR in this 
study, and it has been reported that Chk1 gets activated within 15 minutes following 
DNA damage [363]. It remains possible that Chk1 activation may be observed in 
response to IR or etoposide in Atg7
-/-
 cells minutes following treatment. Further 
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experiments could be carried out to address this, for example, the cells can be 
harvested 10 minutes after IR or etoposide for western blotting and p-Chk1 and 
total Chk1 can be probed. 
 
Autophagy deficient cells displayed high levels of spontaneous cell death, it would 
be insightful to test whether spontaneous and oncogene induced senescence is 
affected by loss of autophagy.  
 
The loss of autophagy has been reported to give rise to increased DNA damage, 
which activates Chk1 kinase. Inhibition of autophagy with CQ or Bafilomycin A1 
leads to increased phosphorylation of Chk1 (Fig. 5.8 and 5.9), however it is not 
known that whether cells have increased Chk1 phosphorylation immediately after 
loss of Atg7 after cre recombination. A direct cause and effect relationship has not 
been established in this project. The retrovirus-mediated Cre infection procedure 
and subsequent antibiotic selection takes approximately one week including 
antibiotics selection. As shown in Fig 3.9, MEF cells from CAG-Cre-ER mice 
containing Atg7
flox/flox 
transgene were treated with Tamoxifen and there was 
increased phosphorylated Chk1 6 days after the cells were first exposed to 
Tamoxifen. One potentially insightful experiment would be to monitor phopho-
Chk1 and total Chk1 over a time course of a week following Tamoxifen treatment 
in these cells. Since CQ and Bafilomycin A1 suppress all lysosomal functions, 
besides autophagy inhibition, genetic approaches of autophagy inhibition should 
rule out potential artefacts.    
 
6.5 Modulation of autophagy for therapeutic purposes 
 
Cancer is a group of diseases with divergent pathologies; and unavoidably there 
were varied responses to anti-tumour treatments. Autophagy is induced by certain 
cancer drugs, possibly a survival mechanism for cancer cells to countract 
chemotherapy, whereas other cancer treatments require intact autophagy pathways 
to achieve sufficient killing. It is therefore important to find out whether autophagy 
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is beneficial or detrimental for each type of cancer during specific treatments. 
Cancer cells that up-regulate autophagy as a pro-survival mechanism in response to 
cancer-killing drugs are referred to as being ‘addicted to autophagy’ [155].   
 
In human patients, autophagosome accumulation has been used as the readout for 
autophagy activity. This method of monitoring autophagy can be misleading; 
because autophagosomes can accumulate after activation of autophagy due to 
increased cargo trafficking but it can also build up due to inhibition of lysosomes, 
which fuse with and degrade autophagosomes. Better ways of monitoring 
autophagy activities in cancer patients are needed in order for the appropriate 
therapies to be applied.  
 
MEF cells which are deficient in Atg7 or treated with CQ or Bafilomycin have been 
used as autophagy-deficient models. In general, both methods of autophagic 
inhibition provided similar experimental conclusions. Fundamental differences exist 
between the two methods and will be discussed here.  
 
Chloroquine (CQ) and Bafilomycin A1 are late stage autophagy inhibitors. They 
both inhibit lysosomal functions [364] [339]. Hydroxychloroquine (HCQ) is 
derivative of CQ; in clinic, CQ has been associated with retinal toxicity in patients 
and is now generally replaced by HCQ, a derivative of CQ, in clinical treatments or 
trials [365]. At least 16 phase I/II clinical trials are currently in progress [366], and 
HCQ has shown promising results in a number of clinical trials as part of 
combination therapy [367]. The current dose of HCQ used for cancer treatment is 
around 400mg -800mg per day (Clinicaltrials.gov) [366], Amaravadi and colleagues 
reported that the clinical dose of HCQ may not efficiently inhibit autophagy in all 
patients [367]. Development of more potent autophagy inhibitors for cancer 
therapies is currently under way. Among these candidates, compound Lys05 is 
structurally related to CQ/HCQ, and it has 10 times more efficacy in autophagy 
inhibition. It has been shown to be a promising anti-cancer drug in mouse studies 
[368]. 
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CQ has been found to activate ATM, by distorting DNA structures. The activation 
of ATM in turn activates Chk1. Baf on the other hand has not been found to have 
similar effects on DNA, and the Chk1 activation from Baf treatment (Fig 5.8) is 
weaker than that of CQ (Fig 5.9).  A potential experiement that can be done is to 
treat the cells with ATM inhibitors and repeat the experiments as shown in Fig 5.8 
and Fig 5.9 and compare between the effect of Baf and CQ on Chk1 levels.  
 
CQ also caused Chk1 protein level to decrease within 8 hours, these observation 
further ties in with the fact that activation of Chk1 facilitates its degradation.      
 
In this study, most majority of the works has been carried out in primary MEFs, the 
advantage of the system is that it is a clean system with complete Atg7 removal and 
DNA damage repair networks are all intact in freshly isolated MEFs. Conclusions 
from this study apply to untransformed cells. Cancer cells harbour genetic defects 
especially in DNA repair pathways, therefore it would be interesting to carry out the 
same experiments in cancer or transformed cell lines and investigate the effect of 
loss of autophagy on Chk1.  
 
Atg7 knockout leads to complete autophagy inhibition, as Atg7 is an essential 
protein for the formation of autophagosomes [369]. In terms of therapeutics, 
knocking down Atg7 in targeted organs is unrealistic due to limitations in the 
availability of gene therapy techniques. Autophagy is a surveillance process 
guarding cellular homeostasis and integrity. Complete inhibition of autophagy may 
contribute towards tumourigenesis and a number of other diseased states. Atg7 is an 
E1-like enzyme; following the successful development of an inhibitor for NEDD8-
activating E1-enzyme, Millennium has undertaken the task of developing Atg7 
small molecule inhibitors [367]. Our studies of autophagy in DNA damage response 
are relevant to the development and potential use of small molecule inhibitors.  
p53  
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The p53 tumour suppressor plays important roles in cell cycle regulation, DNA 
damage responses and programmed cell death. It is reported that p53 is lost in over 
50% of cancers [36]. Chk1 has been found to phosphorylate p53 on multiple sites at 
both N [370] and C termini [371].  The phosphorylation sites include S20, which is 
of particular importance to the half life and activity of p53. Future experiments may 
be carried out to determine the effect of loss of autophagy on p53. It was found that 
autophagy can inhibit tumour progression in transgenic mice with Kras mutation 
when p53 is present; however if p53 is lost then loss of autophagy actually 
accelerates cancer onset. If mice lacking p53 and with Kras mutation are treated 
with CQ, which is being evaluated for its use as combinational therapy for cancer, 
these mice form cancer faster comparing to mice with p53.  
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